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ABSTRACT 
 Development of the mammalian forebrain is a complex process that requires 
coordinated regulation of numerous signaling pathways across space and time.  As such, 
defects in these regulatory mechanisms can lead to severe developmental defects and 
neurological disorders.  Therefore, identification of these regulatory factors is essential for 
our understanding of neurological disorders and subsequent development of targeted and 
effective therapeutics.  Here, I describe three studies that demonstrate novel functions for 
the acetyltransferase GCN5 in the development and function of the murine forebrain.  First, 
I present data to support a broad role for GCN5 in the regulation of transcriptional networks 
implicated in neural tube closure and neuroepithelial cell biology.  Several of these 
pathways are closely tied to the proliferation and differentiation of neuroepithelial cells and I 
show that loss of GCN5 enzymatic activity disrupts differentiation of these cells, resulting in 
cells that exhibit markers of both stemness and terminal differentiation.  Second, I present 
evidence showing that GCN5 acetyltransferase activity is required for restricting 
diencephalic expansion through a novel mechanism of retinoic acid (RA) signaling.  
Specifically, I demonstrate that GCN5 is required to acetylate the protein TACC1 in 
response to RA signaling in the developing diencephalon as a means of relieving TACC1-
mediated transcriptional repression of RA target genes, whose expression is required to 
suppress diencephalic WNT and SHH signaling and restrict tissue expansion.  Last, I 
describe a longitudinal study identifying behavioral, cellular, molecular, and anatomical 
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abnormalities in the brains of adult mice heterozygous for inactivating mutations in Gcn5 
(Gcn5hat/+).  Gcn5hat/+ mice exhibit severe self-induced skin lesions, decreased activity in a 
marble burying assay, and defects in forebrain circuits that are implicated in social 
behavior, cognitive function, and habitual behavior.  Furthermore, disruption of these neural 
circuits is thought to underlie severe neuropsychiatric diseases including autism spectrum 
disorders, obsessive-compulsive disorder, and schizophrenia.  Together, these studies 
implicate GCN5 in wide-ranging processes necessary for the proper development and 
function of the mammalian forebrain and identify Gcn5 as a gene of interest in the etiology 
of neuropsychiatric disease. 
 
The form and content of this abstract are approved.  I recommend its publication. 
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INTRODUCTION AND REVIEW OF THE LITERATURE1 
Neural Induction  
The central nervous system (CNS), which is comprised of the brain and spinal cord, 
is a highly organized structure of ectodermal origin.  Early formation of the nervous system, 
termed neural induction (illustrated in Figure 1.1a,b), begins when a region of dorsal 
mesodermal tissue induces overlying ectodermal tissue to form the neural plate (Smith and 
Schoenwolf 1989; Keller et al. 1992).  This process was first identified in an elegant set of 
experiments performed by Spemann and Mangold nearly 100 years ago, which showed 
that transplantation of tissue from the site of embryonic gastrulation in amphibians 
(Spemann’s organizer) to the ventral region of the embryo is sufficient to induce formation 
of dorsal mesoderm and, in turn, secondary formation of neural tissue (Rogers et al. 2009; 
Spemann and Mangold 2001).  In mouse, the tissue with this ability to induce neural tissue 
is known as the node (Beddington 1994).  Early embryonic development is characterized by 
high levels of TGF-β pathway signaling in the ventral embryonic tissue and it was therefore 
hypothesized that the node is capable of inducing dorsal, neural fate through suppression 
of this activity.  This hypothesis was based upon a set of experiments that suggested a 
default neural fate for dorsal embryonic tissue that also requires cell-cell communication 
(Sato and Sargent 1989; Wilson and Hemmati-Brivanlou 1995).  Furthermore, several 
experiments showed that the node and other tissues with organizer properties secrete high 
levels of inhibitors of the TGF-β signaling pathway, supporting the hypothesis that neural 
induction requires inhibition of TGF-β and, more specifically, BMP signaling emanating 
from the ventral embryo (Zimmerman et al. 1996; Piccolo et al. 1996).   
																																																								
1
 The Neural Tube Closure section of this chapter is condensed from my review of neural 
tube closure (Wilde et al. 2014) with permission from the publisher. 
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Through a variety of studies, the process of BMP inhibition and its role in neural 
induction has now been extensively addressed (Figure 1.1a, right).  Experiments indicate 
that inhibitors of BMP signaling act on BMP ligands in the extracellular space, preventing 
them from binding their receptors and activating downstream targets (Zimmerman et al. 
1996; Piccolo et al. 1996).  The primary BMP ligand involved in this process has been 
shown to be BMP4 (Wilson and Hemmati-Brivanlou 1995) and experiments investigating its 
role in neural induction have shown that it acts through activation of multiple downstream 
target genes, including members of the Msx, Gata, and Vent families of transcription factors 
(Hemmati-Brivanlou and Thomsen 1995).  It should be noted, however, that induction of 
neural fate requires some instructive signals, as inhibition of BMP signaling in ventral 
ectoderm is not sufficient for ectopic neural induction (Wilson and Hemmati-Brivanlou 
1995).  Numerous studies have now shown that inhibition of BMP signaling in dorsal 
ectoderm requires various members of the fibroblast growth factor (FGF) family of proteins, 
though the specific proteins vary along the anterior-posterior (A-P) axis of the developing 
neural plate (Gould and Grainger 1997).  Furthermore, although some experiments suggest 
that FGF signaling plays a direct role in the induction of neural fate, it is unclear if these 
functions are completely independent of BMP inhibition (Rogers et al. 2009; Baker et al. 
1999; Wittler and Kessel 2004; Delaune et al. 2005).  Nonetheless, it is clear that FGF 
signaling is required for neural induction.    
Primary Neurulation 
Neural Tube Closure 
 The completion of neural induction marks the beginning of primary neurulation, 
when the newly formed neural plate elevates and folds into a tube that will become the 
central nervous system.  This process, referred to as neural tube closure, requires complex 
coordination of cell proliferation, apoptosis, patterning, and cytoskeletal regulation (Figure 
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1.1c).  Furthermore, these regulatory processes must be coordinated in time and space 
across multiple tissues, including the neuroepithelium, non-neural ectoderm, and 
mesenchyme.  Neural tube closure occurs between weeks 3 and 4 of human embryonic 
development and between E8.5 and E10.5 in mouse.  Closure begins in the rostral spinal 
cord and then proceeds bi-directionally to close the neural tube along the length of the 
embryo via two processes: (1) a zipping mechanism in the spinal region and (2) an inflection 
mechanism in the head.  Closure along the length of the embryo therefore requires the 
coordinated deployment of multiple distinct and overlapping genetic programs. 
 Genetic studies in mice have identified many of the genes necessary for proper 
neural tube closure and these experiments indicate that neural tube closure is highly 
sensitive to disruption of diverse cellular processes.  Neural tube closure requires 
significant morphogenetic movements and hence disruption of genes important for 
cytoskeletal structure and dynamics, force generation, and cell shape changes leads to 
failure of the closure process.  As primary neurulation proceeds and the embryo continues 
to grow, high levels of proliferation and coordinated apoptosis are required.  Changes in 
either proliferation or apoptosis resulting in either tissue hyperplasia or hypoplasia can 
disrupt force-generating mechanisms and lead to failure of neural tube closure.  Differential 
regulation of these cell behaviors is strongly influenced by cellular identity and the 
concurrent patterning of the embryo that occurs during primary neurulation, as evidenced 
by mouse models with disruption of key neural patterning molecules.  Lastly, even in cases 
where the neural folds properly elevate and approach one another, neural tube closure can 
be disrupted through a failure of adhesion between the neural or non-neural ectoderm.  
This level of complexity therefore means that perturbation of any one of many cellular 
processes can lead to defects in neural tube closure, which can have devastating 
consequences.     
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Neural Tube Defects 
In humans, defects in neural tube closure result in a class of birth defects known as 
neural tube defects (NTDs), which are the second most common birth defect (~1 in 1,000 
live births).  Failure of caudal neural tube closure results in NTDs such as spina bifida and 
myelomeningocele, while failure of the cranial neural tube to close, a defect known as 
exencephaly, results in a fatal birth defect known as anencephaly that results from 
degradation of the exposed brain tissue.  Because of the high prevalence of NTDs, the 
permanent impacts on neural development and function, and significant financial 
consequences, NTDs are devastating birth defects warranting intense study.   
 In humans, NTDs are thought to be largely multigenic in nature and because of the 
complex genetics of these defects in humans, animal studies of individual genes and their 
functions in neural tube closure have been the primary means of our understanding of 
NTDs.  To date, >300 genes have been implicated in neural tube closure in animal models, 
illustrating the highly complex nature of this process.  Moreover, as might be expected by 
this complexity, genes that have the ability to coordinately regulate vast transcriptional 
networks in a spatiotemporal manner play an important role in neural tube closure.  Of the 
~300 genes required for neural tube closure in mouse, more than 20 are involved in 
chromatin remodeling, representing a highly enriched class of proteins.  Furthermore, the 
likely possibility that many human NTDs are caused by compound disruption of multiple 
genes or pathways suggests that chromatin modifiers may be involved in disease etiology.  
This is supported by knowledge that gestational disruption of chromatin modification with 
drugs like the histone deacetylase inhibitors valproic acid and Trichostatin A greatly 
increase the risk for NTDs.  Despite our knowledge of the teratogenic nature of these 
compounds, however, the exact molecular mechanisms underlying their disruption of 
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neural tube closure remain unclear and represent an important area of research for 
understanding and preventing NTDs.  
Neuroepithelial Cell Differentiation 
Completion of neural induction and neural tube closure results in a precursor to the 
CNS that is comprised of neuroepithelial (NE) cells, which are the earliest population of 
neural stem cells (Copp et al. 2003).  These NE cells subsequently give rise to all other 
neural stem and progenitor cell populations of the CNS and are therefore the initial source 
of all differentiated cells in the CNS (Götz and Huttner 2005). Upon completion of primary 
neurulation at embryonic day 9.5 (E9.5) in mouse, NE cells undergo rapid, symmetric cell 
divisions that generate the stem cell pool necessary for complete formation of the CNS 
(Rakic 1995).  As developmental time progresses, cell intrinsic and extrinsic cues induce 
asymmetric divisions of NE cells that produce additional NE cells, as well as the radial glial 
cells, basal progenitor cells, and neurons, ultimately giving rise to the entire adult CNS 
(McConnell 1995).  Despite this essential role of NE cells in neural development, however, 
the mechanisms that regulate their maintenance and differentiation are still poorly 
understood and widely debated.   
Cell Cycle Regulation of Differentiation 
Throughout early neural development, NE cells must precisely regulate their cell 
cycles in order to produce enough cells to populate the adult CNS and defects in the 
generation and proliferation of NE cells can lead to neurological birth defects (Götz and 
Huttner 2005; Duparc et al. 2007).  Mice lacking expression of transcription factors with 
roles in cell cycle regulation exhibit early differentiation of neural stem and progenitor cells, 
which results in premature exhaustion of progenitor cell pools and microcephaly (Bedford 
et al. 2005; Ohnuma et al. 2001; Ohnuma and Harris 2003).  The role of the cell cycle in NE 
cells is not limited to regulating total NE cell numbers, however, as data also indicate that 
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the initiation of asymmetric divisions producing radial glial cells is tightly linked to cell cycle 
length (Takahashi et al. 1995).  In fact, numerous studies support a direct link between cell 
cycle length and the onset of asymmetric, differentiative divisions (Takahashi et al. 1995; 
Calegari 2003; Estivill-Torrus et al. 2002).  In one such study, cumulative BrdU labeling of 
Tis21-GFP mice demonstrated that cells expressing TIS21, a marker of neurogenic cell 
division, have a longer cell cycle than proliferating NE cells lacking TIS21 expression 
(Calegari 2005).  In a subsequent set of experiments based upon the knowledge that TIS21 
inhibits progression of the G1 phase of the cell cycle (Guardavaccaro et al. 2000; Matsuda 
et al. 2001), whole mouse embryos were cultured between E9.5 and E10.5 in the presence 
of olomoucine, a cell permeable CDK inhibitor that halts G1 progression, at a concentration 
adequate to lengthen G1 without inducing cell cycle arrest.  The authors found that this 
lengthening of G1 was sufficient to induce asymmetric, neurogenic cell division (Calegari 
2003), supporting previous studies showing that cell cycle length is directly coupled with 
neurogenesis.  Taken together, these data indicate an essential role for regulators of cell 
cycle progression in both the expansion of NE cell populations and the initiation of 
neurogenesis.        
Chromatin-mediated Regulation of Neural Differentiation 
Over the past decade, significant strides have been made in understanding the 
regulation of stem cell proliferation, maintenance, and differentiation.  A particularly 
important aspect of this research has been the investigation of cellular and molecular 
mechanisms that coordinate these processes, as we now know that they are not mutually 
exclusive (Götz and Huttner 2005; Hirabayashi and Gotoh 2010).  One such mechanism is 
chromatin-based transcriptional regulation.  As NE cells differentiate into more fate-
restricted progenitor cells and neurons, they are exposed to a variety of molecular signals 
that are essential to their identity and survival.  These signals modulate gene regulatory 
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networks involving thousands of potential downstream targets, meaning that the genome 
of these cells must be organized in a highly specific manner to respond efficiently to 
proliferative and differentiative cues.  Additionally, as the cells become more fate-restricted, 
they must effectively silence genes associated with other cell fates.  All of these functions 
appear to be coordinated, at least in part, by dynamic changes in chromatin structure 
induced by chromatin-modifying enzymes (Hirabayashi and Gotoh 2010). 
Proneural bHLH Genes and Neural Differentiation 
 Upon exit from the cell cycle, NE cells rapidly acquire a more differentiated neural 
fate due to the induction of neural transcriptional networks via the up-regulation of a family 
of basic helix-loop-helix (bHLH) transcription factors.  These proneural bHLH proteins, 
expressed in combinatorial patterns throughout the developing CNS, are necessary for all 
neural cell fates and are required throughout the differentiation of NSCs.  Importantly, 
expression of proneural bHLH genes in ectodermal progenitor cells is both necessary and 
sufficient to induce neural cell fate (Bertrand et al. 2002).  Proneural bHLH factors execute 
their functions by regulating key cellular processes and characteristics, including cell cycle 
progression and exit, Notch-mediated lateral inhibition, and cytoskeletal organization 
(Bertrand et al. 2002).  For example, one hallmark of neuronal specification and maturation 
is the process of neurite outgrowth, during which neurons extend multiple processes in 
order to determine the proper trajectory for axonal and dendritic extension (Conde and 
Cáceres 2009).  This requires dynamic changes in cytoskeletal organization that are 
orchestrated by microtubule associated proteins such as DCX and STMN2 (Nectoux et al. 
2012; Manna et al. 2007; Toriyama et al. 2012).  Proneural bHLH factors also function in cell 
cycle regulation, as several studies have shown that overexpression of proneural bHLH 
factors can promote cell cycle withdrawal via up-regulation and/or activation of certain 
CDK inhibitors, such as p27 and p21(Farah et al. 2000; Mizuguchi et al. 2001; Mutoh et al. 
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1998).  Considering the essential roles of proneural genes in neural specification and 
differentiation, identifying factors that regulate their transcription is of great importance for 
future studies aiming to successfully use neural stem cells for therapeutic applications.       
Specification and Patterning of the Mammalian Forebrain 
During primary neurulation, exposure of the neural ectoderm to signaling gradients 
causes regionalization into the embryonic precursors of the three regions of the adult brain 
(Colas and Schoenwolf 2001).  These regions in the embryonic brain, the prosencephalon, 
mesencephalon, and metencephalon, serve as precursors for the adult forebrain, midbrain, 
and hindbrain, respectively.  For the purpose of my studies, I will specifically focus on 
development of the prosencephalon, which gives rise to adult brain structures including the 
cerebral cortex, basal ganglia, nucleus accumbens, and thalamus.   
Specification of the Prosencephalon 
 Upon specification of neural tissue in the embryo, a number of patterning molecules 
and morphogens act in concert to begin regionalization of the nervous system along the A-
P axis.  The prosencephalon, which is the most rostral subdivision of the developing CNS, 
requires an extra-embryonic tissue known as the anterior visceral endoderm to induce the 
expression of several transcription factors in the neural tissue for prosencephalon 
specification (Thomas and Beddington 1996; de Souza and Niehrs 2000; Beddington and 
Robertson 1999).  These factors include Otx2 and Hesx1 and evidence indicates that their 
role is to inhibit posteriorizing factors - such as WNTs, FGFs, and retinoids - that actively 
repress a default anterior neural fate (Beddington and Robertson 1999). The WNT, FGF, 
and Retinoid pathways are inhibited by factors supplied by both the AVE and the node to 
drive the specification and maintenance of anterior neural identity (Rallu et al. 2002; Glinka 
et al. 1998; Bouwmeester et al. 1996).  Additionally, the inhibition of BMP signaling is 
required for specification of the anterior neural plate, as loss of the BMP inhibitors Noggin 
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and Chordin results in embryos lacking anterior neural tissue (Anderson et al. 2002).  
Together, this combination of inductive and repressive signals builds the foundation for 
further forebrain regionalization and patterning, beginning with specification of the two 
major prosencephalic domains, the telencephalon and diencephalon.  
Telencephalic Specification and Patterning 
 The telencephalon is the rostral-most region of the embryonic forebrain that gives 
rise to the cerebral cortex and striatum, structures responsible for functions including 
cognitive processing, sensory perception, motor control, motivation, and habit formation 
(Hébert and Fishell 2008).  As such, defects in telencephalic development can give rise to a 
vast array of neurological and neuropsychiatric disorders.  Telencephalic specification 
begins at ~E8.5 in mouse when expression of the Forkhead box gene Foxg1 delineates the 
primordial telencephalic tissue (Shimamura and Rubenstein 1997; Tao and Lai 1992).  In 
rapid succession, FOXG1 acts coordinately with ventral Sonic hedgehog (SHH) signaling to 
induce Fibroblast growth factor 8 (Fgf8) expression in the anterior neural ridge, setting up a 
complex set of morphogen gradients that begin to confer dorsal-ventral identity upon the 
telencephalic tissue (Figure 1.2a, left)(Martynoga et al. 2005).  In this section, I will discuss 
how these reciprocal interactions between morphogens and transcription factors result in 
specification of the domains necessary for proper development of the forebrain. 
Specification and Patterning of Dorsal and Ventral Telencephalon 
 Expression of Foxg1 begins a rapid process of regionalization of the telencephalon 
that generates a dorsal telencephalic domain referred to as the pallium, which will give rise 
to the cerebrum, hippocampus, and regions of the amygdala, and a ventral domain 
consisting of the medial, lateral, and caudal ganglionic eminences (Figure 1.2b, MGE, LGE, 
CGE).  All three of these ganglionic eminences give rise to distinct subsets of inhibitory 
interneurons that migrate to populate the cortex and basal ganglia, as well as giving rise to 
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cells of the striatum, amygdala, and limbic structures (Hébert and Fishell 2008).  The initial 
specification of these dorsal and ventral domains is the result of a gradient characterized 
by high ventral and low dorsal levels of the morphogen SHH (Figure 1.2a, left)(Echelard et 
al. 1993; Corbin et al. 2003).  This gradient is established through the antagonistic interplay 
between SHH and its negative regulator GLI3.  Gli3 expression initially marks the entire 
early telencephalon, but dorsal expansion of the Shh domain from its source at the ventral 
midline soon limits Gli3 expression to the dorsal telencephalon (Figure 1.2a, right)(Corbin et 
al. 2003; Aoto et al. 2002).  This morphogen gradient is required for proper development of 
the pallium and sub-pallium (ventral telencephalon) and studies of mice lacking both Shh 
and Gli3 indicate that SHH specifically acts to repress the dorsalizing effects of GLI3 in the 
ventral telencephalon (Persson et al. 2002).  This repression of Gli3 in the ventral 
telencephalon acts in conjunction with the ventralizing effects of FGF signaling, which is 
critical for subsequent patterning of the ventral telencephalon (Storm et al. 2006). 
Ventral Telencephalic Patterning 
 Patterning of the ventral telencephalon relies upon the effects of FGF signaling 
acting downstream of SHH.  Loss of Shh expression results in loss of the expression of 
multiple Fgf genes in the ventral telencephalon and additional studies have indicated that 
expression of Fgf receptor genes is required for the downstream ventralizing effects of SHH 
(Shanmugalingam et al. 2000; Gutin et al. 2006).  Additionally, it has been shown that the 
dorsal telencephalon can be converted to tissue with ventral gene expression in response 
to exposure to FGF8-soaked beads (Storm et al. 2006).  Through its antagonistic effects 
with respect to GLI3, SHH sets up a gradient of differential Fgf expression that gives rise to 
the MGE and LGE through expression of Nkx2.1 and Gsh2, respectively (Figure 1.2a, 
right)(Rallu et al. 2002).  Together, these studies have shown that ventral telencephalic 
patterning is established by FGF8 acting downstream of SHH. 
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Dorsal Telencephalic Patterning 
 As previously discussed, the dorsal telencephalon is specified by Gli3 expression, 
which functions to attenuate FGF signaling in the dorsal telencephalic region (Figure 1.2a).  
Dorsal telencephalic identity is reinforced by the transcription factor PAX6, which is first 
expressed broadly in the prosencephalon, but resolves to the dorsal telencephalon at 
~E9.0 in mouse (Inoue et al. 2000; Aoto et al. 2002).  By E9.5, expression of Pax6 ends 
abruptly at the pallial-sub-pallial border where it slightly overlaps with the Gsh2 expression 
domain, which marks the LGE (Figure 1.2b)(Corbin et al. 2003).  PAX6 and GSH2 mutually 
repress each other and, therefore, their proper expression is required for positioning the 
ventral boundary of the pallium (Corbin et al. 2003).  Pax6 expression appears in a gradient, 
with low levels of expression in the dorsal-most regions of the pallium and high levels in the 
more ventral regions and this expression pattern acts to maintain dorsal character in 
regions with decreasing Gli3 expression (Bishop et al. 2000).  Pallial identity is further 
reinforced by the transcription factor EMX2, which lies downstream of GLI3 and functions 
in conjunction with PAX6 to dorsalize the Gli3-expressing domain of the developing 
telencephalon (Yoshida et al. 1997).  Additionally, PAX6 and EMX2 act coordinately with 
COUP-TF1, NGN1, NGN2, and SP8 to pattern the precursor domains of the developing 
cortex (Figure 1.2b)(Bishop et al. 2002; 2000). 
 While PAX6 and EMX2 function to specify and maintain dorsal telencephalic 
identity, the patterning of the dorsal telencephalon results from ventral expression of the 
LIM homeodomain transcription factor LHX2 and dorsal expression of WNTs and BMPs.  
Lhx2 expression largely mirrors that of PAX6 and, as such, functions to specify the pallial 
regions that will go on to form the cerebral cortex and hippocampus (Figure 1.2b)(Peukert 
et al. 2011; Roy et al. 2014; Chou and O'Leary 2013).  The dorsal midline regions of the 
telencephalon, the cortical hem and choroid plexus, are patterned and maintained through 
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the activity of secreted WNT and BMP ligands, as well as LHX2 (Roy et al. 2014; Theil et al. 
2002).  BMP signaling specifically acts in the initial specification of dorsal midline tissues 
and its activity then drives expression and secretion of WNT ligands including WNT3a, 
which is required for maturation of the cortical hem, which acts on the hippocampal anlage 
(Caronia et al. 2010; Lee et al. 2000).  This WNT signaling can be visualized via the 
expression domain of the WNT effector gene Lef1 whose expression is restricted to the 
developing cortical hem and whose expression is reinforced by both EMX1 and EMX2 
(Shinozaki et al. 2004; Yoshida et al. 1997; Muzio et al. 2005).  These factors, which 
regulate and interact with many downstream signaling pathways, are capable of 
orchestrating the highly complex organization of the cortex, hippocampus, and cortical 
hem.      
Diencephalic Specification and Patterning 
The diencephalon lies caudal to the developing telencephalon and is the structure 
that will go on to become the epithalamus, thalamus, and hypothalamus.  These three 
structures function as a switchboard for the forebrain and are important for top-down 
sensory processing via their distribution of incoming sensory information to its 
corresponding cortical circuits (Scholpp and Lumsden 2010).  In mouse, the diencephalon 
is specified in the alar plate at the interface between a rostral domain of Fezf1/2 expression 
and a caudal domain of Irx1expression, though this domain is marked by Otx expression in 
some species (Scholpp et al. 2007; Acampora et al. 1997; Hirata et al. 2006).  The interface 
between these domains is referred to as the zona limitans intrathalamica (ZLI) or mid-
diencephalic organizer (MDO) and it acts as the organizing center of the diencephalon, with 
both mitogenic and patterning functions (Martinez-Ferre and Martinez 2012).  The 
predominant signaling molecule in the ZLI is the secreted morphogen SHH (Rash and 
Grove 2011) and its high levels regulate both the mitogenic and patterning functions (Rash 
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and Grove 2011; Himmelstein et al. 2010; Epstein 2012).  In mice, expression of SHH in the 
alar plate is responsible for early proliferation of diencephalic tissue and later specification 
of thalamic nuclei (Chatterjee et al. 2014; Rash and Grove 2011).  This domain must be 
restricted, however, as ectopic expression of Shh in the dorsal forebrain has been shown to 
result in significant expansion of diencephalic tissue and exencephaly (Epstein et al. 2000).   
In the early stages of diencephalic development, between ~E8.5 and ~E10.5 in 
mouse, SHH acts primarily as a mitogen, while at E10.5 and beyond, the predominant role 
of SHH switches to patterning the thalamic nuclei (Scholpp and Lumsden 2010; Hagemann 
and Scholpp 2012).  The rostral diencephalon (p3 domain) and a restricted domain just 
caudal to the ZLI (p2 domain) express high levels of the transcription factor Her6 and in 
these domains, SHH induces expression of Ascl1 (Mash1)(Scholpp et al. 2009). In more 
caudal regions of the diencephalon that lack Her6 expression, SHH induces expression of 
the bHLH transcription factor Neurog1 (Vue et al. 2007).  These expression domains give 
rise to GABAergic interneurons and excitatory glutamatergic relay neurons, respectively 
(Scholpp and Lumsden 2010).  SHH further patterns the diencephalon through promotion 
of the expression of Nkx2.2, Lhx2, Olig2, Olig3, and Gbx2 (Chatterjee et al. 2014; Epstein 
2012; Guinazu et al. 2007).  The complex interactions of these molecules, many of which 
are antagonistic, serve to differentiate many subtypes of neurons in the diencephalon, 
allowing the development of circuitry with inputs from and outputs to various regions of the 
brain.        
 Multiple signaling molecules, including FEZ, IRX, and WNT, and GLI3 are required to 
specify and shape the ZLI.  Experiments disrupting either Fez or Irx expression in the 
developing diencephalon have shown that these factors are required for establishing the 
lateral boundaries of the ZLI (Hirata et al. 2006; Scholpp et al. 2007).  Further experiments 
have shown that the domains flanking the alar plate express Gli3, which restricts rostral-
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caudal expansion of the ZLI through inhibition of Shh (Guinazu et al. 2007; Martinez-Ferre 
et al. 2013).  Prior to formation of the ZLI, Shh is only expressed in the tissue of the ventral 
midline.  Although specification of the ZLI appears to result from a dorsal expansion of Shh 
from this ventral source, numerous experiments have demonstrated that the ventral midline 
is disposable for alar Shh expression (Schier et al. 1996; Guinazu et al. 2007; Vieira and 
Martinez 2006).  Instead, data support a model whereby a domain of WNT signaling inhibits 
Gli3 expression in the alar plate, rendering the tissue competent for Shh expression (Figure 
1.3)(Martinez-Ferre et al. 2013).  However, it is still unclear how Shh expression is 
repressed in the dorsal-most region of the ZLI, which gives rise to the epithalamus.  One 
line of evidence suggests that the non-canonical retinoic acid synthesizing enzyme 
CYP1B1 is responsible, as ectopic expression is capable of inhibiting Shh (Chambers et al. 
2007; Guinazu et al. 2007).  However, a recent study showed that Cyp1b1-/- mice show only 
modest defects in diencephalic retinoic acid (RA) signaling and do not exhibit the expanded 
diencephalic tissue that would be expected from expansion of Shh in the ZLI (Cunningham 
et al. 2015).  However, several other studies that I will discuss later in this chapter indicate 
that RA signaling is essential for restricting expansion of the diencephalon through 
inhibition of Shh and its mitogenic effects (Molotkova et al. 2007; Lohnes et al. 1994).  
Retinoic Acid Signaling and its Role in Forebrain Development & Function 
Molecular Mechanisms of Retinoic Acid Signaling 
Retinoic acid is a metabolite of vitamin A that acts as a signaling molecule in a wide 
range of tissues.  Dietary RA is stored in the liver, as well as several other sites, and is 
transported as retinol to its sites of activity by the retinol binding protein RBP4 (Blomhoff 
and Blomhoff 2006).  RBP4 binds its receptor STRA6 on target cells, allowing uptake of 
retinol, which is then bound by RBP1 and converted to all-trans retinoic acid (ATRA) in a 
two-step process first mediated by RDH10 and then by the RALDH family of proteins 
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(Kawaguchi et al. 2007; Sandell et al. 2007; Maden 2007).  Once synthesized, ATRA binds 
cellular retinoic acid binding proteins 1 and 2 (CRABP1 and CRABP2), which mediate its 
intracellular activity, as well as its paracrine transport for signaling in nearby cells (Figure 
1.4)(Budhu and Noy 2002).  Activation of RA-responsive genes occurs through transport of 
ATRA to the nucleus by CRABP2 and binding of RA to one of three RA receptors (RARs), 
RARα, RARβ, or RARγ, at defined genomic loci called retinoic acid response elements 
(RAREs) (Balmer 2002).  RARs form heterodimeric complexes at RAREs with another set of 
receptors, the RXRs, and these binding events result in recruitment of transcriptional 
activators and subsequent transcription of downstream target genes (Tanoury et al. 2013).  
Transcriptional activation of target genes requires interaction of the RA complex with a 
number of transcriptional regulators and chromatin modifiers.  Previous studies have 
shown that RA transcriptional complexes associate with histone acetyltransferases such as 
CBP/p300 (Hou et al. 2015; Chakravarti et al. 1996), but it remains unclear whether the role 
of these enzymes is restricted solely to chromatin modification.  Although there are more 
than 10,000 predicted RAREs in mammalian genomes and at least 500 genes respond to 
RA signaling, less than 30 RAREs have been definitively shown to directly induce target 
gene transcription in response to RA complex binding (Maden 2007; Lalevee et al. 2011; 
Balmer 2002). 
While RA signaling has been intensely studied, there is still little known about its 
tissue-specific regulation in most of the tissues where it is active.  Although ATRA 
production is regulated in a tissue-specific manner through differential expression of the 
Raldh gene family, as well as several other putative RA-synthesizing enzymes, few studies 
have uncovered further mechanisms for regulating the differential effects of RA signaling on 
different tissues (Chambers et al. 2007; Blomhoff and Blomhoff 2006).  One such 
mechanism lies in the differential expression of RAR and RXR isoforms, which presumably 
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dictates differential RARE-binding in different cell types  (Yamagata et al. 1994).  
Furthermore, certain cell types have the ability to signal through RARs in a ligand-
independent manner, a process which is tightly regulated by inhibitory proteins that 
negatively influence target gene activation in the absence of ligand (Park et al. 2010).  
Nonetheless, genetic studies in mouse indicate that the regulation of cell type-specific RA 
signaling in the developing forebrain likely involves regulatory mechanisms that remain 
unknown (Lohnes et al. 1994; Cunningham et al. 2015; Molotkova et al. 2007; Fan et al. 
2003). 
Roles of Retinoic Acid Signaling in the Developing Forebrain 
Retinoic acid signaling plays an important role in both development and 
maintenance of the central nervous system (CNS)(Maden 2007), but its functions in early 
development of the forebrain are still disputed.  Numerous studies have now concluded 
that RA signaling is required for the specification of certain subtypes of cortical progenitor 
cells through its interaction with COUPTF1 (Siegenthaler et al. 2009; Harrison-Uy et al. 
2013).  Furthermore, activated retinoic acid receptors have been implicated in the migration 
and fate maintenance of layer V-III cortical neurons (Choi et al. 2014).  Lastly, defects in RA 
signaling have been linked to disrupted patterning and progenitor cell proliferation in the 
telencephalon (Rajaii et al. 2008).  Nonetheless, the high levels of RA synthesis in the early 
forebrain indicate that RA plays a wider role in its gross morphological development and 
patterning.  To address this, Lohnes et al. made compound mutants for RARα, β, and γ and 
analyzed the mutant embryos for gross defects in development.  While the data presented 
indicates severe disruption of forebrain development in RARα-/-; RARγ-/- mutants (tissue 
expansion, ventricular collapse, lengthening of the dorsal-ventral axis), the authors 
dismissed this phenotype as a secondary effect of hindbrain neural tube defects 
(exencephaly)(Lohnes et al. 1994).  Additional experiments performed by Molotkova et al. 
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concluded that retinoic acid signaling does not play a significant role in forebrain 
development in mice until E12.5 (Molotkova et al. 2007).  However, their experimental data 
appears to show a significant increase in diencephalic size in the absence of Raldh3, which 
they show is strongly expressed in the dorsal p3 and p2 domains of the diencephalon that 
flank the ZLI.  The authors, however, did not discuss this phenotype and concluded that RA 
signaling is largely dispensable for forebrain development.  The previously mentioned 
studies suggest but did not explore the possibility that RA may be the factor responsible for 
limiting dorsal expansion of Shh in the ZLI. As such these studies may have failed to 
recognize an important role for RA in the development of the forebrain.        
Roles of Retinoic Acid in the Adult Brain   
 Retinoic acid is produced and Rar and Rxr genes are expressed throughout the 
adult forebrain, indicating that RA signaling is important for forebrain function (Maden 
2007).  In addition to its roles in CNS development, retinoic acid is involved in several 
processes in the adult brain, including neuronal plasticity, function of the nigrostriatal 
system, neural stem cell differentiation, and injury repair. With respect to neuronal 
plasticity, numerous studies have illustrated that RA signaling components and active RA 
signaling are concentrated in areas of the brain that undergo high levels of plasticity, such 
as the dentate gyrus, hippocampus, and olfactory bulb (Jacobs et al. 2006; McCaffery et al. 
2006; Hägglund et al. 2006).  In support of these observations, disruption of RA signaling in 
songbirds impedes song learning, which is highly dependent on neuronal plasticity 
(Denisenko-Nehrbass and Mello 2001; Denisenko-Nehrbass et al. 2000).  Furthermore, 
disruption of RA signaling in rats impairs spatial and working memory through a process 
involving alterations in long-term potentiation (LTP) and long-term depression (LTD), which 
are reflective of synaptic plasticity(Chiang et al. 1998; Cocco et al. 2002; Etchamendy et al. 
2003).  Additionally, recent work has shown that RARα and RA synthesis are required for 
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the process of homeostatic plasticity, a mechanism of buffering circuit activity during 
prolonged periods of circuit disruption (Arendt et al. 2015). 
 RA activity is also important for dopaminergic function of the nigrostriatal system 
(Samad et al. 1997).  The dopamine D2 receptor contains a conserved RARE in its 
promoter that functions through the binding of an RARα/RXRγ heterodimer and RA-
mediated activity of this complex is required for Drd2 expression in differentiated neurons 
and during development (Molotkova et al. 2007; Valdenaire et al. 1998).  These data are 
supported by studies of mice lacking both Rara and Rxrg, which display locomotor defects 
with no apparent disruption of motor neurons of the peripheral nervous system (Krel 1998).  
Furthermore, data indicate that alcohol, a known RA antagonist, exacerbates nigrostriatal-
related diseases such as Parkinson’s (Krauss et al. 1991; Deltour et al. 1996; Laplane et al. 
1992).  Nonetheless, RA signaling defects have not been identified as causative factors in 
any neurological disease to-date (Bremner et al. 2012; Bremner and McCaffery 2008).  
However, the observed functions in multiple aspects of CNS development and function and 
the widespread production of RA in the brain suggest that it may serve as a valuable 
therapeutic target for specific CNS diseases and that some of these functions may be 
targeted through its interaction with GCN5.            
The GCN5 Acetyltransferase and its Functions 
SAGA, ATAC, and Histone Acetylation 
 In the previous section, I discussed the interactions between RAR complexes and 
histone modifying enzymes, including CBP/p300.  Another chromatin modifier that has 
been shown to interact with RARα is the acetyltransferase GCN5 (Brown 2003).  GCN5 
(Kat2a) was first identified in yeast as an enzyme capable of positively regulating 
transcription through the acetylation of multiple lysine residues on histone H3 (Grant et al. 
1999; Georgakopoulos and Thireos 1992; Brand et al. 1999).  GCN5 is as a member of the 
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SAGA (SPT-ADA-GCN5 acetyltransferase) and ATAC (ADA-Two-A containing) 
transcriptional complexes, which have genome-wide functions in both positive and 
negative regulation of transcription (Nagy et al. 2010).  Multiple studies indicate that these 
complexes are ubiquitously expressed, but that their activity is regulated in a tissue-
specific manner through differential association with co-factors, alterations in enhancer 
binding, and changes in subunit composition (Bhaumik 2011; Rodríguez-Navarro 2009).  
While little is known about ATAC function, experiments suggest that GCN5’s 
substrate specificity switches from residues on histone H3 to residues on histone H4 when 
incorporated into the ATAC complex, thus altering GCN5’s role in regulating transcription 
(Suganuma et al. 2008; Ciurciu et al. 2008).  Much more is known about the roles of GCN5 
within the SAGA complex, which is comprised of multiple subunits:  a HAT module 
consisting of GCN5 and ADA proteins, a deubiquitination (DUB) module consisting of UBP8 
and several SPT proteins, an SPT module important for the structural integrity of the 
complex, and a TAF module that mediates interaction with transcriptional machinery 
(Figure 1.5)(Weake and Workman 2011).  While GCN5 targets histone H3 residues for 
acetylation, the DUB module is responsible for ubiquitination of H2B, which has been 
linked to both positive and negative regulation of transcription (Zhang 2003).  Furthermore, 
GCN5 can be replaced within the HAT module by the structurally similar acetyltransferase 
PCAF, conferring additional means of regulating SAGA targets and functions (Wang et al. 
2008; Xu et al. 1998; 2000). 
 GCN5 is essential for proper embryonic development.  Gcn5-/- mice exhibit severe 
morphological defects by E7.5 and die by E10.5 after failing to specify dorsal mesodermal 
cell lineages (Xu et al. 2000).  The severity of the defects is due, in part, to the loss of GCN5 
functions beyond its acetyltransferase activity because mice expressing an enzymatically 
inactive form of GCN5 (Gcn5hat/hat) survive until E16.5 (Figure 1.6)(Bu et al. 2007).  
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Furthermore, the widespread apoptosis seen in the null mutants is not observed in 
Gcn5hat/hat embryos and is partially rescued by breeding the null mice on a p53-/- 
background, indicating that an acetylation-independent function of GCN5 function involves 
p53-dependent pathways (Bu et al. 2007).  Surprisingly, despite the fact that Gcn5 is 
expressed ubiquitously during development (except in the developing heart), Gcn5hat/hat 
mutants show relatively normal gross embryonic development.  Other than exhibiting 
developmental delay, the most striking defect in the development of Gcn5hat/hat embryos is 
fully penetrant exencephaly accompanied by significant overgrowth of neural tissue (Figure 
1.6d).  These mice, initially generated by the laboratory of Dr. Sharon  Dent, were examined 
for defects in numerous pathways that are typically disrupted in mutants with neural tube 
defects, but these studies were unable to identify the basis of the observed CNS 
malformations (Bu et al. 2007).  Nonetheless, their studies strongly implicated GCN5 
enzymatic activity in mammalian CNS development.            
Histone-independent Functions of GCN5 
 GCN5 was first identified as a histone acetyltransferase that deposits activating 
modifications on histones to positively regulate transcription. However, like many 
chromatin-modifying enzymes we now know that GCN5 acts on numerous non-histone 
proteins.  The first evidence of non-histone substrate acetylation by GCN5 came when 
Jacob et al. demonstrated that GCN5-mediated acetylation of the orphan nuclear receptor 
steroidogenic factor-1 (SF-1) positively regulates its activity (Jacob 2001).  Other lines of 
evidence support a role for GCN5 in the acetylation-induced repression of PGC-1α, which 
is a key regulator of gluconeogenesis (Lerin et al. 2006; Sakai et al. 2012; Carradori et al. 
2011).  These results importantly showed that analysis of transcriptional changes in the 
absence of GCN5 cannot be performed simply in the context of losing transcriptional 
activation, as would be suggested by GCN5’s role in the deposition of activating chromatin 
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modifications.  This conclusion was further supported by an elegant set of experiments that 
showed an interaction between GCN5 and the molecular chaperone p23 and demonstrated 
that this interaction results in GCN5-catalyzed acetylation of transcription factors resulting 
in their dissociation from target promoters.  This repressive function of GCN5 was shown in 
yeast, mouse, and human cells and acts upon a diverse set of transcription factors (Zelin et 
al. 2012).  Lastly, emerging studies have shown that GCN5 may play a role in regulating the 
cytoskeleton through direct acetylation of the microtubule subunit alpha tubulin and that 
this activity is capable of promoting muscle differentiation (Conacci-Sorrell et al. 2010; 
Friedmann et al. 2012; Kormendi et al. 2012).  Together, these lines of research strongly 
support additional roles for GCN5 in organismal development and cell biology through 
acetylation of non-histone proteins. 
Functions of GCN5 in Neural Progenitor Cells 
 Little is known about what role GCN5 may play in neuroepithelial cell biology, but 
one study indicated that GCN5 regulates broad transcriptional networks required for their 
proliferation and differentiation (Martínez-Cerdeño et al. 2012).  The authors crossed mice 
carrying a floxed Gcn5 allele with mice carrying Cre recombinase driven by the Nes 
promoter to drive deletion of Gcn5 specifically in neural stem cells.  In these mice, Nes-Cre 
is activated at ~E11.0, after the time of neural tube closure and early forebrain patterning 
and development.  The authors found that mice lacking Gcn5 in NSCs exhibit a significant 
decrease in hindbrain volume caused by decreased proliferation and differentiation of 
NSCs.  Furthermore, microarray analysis revealed significant overlap between the genes 
disrupted in mutants and those disrupted in mice lacking the transcription factor N-Myc.  
While preliminary, their results indicate that GCN5 may act in conjunction with the N-Myc 
complex to regulate its downstream function, presumably through chromatin modification 
(Martínez-Cerdeño et al. 2012; Knoepfler et al. 2006; Zhang et al. 2014). 
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A Potential Role for GCN5 in RA Signaling 
 As previously discussed, Gcn5hat/hat embryos exhibit significant neuroepithelial 
expansion as early as E10.5 (Bu et al. 2007).  Further examination of these mutants shows 
that the expansion occurs in both the observed thickness of the neuroepithelium and its 
dorsal-ventral length.  In the previous section, I discussed a proposed role for RA signaling 
in the restriction of ZLI expansion and, therefore in limiting diencephalic size.  Because 
GCN5 and the SAGA/ATAC subunit ADA3 have been implicated in retinoic acid signaling, it 
is therefore possible that the neuroepithelial expansion observed in Gcn5hat/hat mutants 
results from decreased RA signaling and diencephalic overgrowth (Li et al. 2010; Brown 
2003). Published work in avian models has implicated RA signaling in restriction of Shh 
expression in the developing diencephalon; however this has not been tested in mammals 
(Chambers et al. 2007).  Additionally, experiments implicating GCN5 in RA signaling were 
not performed in neural tissue.  In Chapter 3, I present evidence for a novel mechanism of 
RA signaling in the murine diencephalon that involves a novel, histone-independent 
function of the acetyltransferase GCN5 and is required to limit diencephalic expansion 
during early development of the CNS. 
Roles of GCN5 in the Adult Brain 
 As previously discussed, GCN5 is expressed ubiquitously throughout life and plays 
genome-wide roles in transcription, while playing additional roles in regulating cellular 
function through the acetylation of non-histone proteins.  The past decade has seen great 
strides in our understanding of the development and function of the brain and a particular 
topic of interest has been the role of chromatin modifications.  Beyond regulating neural 
differentiation, however, chromatin modifications are also important for the long-term 
changes in neuronal activity associated with plasticity, learning, and addiction (Dulac 2010).  
With respect to these processes, GCN5 has been implicated in memory consolidation and 
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plasticity in the hippocampal CA1 region (Stilling et al. 2014).  Furthermore, a recent study 
showed that early maternal separation of mice can lead to dysregulation of histone 
modifiers, including Gcn5, in the medial prefrontal cortex throughout life (Pusalkar et al. 
2015).  Beyond these functions, however, the role of GCN5 in the adult forebrain is unclear.  
Interestingly, with respect to the histone-independent functions of GCN5, studies of α-
tubulin acetyltransferases including αTAT1 and MEC17 have indicated that disruption of 
these proteins can lead to neuronal migration defects and axon guidance defects (Akella et 
al. 2010; Li et al. 2012; Kim et al. 2013).  Because GCN5 has been shown in multiple 
studies to acetylate α-tubulin, it is possible that it plays additional roles related to α-tubulin 
function in processes such as neuronal migration, axon guidance and synaptic plasticity 
that require rearrangement of the cytoskeleton in the adult brain (Liu et al. 2013; Conacci-
Sorrell et al. 2010).  Together, these studies indicate that GCN5 has important roles in the 
forebrain and in the regulation of complex behavior. As such, deficits in GCN5 function has 
the potential to be implicated in neuropsychiatric disease and thus warrants increased 
attention. 
The Cortico-striato-thalamo-cortical Loop 
Structures and Circuitry 
 The mammalian forebrain is a highly interconnected and complex structure that is 
responsible for complex cognitive functions, interpretation of sensory stimuli, motivation, 
action selection, habit formation, and numerous other functions.  These processes are 
carried out through computational methods involving the integration of multiple signals 
through defined circuits that allow for top-down processing of information, propagation of 
computational results, and feedback mechanisms to control activity (Shepherd 2013).  One 
such circuit that is important for motivation, action selection, habitual behavior, and 
sequence learning is the cortico-striato-thalamo-cortical (CSTC) loop (Figure 1.7).  As 
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suggested by its name, this circuit involves unidirectional flow of information from cortical 
fields via monosynaptic intratelencephalic (IT) projections to the striatum, where information 
is processed through polysynaptic downstream connections with structures of the basal 
ganglia and thalamus (Shepherd 2013; Pauls et al. 2014).  This can occur through two 
pathways: (1) a direct pathway connecting the striatum to the thalamus via the globus 
pallidus interna and substantia nigra and (2) an indirect pathway connecting the striatum to 
the thalamus through the globus pallidus externa and subthalamic nucleus (Pauls et al. 
2014).  Thalamic efferents then relay information back to the cortex, allowing for fine-tuning 
of cortical activity, activation of motor circuits, and input of feedback information into the 
loop (Smith et al. 2014).  An additional set of multisynaptic cortical outputs, referred to as 
pyramidal tract (PT) neurons, feeds into this circuit to modulate its activity while 
simultaneously projecting to the brainstem and associated areas to regulate complex 
behavior through directed motor control (Levesque et al. 1996; Kita and Kita 2012). 
 Within the CSTC loop lie a subset of microcircuits important for computation, fine-
tuning of activity, and buffering of noise.  These connections are arranged hierarchically, 
allowing for serial processing of computed information within the loop (Kiritani et al. 2012; 
Morishima and Kawaguchi 2006).  Nonetheless, recurrent connections within local circuits 
allows for temporary information storage, as well as signal integration, amplification, and 
distribution (Morishima and Kawaguchi 2006; Douglas et al. 1995; Lübke et al. 2000).  This 
circuitry is important, as it allows for the integration of numerous inputs to a single 
microcircuit and subsequent propagation of this information to multiple outputs.  Through 
this process, output regions can be differentially regulated through threshold-mediated 
interpretation of activity from multiple upstream regions (Shepherd 2013).  Furthermore, 
because this forebrain circuit feeds back upon itself, both through thalamic output to the 
cortex and through PT neuron-mediated regulation of IT neurons, it is able to perform 
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highly complex calculations in an extremely precise manner, allowing for coordinated and 
reproducible regulation of complex behavior.      
Excitation, Inhibition, and Modulation  
All cortical outputs in the CSTC loop, whether IT or PT, are excitatory 
(glutamatergic) and, as such, propagate signals through activation of downstream neurons 
(Reiner et al. 2010).  In the case of PT outputs, a single glutamatergic projection can 
synapse with multiple downstream neurons in the striatum, thalamus, brainstem, and spinal 
cord (Kita and Kita 2012).  IT neurons, on the other hand, synapse with either striatal 
neurons or cortical glutamatergic neurons within the CSTC pathway (Reiner et al. 2010).  As 
mentioned in the previous section, there is hierarchical ordering within both the local and 
global neuronal circuits and this ordering is conserved with respect to IT-PT connections.  
While IT neurons synapse onto PT neurons to regulate their activity, PT neurons only 
project to regions outside of the cortex, suggesting that PT neurons lie downstream of IT 
neurons with respect to signal processing and propagation (Shepherd 2013).  Furthermore, 
IT and PT neurons are differentially regulated by dopamine, with IT neurons specifically 
expressing the D1 dopamine receptor and PT neurons specifically expressing the D2 
receptor (Gaspar et al. 1995).  The utilization of multiple distinct and/or combinatorial 
regulatory pathways in the regulation of these circuits adds both computational power and 
resistance to natural variation, again promoting precise and reproducible reactions to 
external stimuli.    
The striatum, which can be separated into dorsal and ventral compartments, is 
primarily comprised of inhibitory GABAergic neurons called medium spiny neurons (MSNs) 
(Graybiel et al. 1994).  The dorsal striatum, which can be further separated into two 
structures referred to as the caudate nucleus and putamen, is primary responsible for 
motor control and executive function.  The ventral striatum, mainly consisting of the 
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nucleus accumbens, is the primary brain structure responsible for motivation and reward 
perception, although the dorsal striatum plays a role in these functions, as well (Graybiel et 
al. 1994; Ferré et al. 2010).  MSNs from both regions of the striatum are regulated by 
multiple mechanisms, including excitatory input from the cortex and neuromodulatory input 
from within the striatum (Menegas et al. 2015; Reiner et al. 2010; Shepherd 2013).  MSNs 
come in three types based on their expression of specific dopamine receptors.  D1-MSNs, 
which regulate thalamic activity through the direct pathway, express D1 dopamine receptor 
while, conversely, D2-MSNs express the D2 dopamine receptor and regulate the indirect 
pathway of thalamic regulation.  A third type of MSN expresses both D1 and D2 receptors, 
though their function is not well understood (Lobo and Nestler 2011; Pauls et al. 2014).  As 
this pattern of dopamine receptor expression suggests, MSNs are strongly regulated by the 
neuromodulator dopamine, which is primarily supplied to the striatum by the substantia 
nigra pars compacta (Menegas et al. 2015).  Additional neuromodulation in the striatum is 
provided by a population of cholinergic neurons, largely localized to the dorsal structures 
(Xu et al. 2015).  Furthermore, the striatum is regulated by a number of inhibitory 
interneuron subtypes that function to tune signal strength within the striatum (Tepper et al. 
2010). 
While the thalamus consists of many different cell types, its primary effector 
neurons are excitatory efferents that project to both the cortex and striatum (Molnar et al. 
1998).  The thalamus acts as a switchboard within the forebrain, disseminating sensory 
information to the proper regions for processing and decision-making (Scholpp and 
Shimogori 2013).  Through the process of receiving inputs from both the CSTC loop, as 
well as the cortex itself, the thalamus allows integration of new sensory information to fine-
tune decision making and action selection (Scholpp and Shimogori 2013; Grant et al. 2012).  
Most of this integration of bi-directional information occurs through a thin layer of poorly 
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understood GABAergic neurons called the thalamic reticular nucleus (TRN) (Lam and 
Sherman 2011).  The TRN’s ability to interact with both thalamic input and output relay cells 
and its strong inhibitory properties therefore suggest that it acts as a gating mechanism to 
filter information arriving at and leaving the thalamus (Pinault 2004).  Nonetheless, the 
output of the thalamus back to the cortex is excitatory in nature and serves to activate 
cortical neurons for downstream functions in sensory perception, action selection, 
cognition, and complex behavior.  Through these connections, the CSTC forms a positive 
feedback loop on itself that enables and reinforces its diverse roles in forebrain function. 
Roles of the CSTC Loop in Behavior and Neuropsychiatric Disease 
The CSTC loop is important for the regulation of complex behaviors via its role in 
the integration of activity from multiple forebrain regions that are necessary for diverse 
cognitive processes.  Up until several years ago when optogenetic techniques became 
widely tractable, the study of circuit function in the mammalian brain was extremely 
difficult.  As such, most of our knowledge of the role of the CSTC loop in behavior comes 
through our understanding of neuropsychiatric disorders characterized by dysfunction of 
specific modules of the CSTC pathway.  Recent studies, as I will discuss, have confirmed 
these causal relationships and emerging integrative approaches to behavior and circuits 
has provided significant insight into our understanding of the forebrain and its functions.   
One of the most intensively studied functions of the CSTC loop is its role in habitual 
behavior.  One of the main IT inputs to the striatum originates in a region of the prefrontal 
cortex called the orbitofrontal cortex and hyperactivity of this region has been strongly 
implicated in obsessive-compulsive disorder (OCD) etiology (Beucke et al. 2013; Harrison 
et al. 2009).  These phenotypes have been observed in human fMRI studies and have been 
confirmed via immunohistochemistry for persistent neuronal activation in mouse models of 
OCD (Harrison et al. 2009; Shmelkov et al. 2010).  Studies of mice lacking the post-
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synaptic density protein SAPAP3 indicate that defects in cortical glutamatergic 
transmission and subsequent activation of GABAergic neurons in the striatum are causative 
of the repeated behaviors seen in OCD, and lentiviral re-expression of Sapap3 specifically 
in the striatum is capable of rescuing the phenotype (Welch et al. 2007; Wan et al. 2014).  
More recent studies have shown that optogenetic activation of the lateral OFC to striatum 
pathway is capable of rescuing OCD-like behaviors in mice (Burguière et al. 2013).  
Although the striatum itself is thought to be the relevant structure for habit formation itself, 
these and other studies suggest that the CSTC loop is important for controlling gating 
mechanisms of these behaviors (Smith and Graybiel 2013; Graybiel et al. 1994).  In other 
words, the CSTC loop acts as a filter for habitual behaviors by regulating the level of striatal 
activity through the activation of inhibitory MSN activity.  In the absence of strong cortical 
input, inhibitory signals from the striatum to the thalamus are decreased, leading to 
increased glutamatergic activity between the thalamus and cortex.  This, in turn, leads to 
increased CSTC loop activity and amplifies repetitive behaviors to a pathological level 
(Smith and Graybiel 2013; Pauls et al. 2014; Milad and Rauch 2012). 
CSTC circuitry has been further implicated in a number of other neuropsychiatric 
diseases, including Tourette’s syndrome, Parkinson’s disease, and autism spectrum 
disorders (ASDs) (Xu et al. 2015; Shepherd 2013).  Recent studies have indicated that 
cholinergic neurons in the dorsal striatum are required for modulation of striatal MSN 
activity and that loss of these neurons results in tic-like phenotypes in mice that resemble 
Tourette’s syndrome (Xu et al. 2015).  Similar observations have been made with respect to 
dopaminergic modulation of striatal circuits, as the dopamine system is heavily implicated 
in the onset and progression of motor phenotypes associated with Parkinson’s disease 
(Hegarty et al. 2013; Strafella et al. 2005).   
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Autism spectrum disorders are heterogeneous group of behavioral disorders 
defined by social behavior deficits, stereotyped behaviors, and limited interests (Sahin and 
Sur 2015).  While the underlying genetic contributions to these diseases are complex, with 
more than 70 genomic loci associated with their presentation, defects in CSTC circuitry are 
now thought to underlie disease phenotypes (Sanders et al. 2015).  Social withdrawal is a 
common behavior seen in patients with ASDs and clinical studies suggest that hyperactivity 
of sensory pathways is partially to blame.  As previously mentioned, the CSTC loop is 
important for sensory perception and integration of sensory information into circuits 
relevant for action selection and complex behavioral responses to stimuli.  One hypothesis 
that has been supported by human behavioral and imaging studies suggests that social 
withdrawal in ASD patients is due to overstimulation of sensory circuits that integrate with 
circuits regulating social behavior via the CSTC loop (Green et al. 2015).  This results in an 
inability to properly interpret sensory stimuli, particularly in cases where multiple stimuli are 
encountered, leading to anxiety and social withdrawal.  Furthermore, mutations in the 
promoter of the autism-implicated gene Met, which is specifically expressed in IT neurons 
of the CSTC loop, result in an increased response to social stimuli and disruption of IT 
neuron connectivity (Rudie et al. 2012).  Additional studies of autism-associated genes that 
are specifically expressed in CSTC loop, including Shank1 and Shank3, which is disrupted 
in the autism-like Phelan-McDermid Syndrome, indicate that disruption of these circuits 
results in pronounced social behavior defects (Wurzman et al. 2015; Peca et al. 2011; 
Speed et al. 2015).   
With respect to the stereotyped behavior observed in ASDs, mouse models based 
on human mutations identified in patients with ASDs suggest a corticostriatal basis.  The 
previously mentioned Shank1 and Shank3 mouse models of autism show significantly 
increased repetitive behavior and evidence of self-injury (Peca et al. 2011; Speed et al. 
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2015; Wurzman et al. 2015).  Similar phenotypes are observed in mice carrying mutations in 
Ephb, which has also been implicated in autism etiology through human genetic studies 
(Wurzman et al. 2015).  Repetitive behaviors are observed in mice lacking Cntnap2, a 
synaptic gene associated with autism, and Nl3 (neuroligin-3), an autism-associated gene 
involved in synaptic adhesion (Peñagarikano et al. 2011; Rothwell et al. 2014).  In the case 
of Cntnap2 mutants, the repetitive behaviors can be ameliorated through the administration 
of the atypical antipsychotic Risperidone, which primarily targets the receptors of 
neuromodulatory neuropeptides and neurotransmitters enriched in the CSTC loop 
(dopamine, serotonin, etc.)(Peñagarikano et al. 2011).  These conclusions have been 
supported by human imaging studies that have shown an inverse correlation between 
caudate size and repetitive behavior and self-injury in autistic patients (Wolff et al. 2013).  
Taken together, these data support a causative role for CSTC dysfunction in the 





Figure 1.1 – Neural Induction and Primary Neurulation 
(a) A schematic diagram of the positions and fates of ventral mesoderm (pink), epidermis 
(yellow), neural tissue (blue), the organizer (red; node in mouse), and yolky endoderm 
(green) in a blastula-stage embryo (V, ventral; D, dorsal).  Red lines indicate BMP inhibition, 
depicted on the right.  Chordin, Noggin, and Follistatin inhibit epidermal and mesodermal 
BMP signaling to stabilize neural fate [panel reproduced, with permission, from (Stern 
2005)]. (b) Schematic of neural induction in the mouse embryo beginning at E6.0.  Light 
blue represents the pre-neural state, which is followed by formation of the node (red).  
Node formation allows induction of neural fate and specification of neural structures, 
beginning with the anterior CNS (blue).  By E7.5, future forebrain (FB, blue), midbrain (MB, 
light blue), and hindbrain (HB, light blue) have been specified.  Disappearance of the 
primitive streak (orange) corresponds with specification of spinal cord (SC, turquoise) and 
also marks the beginning of the process of primary neurulation [panel reproduced, with 
permission, from (Levine and Brivanlou 2007)]. (c) Schematic of neural tube closure 
beginning at the top with the flat neural plate stage.  As primary neurulation progresses, the 
flat neural plate (green) elevates into two neural folds via the formation of hingepoints.  The 
neural folds undergo apposition and neural tube closure completes with meeting and 
remodeling of the tissue to form a closed neural tube covered by non-neural ectoderm 




Figure 1.2 – Patterning and Specification in the Telencephalon 
(a) The dorsal and ventral subdivisions of the embryonic mouse telencephalon at embryonic 
day (E) 9.0 (a), and the fourbroad subdivisions at E10.0 (b). In both schematics, dorsal is 
up, ventral is down. The Gli3-expressing dorsal region at E9.0 is split, by E10.0, into a Bone 
Morphogenetic Protein (BMP)- and Wingless/Int protein (WNT)-expressing medial region 
and a more lateral cortical region that expresses countergradients of Empty Spiracles 
Homeobox 2 (Emx2) and Paired Box 6 (Pax6). The ventral region at E9.0 is split, by E10.0, 
into medial Nkx2.1-expressing domains and lateral Gsh2-expressing domains. At E10.0 the 
expression domain of Gsh2 overlaps with that of Nkx2.1; this is not represented for the 
sake of illustrative simplicity. Similarly, Sonic Hedgehog (Shh), Fibroblast Growth Factor 
(FGF) and Forkhead Box G1 (Foxg1) expression at E10.0 is omitted. (b) Factors that act 
early to establish broad telencephalic regions are shown in blue. SHH ventralizes the 
telencephalon by antagonizing the dorsalizing effect of GLI3. By repressing Gli3, SHH, 
together with FOXG1 activates FGF expression. FGF might feedback and promote Foxg1 
expression (dotted arrow). FOXG1 and FGF signaling are necessary for forming all regions 
of the telencephalon (green), except for the dorsomedial region (orange). Downstream 
transcription factors, such as GSH2 and NKX2.1, then form specific subdivisions. In the 
dorsal telencephalon, GLI3’s promotion of the expression of BMPs and WNTs is required 
for EMX-gene expression. The products of the EMX genes, along with PAX6 and LHX2, 
further subdivide the dorsal telencephalon. LGE, lateral ganglionic eminence; MGE, medial 
ganglionic eminence [figure reproduced, with permission, from (Hébert and Fishell 2008)]. 
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Figure 1.3 – Signaling Pathways in Diencephalic Development 
At E9.5, SHH signaling (yellow) in the alar plate extends dorsally and expands diencephalic 
tissue.  Dorsal WNT signaling (red) extends ventrally and acts to suppress GLI3, thereby 
rendering the ZLI (yellow and red) competent for Shh expression.  At the same time, GLI3 
antagonizes SHH and shapes the ZLI domain, acting as a necessary factor for border 



















Figure 1.4 – An Overview of Retinoic Acid Signaling 
Retinol, bound to retinol-binding protein 4, plasma (RBP4), is taken up by cells through a 
membrane receptor (STRA6) that interacts with the RBP4. In embryos, retinol 
dehydrogenase 10 (RDH10) metabolizes retinol to retinaldehyde (Ral), which is then 
metabolized to retinoic acid (RA) by retinaldehyde dehydrogenases (RALDHs). RA can be 
released from the cytoplasm and taken up by the receiving cell (paracrine signaling), or can 
act back on its own nucleus (autocrine signaling). Cellular retinoic-acid-binding protein 2 
(CRABP2) assists RA entry into the nucleus. In the nucleus, RA binds to RA receptors 
(RARs) and retinoid X receptors (RXRs), which themselves heterodimerize and bind to a 
sequence of DNA that is known as the retinoic acid-response element (RARE). This binding 
activates the transcription of target genes. RA is catabolized in the cytoplasm by the 
CYP26 class of P450 enzymes [figure reproduced, with permission, from (Maden 2007)]. 
 35 
 
Figure 1.5 – Functions and Disease Associations of SAGA and ATAC Modules 
The modular structure and composition is based on a model of yeast SAGA. In contrast to 
SAGA, the physical relationships between subunits in ATAC are less well defined. This 
figure only summarizes the presence of subunits, not their arrangement within ATAC.  The 
modules are indicated by the following color codes: red, HAT module; purple, DUB module; 
orange, SPT module; grey, TAF module; and green, ATAC-specific unit. The disease 
implications are based on studies using mammalian cells or mouse model systems, as well 
as from human patient samples. (DUB: Deubiquitination; HAT: Histone acetyltransferase; 










Figure 1.6 – Disrupted CNS Development in Gcn5hat/hat Embryos 
(a) Assay of acetyltransferase activity of Gcn5 HAT mutations expressed in bacteria with 
wildtype GCN5 set to 100%. (b) Western blots performed on protein isolated from MEFs 
derived from E13.5 Gcn5+/+, Gcn5hat/+, and Gcn5hat/hat embryos indicate decreases in 
acetylated H3K9,18 and acetylated H4K12, but not acetylated H3K14.  (c) Western blots 
indicate that Gcn5hat mutants produce wildtype levels of full-length GCN5. (d) Wildtype (left) 
and Gcn5hat/hat (right) embryos at the indicated stages illustrate developmental delay and 












Figure 1.7 – The Cortico-striato-thalamo-cortical Loop 
Pyramidal tract (PT) excitatory neurons originating in the cortex project to the brainsteam 
and spinal cord, with multisynaptic outputs to the cortex and other CSTC targets.  
Intratelencephalic (IT) excitatory neurons form either local connections with cortical IT or PT 
neurons or synapse onto cells within the striatum.  Striatal outputs of the direct pathway 
(D1 MSNs) modulate thalamic activity through inhibition of targets in the globus pallidus 
interna (GPi) and substantia nigra (SNr), while D2 MSNs of the indirect pathway activate the 
GPi and SNr through repression of the globus pallidus externa (GPe) and subthalamic 
nucleus (STN).  Thalamic efferents either connect with striatal targets or activate cortical 















A ROLE FOR GCN5 IN NEURAL TUBE CLOSURE AND THE PROGRESSION OF 
NEURAL DIFFERENTIATION IN THE DEVELOPING FOREBRAIN 
Introduction  
 Previous studies performed by the laboratory of Dr. Sharon Dent at MD Anderson 
revealed a specific requirement for GCN5 enzymatic activity in the process of cranial neural 
tube closure, but their initial experiments were unable to determine the cellular and 
molecular basis of this function (Bu et al. 2007).  While their studies of Gcn5-null embryos 
suggested a specific requirement for GCN5 in development of mesoderm, their 
experiments using Gcn5hat/hat mice showed no signs of disruption in this tissue layer.  In 
fact, additional experiments suggested that the mesodermal defects in null embryos arise 
from a p53-dependent function of GCN5 that does not require its acetyltransferase activity.  
In the experiments outlined in this chapter, I will describe preliminary work investigating the 
functions of GCN5 acetyltransferase activity in both neural tube closure and neuroepithelial 
cell biology and will propose hypotheses that can serve as the foundation for future studies 
of Gcn5hat/hat embryos. 
Materials and Methods 
Mouse Strains and Genotyping 
All mice were maintained according to protocols approved by the UC Denver 
Institutional Animal Care and Use Committee.  Gcn5hat/+ heterozygous mice have been 
described by the Dent lab (Bu et al. 2007). This strain was created by targeted generation 
of E568A and D609A mutations. Analysis of patterning and proliferation during the time of 





Wildtype and Gcn5hat/hat embryos (n=6 per genotype) between 19 and 22 somites 
were dissected and head tissue was removed and snap frozen in liquid nitrogen.  Samples 
were stored at -80°C until the time of RNA extraction.  All RNA extractions were performed 
simultaneously.  Briefly, tissue samples were removed from the -80°C freezer, placed on 
ice, and resuspended in cold Trizol reagent (Life Technologies).  Following Trizol extraction, 
RNA samples were processed with the RNeasy Micro Kit (Qiagen) according to 
manufacturer’s instructions.  RNA quality was assessed using the 2100 Bioanalyzer 
(Agilent) and high-quality RNA was used for microarray analysis on the Mouse Gene Chip 
1.0ST (Affymetrix) according to manufacturer’s protocols.  Microarray data were analyzed 
using Ingenuity iReport (Qiagen).  
Immunohistochemistry 
Embryos were fixed for 30 minutes at room temperature in 4% paraformaldehyde 
(PFA) and placed in 30% sucrose overnight at 4°C on a nutator.  Heads were embedded in 
O.C.T. Compound (Tissue-Tek) and frozen on dry ice before storage at -80°C.  14µm 
cryosections were cut on a Leica CM3050S and mounted on Superfrost Plus slides (Fisher).  
For immunostaining, slides were dried for 30 minutes at room temperature, subjected to 
heat mediated antigen retrieval in sodium citrate buffer (10mM sodium citrate, pH 6.0) for 
12 minutes, blocked for 1 hour at room temperature, and stained with primary antibody 
overnight at 4°C.  Secondary antibody staining was performed for 1 hour at room 
temperature and slides were mounted using Dako Faramount mounting media (Dako).  The 
following Alexafluor (Life Technologies) secondary antibodies were used at 1:250 in 
blocking buffer for 1 hour at room temperature: 488 goat anti-rabbit IgG (H+L), 488 goat 
anti-mouse IgG (H+L), 555 goat anti-rabbit IgG (H+L), 555 goat anti-mouse (H+L).  Scale 
bars were added using FIJI (Schindelin et al. 2012) and brightness, contrast, and color 
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levels were adjusted using Adobe Photoshop CS5 (Adobe Systems).  Antibody-specific 
conditions and antibody information can be found in Table 2.2. 
Cell Culture 
NE-4C cells (ATCC) were grown at 37°C and 5% CO2 in MEM (Invitrogen) 
supplemented with 5% FBS, 1X MEM non-essential amino acids (Invitrogen), and 1X 
GlutaMax (Invitrogen).  For differentiation experiments, cells were treated with either DMSO 
(1:1000) or all-trans retinoic acid (Sigma; 1µM) for 48 hours at 37°C and 5% CO2.  Inhibition 
of GCN5 was achieved using the designated concentrations of MB-3 (Sigma).  Following 
drug treatment, cells were washed twice with growth medium and grown until the indicated 
timepoints before processing for subsequent experiments.  For experiments involving 
differentiation and long-term culture, cells were seeded at 1.0x105 cells per well in 24-well 
plates onto round coverslips coated with poly-L-lysine (Sigma) and laminin (Invitrogen). 
Western Blotting and Quantitative Imaging 
Western blot experiments were performed as previously described (Chen et al. 
2014).  Primary antibody incubations were performed overnight at 4°C on a rocking 
platform.  Primary antibodies used were:  Rabbit anti-cyclin D1 (Thermo, RB-212-P, 1:100), 
Mouse anti-beta-tubulin (Sigma, T4026, 1:1000), Mouse anti-p21 (BD Pharmigen, 556431, 
2µg/mL), and Rabbit anti-TIS21 (Bioss, bs-0031R, 1:100).  Western blots were visualized on 
an Odyssey CLx (LiCor) with the following LiCor secondary antibodies:  IRDye 650 goat 
anti-mouse IgG (H+L), IRDye 650 goat anti-rabbit IgG (H+L), IRDye 800CW goat anti-
mouse IgG (H+L), and IRDye 800CW goat anti-rabbit IgG (H+L).  Western blots were 
quantified using Image Studio software (LiCor).  
Immunocytochemistry 
Cultured NE-4C cells were grown on coverslips treated with poly-L-lysine and 
mouse laminin (Invitrogen).  At the time of processing, media was aspirated and cells were 
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washed once with ice-cold 1X PBS.  Cells were fixed for 10 minutes at 4°C with ice-cold 
methanol and then washed 3 times for 5 minutes at room temperature with 1X PBS.  Cells 
were blocked for 1 hour at room temperature with appropriate blocking buffer and 
incubated at 4°C overnight with primary antibody diluted in blocking buffer.  Cells were 
washed 3 times for 5 minutes each at room temperature and then stained with secondary 
antibody (1:500) in blocking buffer for 2 hours at room temperature in the dark.  Nuclei were 
counter-stained with Hoechst diluted in 1X PBS for 10 minutes at room temperature and 
cells were washed an additional 3 times in 1X PBS at room temperature before coverslips 
were inverted and mounted on SuperFrost Plus slides using Dako Faramount Mounting 
media.  Specific antibody conditions can be found in Table 2.1.  Images were collected on 
a Zeiss LSM 510 Meta.  Scale bars were added using FIJI (Schindelin et al. 2012) and 
brightness, contrast, and color levels were adjusted using Adobe Photoshop CS5 (Adobe 
Systems).  
qRT-PCR 
RNA was isolated according to manufacturer’s instructions using the High Pure 
RNA Isolation Kit (Roche) and cDNA was generated using random hexamers and the 
Transcriptor First Strand cDNA Synthesis Kit (Roche).  qPCR was performed on a 
LightCycler 480 (Roche) using the LightCycler 480 Probes Master reagent (Roche) and 
Universal Probe Library (Roche) according to manufacturer’s protocol.  All primers and 
probes are listed in Table 3.2.  Two endogenous controls were used for each experiment.  
Data were collected and analyzed with LightCycler 480 Software (Roche, Version 1.5.1). 
Primer and UPL probe information are listed in Table 2.2. 
Statistical Analyses 
Statistical analyses were performed using Prism 6 (GraphPad).  Specific details of 




Transcriptional Regulation by GCN5 in the E9.5 Mouse Head  
Gcn5hat/hat mutants exhibit fully penetrant exencephaly and significant overgrowth of 
the neuroepithelium.  Because GCN5 is well-characterized for its functions in 
transcriptional regulation, I examined transcriptome-wide changes in gene expression via 
microarray using whole head tissue from E9.5 wildtype and Gcn5hat/hat mutants (19-22 
somites)(Figure 2.1a, red denotes tissue used for array).  Because neural tube closure 
requires coordination of many transcriptional programs across numerous cell types, 
phenotype-relevant changes in gene expression may occur in only a subset of cells in the 
head, meaning that the apparent fold-change of these genes may be low due to dilution of 
the signal.  I therefore analyzed the array results using conservative p-value and fold-
change cutoffs of 0.05 and ±1.20, respectively.  This analysis revealed statistically 
significant disruption of 1,815 genes in Gcn5hat/hat embryos, suggesting widespread 
disruption of transcriptional programs in these mutants (Figure 2.1b).  Furthermore, 33 of 
the dysregulated genes in Gcn5hat/hat embryos have been previously implicated in neural 
tube closure in animal models (Table 2.3)(Wilde et al. 2014). 
The observation that more than 10% of the known genes required for neural tube 
closure in mouse are dysregulated in Gcn5hat/hat embryos combined with the requirement for 
broad coordination of many cellular processes suggests that GCN5 plays a pivotal role in 
this coordination.  This is supported by the fact that the 33 dysregulated genes are involved 
in diverse cellular processes, including patterning, proliferation, apoptosis, cytoskeletal 
regulation, cell-extracellular matrix interaction, cell polarity, and cell signaling (Table 
2.3)(Wilde et al. 2014).  It should be noted however that, although dysregulated, a number 
of these genes’ expression increase upon loss of GCN5 activity and it is unclear how up-
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regulation of these genes may affect neural tube closure.  Furthermore, the sheer number 
of dysregulated genes, in combination with the modest fold-changes, makes testing the 
combinatorial contributions of these genes to the neural tube defects in Gcn5hat/hat embryos 
very challenging.   
In addition to genes previously identified for their requirement for proper neural tube 
closure, pathway analysis of the microarray data indicated enrichment of genes involved 
cell cycle regulation, stem cell maintenance, and neural differentiation.  Of these genes, 
several were of significant interest, both for their levels of dysregulation and for their 
established roles in cell cycle regulation and neural differentiation (Table 2.4).  In the next 
section, I will discuss how the observed dysregulation of this set of genes led to further 
preliminary data supporting a role for GCN5 in terminal differentiation of neurons in the 
developing forebrain.               
A Role for GCN5 Activity in Suppression and Promotion of Neuronal Differentiation 
The dysregulated set of genes presented in Table 2.4 suggests that GCN5 plays a 
role in both the maintenance of stem cell identity and the opposing process of neuronal 
differentiation.  Cdkn1a (p21) is a cyclin-dependent kinase inhibitor that restricts the G1 to 
S-phase transition of the cell cycle, while Ccnd1 (cyclin D1), conversely, promotes the G1/S 
transition.  The observed up-regulation of Cdkn1a and down-regulation of Ccnd1 therefore 
indicates that GCN5 enzymatic activity promotes the G1/S transition and that loss of GCN5 
activity results in stalling of cells in G1.  As discussed in Chapter 1, previous studies 
suggest that lengthening of G1 in neuroepithelial cells is sufficient to significantly increase 
their likelihood to differentiate (Calegari 2005).  This is supported by dysregulation of Id4, 
an inhibitor of neural differentiation whose expression is required for maintenance of neural 
progenitor cell pools (Bedford et al. 2005).  These observations suggest that loss of GCN5 
activity results in an increase in neural differentiation through lengthening of the G1 phase 
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of the cell cycle.  Interestingly, however, Gcn5hat/hat embryos display down-regulation of 
both Neurod1 and Neurod4, two proneural bHLH genes with important roles in terminal 
differentiation of neurons (Pataskar et al. 2015; Hardwick and Philpott 2015; Castro et al. 
2006).  Additionally, expression of the neuronal cytoskeletal regulators Stmn2 and Dcx is 
down-regulated suggesting a decreased ability of the neural progenitors to fully 
differentiate upon loss of GCN5 acetyltransferase activity. While these data contradict the 
hypothesis of increased differentiation in Gcn5hat/hat embryos, they indicate a possible stall 
in the differentiation process, resulting in increased numbers of intermediate and/or 
partially differentiated progenitors. 
In order to better assess the requirement of GCN5 enzymatic activity for neuronal 
differentiation, I first examined forebrain tissue at E10.5 when there are a greater number of 
differentiative divisions occurring.  In the dorsal telencephalon, where PAX6 marks 
neuroepithelial cells and TUJ1 marks differentiated neurons, wildtype animals showed 
mutually exclusive expression of PAX6 and TUJ1 (Figure 2.2a, left).  In Gcn5hat/hat embryos, 
however, I frequently observed double-labeling with both PAX6 and TUJ1 of radially 
migrated cells suggesting the presence of cells with an intermediate fate (Figure 2.2a, 
right).  Additionally, these PAX6/TUJ1 double-positive cells appear to express higher levels 
of PAX6 than cells located closer to the ventricle, indicating severe dysregulation of the 
transcriptional programs necessary for neural differentiation.  These experiments also 
revealed statistically significant thickening of the neuroepithelium in Gcn5hat/hat mutants, 
which could result from either increased proliferation of the observed intermediate cells or 
an inability of these cells to properly migrate away from their region of origin (Figure 2.3).   
To further test the requirement of GCN5 enzymatic activity in both stem cell 
maintenance and differentiation, I performed a set of experiments using an immortalized 
neuroepithelial cell line (NE-4C) derived from E9.5 forebrain tissue (Schlett and Madarász 
 45 
1997). Treatment of these cells via administration of MB-3, a specific inhibitor of GCN5 
acetyltransferase activity, was sufficient to induce changes in Cyclin D1 and p21 protein 
levels in accordance with the transcriptional changes observed in the microarray data 
(Figure 2.2b).  Furthermore, treatment with MB-3 induced expression of TIS21, a marker of 
asymmetric neurogenic divisions, suggesting that loss of GCN5 enzymatic function is 
sufficient to initiate a neurogenic program in NE cells (Figure 2.2, lower panel).  However, it 
should be noted that long-term treatment with MB-3 resulted in extensive detachment of 
cells from the culture dish, even in plates treated with poly-L-lysine and laminin.  Because 
neuronal differentiation first requires delamination of NE cells from the ventricular zone and 
later reestablishment of cell adhesion (Götz and Huttner 2005), the lack of reattachment of 
MB-3-treated NE-4C cells may be evidence of an inability for GCN5 activity loss alone to 
drive complete neuronal differentiation.   
Combined, the array data and observations in NE-4C cells treated with MB-3 
indicate that GCN5 may be required for both stem cell maintenance and terminal 
differentiation.  To more directly test the requirement of GCN5 activity for neuronal 
differentiation, I concurrently treated NE-4C cells with all-trans retinoic acid (RA, which 
induces neuronal differentiation) and MB-3 and subsequently stained for NeuroD1 and 
neurofilament (NF), two markers of terminal neuronal differentiation (Pataskar et al. 2015; 
Chiu et al. 1995).  Seven days after treatment with RA, DMSO-treated control cells showed 
high levels of both NeuroD1 and NF expression in cells displaying neuronal morphology 
(Figure 2.2c, left).  Cells treated with RA and MB-3, however, showed severely reduced 
levels of NeuroD1 and NF staining and cells positive for NF lacked neuronal morphology, 
suggesting an inability of these cells to terminally differentiate (Figure 2.2c, right).  A 
previous study identified the Ig superfamily protein protogenin (PRTG) as a factor that is 
required for maintenance of an intermediate state of neuronal differentiation during early 
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stages of neurogenesis in the mouse (Wong et al. 2010).  This work suggested that PRTG 
acts to prevent precocious NE cell differentiation and this led me to ask whether PRTG 
expression may be prolonged in the absence of GCN5 activity.  To test this, I treated NE-
4C cells with varying combinations of RA and MB-3 and assessed Prtg expression by qRT-
PCR.  In accordance with the study from Wong et al. (2010), treatment of NE-4C cells with 
RA increased Prtg expression transiently, with high levels of expression after 24 hours of 
treatment and levels below baseline after 48 hours of treatment (Figure 2.2d).  In support of 
my hypothesis, GCN5 inhibition enhanced Prtg expression after 24 hours of RA treatment 
and sustained Prtg expression after 48 hours of treatment, indicating that GCN5 activity is 
required for proper kinetics of Prtg expression (Figure2.2d).  Together, these preliminary 
studies support a role for GCN5 enzymatic activity in both the maintenance of NE cell 
identity and terminal differentiation, two processes with importance for both neural tube 
closure and brain development (Chen et al. 2014; Close et al. 2012; Hemberger et al. 2009).    
Discussion 
Although the requirement for GCN5 activity for neural tube closure has been known 
for almost 10 years, it has remained unclear what role the protein plays in this process (Bu 
et al. 2007).  My studies showing aberrant transcriptional regulation, neuroepithelial cell 
maintenance, and neural differentiation in Gcn5hat/hat embryos, which completely lack GCN5 
enzymatic function, indicate that GCN5 plays a critical role in multiple processes during 
and immediately following neural tube closure.  Microarray analysis of E9.5 head tissue 
from Gcn5hat/hat mutants showed significant dysregulation of nearly 2,000 genes, which 
supports a broad role for GCN5 in transcriptional regulation, most likely through its 
functions in both histone acetylation and direct acetylation of transcription factors (Zelin et 
al. 2012; Weake and Workman 2011).  Although many of these genes were only modestly 
dysregulated, the starting tissue (whole head) represents a complex mixture of cell types 
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with spatially distinct patterned domains and hence it is likely that the signal from any 
particular gene is diluted within this overall analysis of transcriptional changes.  Supporting 
this possibility is the observation that only 10 genes in the entire genome showed 
dysregulation greater than ±2.5 fold. Nonetheless, the extent of transcriptional 
dysregulation suggests that the neural tube defect in Gcn5hat/hat mutants results from the 
combinatorial effect of aberrant expression of multiple genes and/or pathways, similar to 
how we now believe NTDs in humans occur as a multigenic multifactorial trait.     
The hypothesis that the compounded effect of dysregulation of multiple genes and 
pathways contributes to NTDs in both Gcn5hat/hat mice and humans is extremely difficult to 
test.  Nonetheless, I began to address this by cross-referencing the list of dysregulated 
genes in mutant embryos with genes previously identified to be required for neural tube 
closure in mouse.  This analysis indicated that >10% of all known NTD-related genes in 
mice are significantly dysregulated in mutant head tissue at the time of neural tube closure.  
Although this level of enrichment may be expected based on the sheer number of 
dysregulated genes, the results still support a broad and essential role for GCN5 in the 
coordination of multiple cellular events during neural tube closure.  Although it is still not 
possible to test the combinatorial role of more than a few genes in a given developmental 
process, particularly when some of the implicated genes are up-regulated, emerging 
genetic technologies using CRISPR/Cas now allow us to readily engineer compound 
mutant mouse strains that can address these types of questions.  Furthermore, modified 
Cas enzymes enable the targeting and activation or repression of specific genes in vitro as 
a means of better understanding how transcriptional changes in one or more genes 
contribute to a specific cellular phenotype.  Future studies of the role of GCN5 in neural 
tube closure must therefore undoubtedly utilize such technologies to elucidate 
function/phenotype relationships. 
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 In addition to its role in genome-wide transcriptional regulation during neural tube 
closure, I also identified requirement of GCN5 for stem cell maintenance and neuronal 
differentiation between E9.5 and E10.5.  As a protein with many known functions in 
addition to chromatin modification, GCN5 serves as an appealing candidate for a factor 
that can aid in the coordination of both stem cell biology and differentiation, two opposing 
processes that must be precisely synchronized.  My experiments in Gcn5hat/hat embryos 
suggest that GCN5 activity is required to maintain neuroepithelial cell populations, 
potentially through regulation of genes and/or proteins involved in cell cycle progression.  
In support of this function, previous studies have shown that loss of Gcn5 in ES cells leads 
to precocious down-regulation of pluripotency factors such as Oct4 and Nodal (Lin et al. 
2007).  Based on these observations, it would be expected that loss of GCN5 activity 
would result in increased neuronal differentiation; however my experiments also indicate 
that GCN5 is required for neuronal differentiation.  NE-4C cells stimulated to differentiate 
with RA show prolonged expression of the intermediate progenitor gene Prtg and although 
they express NF, NF-positive cells do not show neuronal morphology, suggesting a stall in 
the differentiation process.  Dysregulation of Neurod1, which acts as a coordinator of 
terminal neuronal differentiation, indicates that GCN5-mediated transcriptional regulation of 
proneural bHLH genes is an essential factor for proper development of the brain.  
Furthermore, down-regulation of cytoskeletal factors important in the process of neurite 
outgrowth and neuronal maturation helps explain the partially differentiated NF-positive 
cells with abnormal morphology.  Together, these data provide a framework for further 
studies of the multi-faceted function of GCN5 during both primary neurulation and early 
neural differentiation that have the potential to lead to improved NTD prevention and 




Figure 2.1 – Transcriptional Dysregulation in Gcn5hat/hat Head Tissue 
(a) False-coloring (red) of an E9.5 mouse embryo illustrates the tissue source used to obtain 
RNA for microarray analysis. (b) A volcano plot showing the distribution of the 1,815 
significantly dysregulated transcripts in E9.5 Gcn5hat/hat embryos.  Higher –log(pValue) 


















Figure 2.2 – Altered Neuronal Differentiation in Gcn5hat/hat Embryos 
(a) Immunohistochemistry illustrates incomplete differentiation of neuroepithelial cells in 
Gcn5hat/hat mutants at E10.5.  Mutant embryos show large numbers of TUJ1/PAX6 double-
positive cells that are not observed in wildtype embryos (n=4 biological replicates per 
genotype, scale bar = 50µm).  (b) NE-4C cells treated with either DMSO or 100µM MB-3 for 
24 hours indicate that GCN5 inhibition results in decreased Cyclin D1 and increased p21 
and TIS21 protein levels.  Numbers below blots indicate relative protein quantity normalized 
to beta-tubulin. (c) NE-4C cells cultured for 5 days after treatment with either RA or RA and 
100µM MB-3 for 2 days (7 days total) indicate that GCN5 enzymatic activity is required for 
terminal neuronal differentiation, as evidenced by decreased NF and NeuroD1 expression 
in MB-3 treated cells (n=3 technical replicates per condition). (d) qRT-PCR demonstrates 
that inhibition of GCN5 activity with MB-3 enhances and prolongs expression of the 
intermediate neural progenitor marker Prtg in NE-4C cells treated as in (c) (n=3 biological 








Figure 2.3 – Increased Neuroepithelial Thickness in E10.5 Gcn5hat/hat Embryos 
Neuroepithelial thickness was measured in ventral, medial, and dorsal telencephalic regions 
from E10.5 wildtype and Gcn5hat/hat embryos.  Gcn5hat/hat embryos exhibit increased width of 



























































Antigen Company Catalog # Species Concentration Antigen Retrieval Blocking Buffer Process
PAX6 DSHB Pax6-s Ms 1:50 10mM sodium citrate, 12 minutes in steamer 1% NGS, 0.1% Tween, PBS Immunohistochemistry
TUJ1 Covance PRB-435P Rb 1:1000 10mM sodium citrate, 12 minutes in steamer 1% NGS, 0.1% Tween, PBS Immunohistochemistry
NEUROD1 Cell Signaling 4373 Rb 1:500 N/A 1% NGS, 0.1% Tween, PBS Immunocytochemistry
NF abcam ab24574 Ms 1:500 N/A 1% NGS, 0.1% Tween, PBS Immunocytochemistry
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Target Forward Primer Reverse Primer UPL Probe
Actb ctaaggccaaccgtgaaaag accagaggcatacagggaca 64
Prtg caggcacacgtaacttcacag tttcaggccattcgacaaa 63
Rrn18s gcaattattccccatgaacg gggacttaatcaacgcaagc 48
 54 
Table 2.3 – Dysregulated Neural Tube Closure Genes in Gcn5hat/hat Embryos 
Thirty-three of the genes significantly dysregulated in Gcn5hat/hat head tissue at E9.5 have 









Gene Fold Change p-value Function(s)
Alx3 -2.12533655 0.00396058 Signaling, Transcription/Translation
Bmp2 1.70253269 0.00262938 Signaling
Casp3 -1.28999733 0.00130039 Cell Survival
Celsr1 1.27618524 0.00607115 Polarity
Dync2li1 1.43347085 0.00307196 Cilia assembly
Epor -1.38529776 0.00215496 Signaling
F2rl1 1.22903154 0.03156779 Signaling
Fat4 -1.32568112 0.0247647 Polarity
Frem2 1.41211641 0.00052466 Cell Adhesion
Fuz 1.42523278 0.00238333 Cilia
Gja5 -1.28403881 0.00856754 Cell Adhesion
Hipk2 -1.25900399 0.00119266 Signaling, Transcription/Translation
Ift122 1.25456416 0.00065428 Cilia
Ift172 1.31299384 0.00940079 Cilia
Itga3 1.29128322 0.00192004 Cell Adhesion
Lama5 1.60416688 0.00058185 Cell Adhesion
Lmnb1 -1.31040754 0.00118238 Cell Adhesion
Marcks -1.33398289 0.00129413 Cytoskeleton
Mks1 1.27393891 0.00234166 Cilia
Ppm1g -1.24294538 0.00856754 Chromatin Modification
Ptpn9 -1.21610576 0.000962 Cellular Transport
Rab23 -1.20170495 0.043381 Cellular Transport
Rara 1.2711126 0.0015148 Signaling
Scarb1 1.2661316 0.00156649 Signaling
Sdc4 1.52801212 0.00421572 Polarity
Sobp -1.27424277 0.00040291 Unknown Function
Spint2 1.26464862 0.00167417 Signaling
Tmem107 1.31377237 0.00993236 Cilia
Tmem67 1.24684405 0.01191905 Cilia
Twist1 -1.39663984 0.00364649 Signaling, Transcription/Translation
Vangl1 1.22891274 0.00126508 Polarity
Wnt5a -1.40686528 0.00072844 Polarity
Zic3 -1.64859082 0.00013273 Signaling, Transcription/Translation
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Table 2.4 – Cell Cycle Regulators and Neural Differentiation Factors of Interest 
Genes of interest that are involved in cell cycle regulation, stem cell maintenance, and 




















Gene Protein Fold Change p-Value Function
Cdkn1a p21 2.188582757 2.96722E-06 Inhibits G1/S Transition
Dcx DCX -2.01973561 0.00456731 Microtubule dynamics, neurite outgrowth
Stmn2 STMN2 -1.947222797 0.001074048 Microtubule dynamics, neurite outgrowth
Stmn4 STMN4 -1.210610544 0.04500544 Microtubule dynamics, neurite outgrowth
Id4 ID4 -1.971855826 0.001300386 Neural Differentiation Inhibitor
Nes NES -1.457256259 0.001484323 Neural Differentiation Inhibitor
Ccnd1 Cyclin D1 -1.250796102 0.001894506 Promotes G1/S Transition
Elavl3 ELAVL3 -1.578556573 0.004305353 Promotes Neural Differentiation
Neurod1 NeuroD1 -2.524269463 0.002293933 Proneural bHLH
Neurod4 NeuroD4 -1.650045993 0.001023744 Proneural bHLH
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One-way ANOVA, Tukey's Multiple-Comparisons Test
Comparison Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
DMSO vs. 50µM MB-3 -0.345 -0.7980 to 0.1080 No ns 0.2262
DMSO vs. 100µM MB-3 -0.384 -0.8370 to 0.06904 No ns 0.1358
DMSO vs. RA (24hrs) -0.757 -1.210 to -0.3040 Yes *** 0.0004
DMSO vs. RA+50µM MB-3 (24hrs) -1.769 -2.222 to -1.316 Yes **** < 0.0001
DMSO vs. RA+100µM MB-3 (24hrs) -1.592 -2.045 to -1.139 Yes **** < 0.0001
DMSO vs. RA (48hrs) 0.2781 -0.1749 to 0.7311 No ns 0.4727
DMSO vs. RA+50µM MB-3 (48hrs) -0.348 -0.8010 to 0.1050 No ns 0.2179
DMSO vs. RA+100µM MB-3 (48hrs) -1.236 -1.689 to -0.7830 Yes **** < 0.0001
50µM MB-3 vs. 100µM MB-3 -0.039 -0.4920 to 0.4140 No ns > 0.9999
50µM MB-3 vs. RA (24hrs) -0.412 -0.8650 to 0.04104 No ns 0.0916
50µM MB-3 vs. RA+50µM MB-3 (24hrs) -1.424 -1.877 to -0.9710 Yes **** < 0.0001
50µM MB-3 vs. RA+100µM MB-3 (24hrs) -1.247 -1.700 to -0.7940 Yes **** < 0.0001
50µM MB-3 vs. RA (48hrs) 0.6231 0.1701 to 1.076 Yes ** 0.0034
50µM MB-3 vs. RA+50µM MB-3 (48hrs) -0.003 -0.4560 to 0.4500 No ns > 0.9999
50µM MB-3 vs. RA+100µM MB-3 (48hrs) -0.891 -1.344 to -0.4380 Yes **** < 0.0001
100µM MB-3 vs. RA (24hrs) -0.373 -0.8260 to 0.08004 No ns 0.1576
100µM MB-3 vs. RA+50µM MB-3 (24hrs) -1.385 -1.838 to -0.9320 Yes **** < 0.0001
100µM MB-3 vs. RA+100µM MB-3 (24hrs) -1.208 -1.661 to -0.7550 Yes **** < 0.0001
100µM MB-3 vs. RA (48hrs) 0.6621 0.2091 to 1.115 Yes ** 0.0018
100µM MB-3 vs. RA+50µM MB-3 (48hrs) 0.036 -0.4170 to 0.4890 No ns > 0.9999
100µM MB-3 vs. RA+100µM MB-3 (48hrs) -0.852 -1.305 to -0.3990 Yes **** < 0.0001
RA (24hrs) vs. RA+50µM MB-3 (24hrs) -1.012 -1.465 to -0.5590 Yes **** < 0.0001
RA (24hrs) vs. RA+100µM MB-3 (24hrs) -0.835 -1.288 to -0.3820 Yes *** 0.0001
RA (24hrs) vs. RA (48hrs) 1.035 0.5821 to 1.488 Yes **** < 0.0001
RA (24hrs) vs. RA+50µM MB-3 (48hrs) 0.409 -0.04404 to 0.8620 No ns 0.0957
RA (24hrs) vs. RA+100µM MB-3 (48hrs) -0.479 -0.9320 to -0.02596 Yes * 0.0336
RA+50µM MB-3 (24hrs) vs. RA+100µM MB-3 (24hrs) 0.177 -0.2760 to 0.6300 No ns 0.8955
RA+50µM MB-3 (24hrs) vs. RA (48hrs) 2.047 1.594 to 2.500 Yes **** < 0.0001
RA+50µM MB-3 (24hrs) vs. RA+50µM MB-3 (48hrs) 1.421 0.9680 to 1.874 Yes **** < 0.0001
RA+50µM MB-3 (24hrs) vs. RA+100µM MB-3 (48hrs) 0.533 0.07996 to 0.9860 Yes * 0.0144
RA+100µM MB-3 (24hrs) vs. RA (48hrs) 1.87 1.417 to 2.323 Yes **** < 0.0001
RA+100µM MB-3 (24hrs) vs. RA+50µM MB-3 (48hrs) 1.244 0.7910 to 1.697 Yes **** < 0.0001
RA+100µM MB-3 (24hrs) vs. RA+100µM MB-3 (48hrs) 0.356 -0.09704 to 0.8090 No ns 0.1969
RA (48hrs) vs. RA+50µM MB-3 (48hrs) -0.6261 -1.079 to -0.1731 Yes ** 0.0032
RA (48hrs) vs. RA+100µM MB-3 (48hrs) -1.514 -1.967 to -1.061 Yes **** < 0.0001
RA+50µM MB-3 (48hrs) vs. RA+100µM MB-3 (48hrs) -0.888 -1.341 to -0.4350 Yes **** < 0.0001
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Genotype Mean (µm) Std Dev n Replicate Type Statistical Test p-value
+/+ 89.7796 13.83 4 Biological Unpaired t-test w/ 0.0347




GCN5 ACETYLTRANSFERASE ACTIVITY RESTRICTS DIENCEPHALIC SIZE THROUGH 
A NOVEL MECHANISM OF RETINOIC ACID SIGNALING2 
Introduction 
Microcephaly disorders have provided significant insights into the mechanisms 
required for achieving proper size of the mammalian brain (Lancaster et al. 2013; Gilmore 
and Walsh 2013; Chen et al. 2014).  However, much less is known about the mechanisms 
that are required to restrict brain size during development, despite the fact that overgrowth 
of the brain or regions of the brain is associated with several neurological and 
developmental disorders (Mirzaa et al. 2013).  In this chapter, I will discuss a set of findings 
that show a novel function of the acetyltransferase GCN5 that regulates retinoic acid 
signaling in the developing diencephalon and restricts its size during embryonic 
development. 
Materials and Methods 
Mouse Strains and Genotyping 
All animals were maintained according to protocols approved by the UC Denver 
Institutional Animal Care and Use Committee.  Gcn5hat mice were genotyped according to 
previously published protocols (Bu et al. 2007).  Gcn5hat/+;RAREhspLacZ  mice were 
generated by crossing Gcn5hat/+ mice with homozygous RAREhspLacZ mice and were 
maintained as F1 offspring to avoid disruption of reporter activity by the Gcn5hat C57BL/6J 
background.  The same breeding scheme was used to generate Gcn5hat/+;TOPGAL mice.  
Both TOPGAL and RAREhspLacZ mice were genotyped via PCR according to standard 
lacZ genotyping protocols provided by The Jackson Laboratory (http://www.jax.org). 
 
																																																								
2 Manuscript currently under revision for Nature Communications. 
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Immunohistochemistry and Confocal Microscopy 
Immunohistochemistry was performed as described in Chapter 2.  The following 
Alexafluor (Life Technologies) secondary antibodies were used at 1:250 in blocking buffer 
for 1 hour at room temperature: 488 goat anti-rabbit IgG (H+L), 488 goat anti-mouse IgG 
(H+L), 555 goat anti-rabbit IgG (H+L), 555 goat anti-mouse (H+L).  P21, LEF1, and MASH1 
were stained using the Tyramide Signal Amplification kit (Life Technologies) according to 
manufacturer’s protocol.  Antibody-specific conditions and antibody information can be 
found in Table 3.1.  
Whole-Mount in situ Hybridization 
Whole-mount in situ hybridization was performed as previously described (Holmes 
and Niswander 2001).  The following probes were used:  mShh (HindIII, T3; provided by A. 
Joyner), mGli3 (NcoI, SP6; provided by J. Eggenschwiler), mAxin2 (XbaI, Sp6; provided by 
M. Buckingham), mWnt8b (EcoRI, T7; provided by E. Grove).   
Quantitative RT-PCR 
Quantitative RT-PCR was performed as described in Chapter 2.  Primer and UPL 
probe information can be found in Table 3.2.  
Whole Mount Beta-Galactosidase Assays 
E10.5 embryos were washed briefly in PBT (PBS + 0.1% Tween-20) and fixed at 
room temperature in 4% PFA for 45 minutes.  Embryos were then washed three times for 
15 minutes each at room temperature in wash buffer (0.2mM MgCl2, 0.02% NP-40, 0.01% 
deoxycholate in PBT) before staining overnight at 37°C in X-gal staining solution (1mg/mL 
X-gal, 5mM potassium ferrocyanide, 5mM potassium ferricyanide in wash buffer).  Embryos 
were then briefly rinsed in wash buffer and fixed for 30 minutes at room temperature in 4% 
PFA before imaging on a Nikon SMZ18 stereomicroscope using Nikon NIS-Elements 




NE-4C cells were grown at 37°C and 5% CO2 in MEM (Invitrogen) supplemented 
with 5% FBS, 1X MEM non-essential amino acids (Invitrogen), and 1X GlutaMax 
(Invitrogen).  For RA treatments, cells were treated with 0.01-10µM all-trans retinoic acid 
(Sigma Aldrich) dissolved in DMSO.  DMSO was used as a vehicle control for all 
experiments.  For MB-3 treatments, MB-3 (Sigma Aldrich) was prepared in sterile ddH2O at 
a stock concentration of 100mM.     
Western Blots and Quantitative Imaging 
Western blots were performed as described in Chapter 2 and were visualized on an 
Odyssey CLx (LiCor) with the following LiCor secondary antibodies:  IRDye 650 goat anti-
mouse IgG (H+L), IRDye 680LT donkey anti-goat IgG (H+L), IRDye 650 goat anti-rabbit IgG 
(H+L), IRDye 800CW goat anti-mouse IgG (H+L), and IRDye 800CW goat anti-rabbit IgG 
(H+L).  Western blots were quantified using Image Studio software (LiCor). 
Protein Acetylation Assay 
NE-4C cells treated with vehicle control (DMSO, 1:1000), 100µM MB-3, 0.1µM RA, 
or 100µM MB-3 and 0.1µM RA were grown for 16 hours and subcellular fractionation was 
performed using the Nuclear Complex Co-IP kit (Clontech).  Indirect immunoprecipitation 
was performed on 500µg input using rabbit anti-acetylated lysine antibody (Cell Signaling, 
1:100) or normal rabbit IgG (EMD Millipore, 12-370, 2µg) and PureProteome Protein G 
Magnetic Beads (Millipore) according to manufacturer’s protocol.  To quantify acetylated 
TACC1, Western blotting was performed on IP and input using rabbit anti-TACC1 (Sigma 
Aldrich, SAB4502910, 1:500) and mouse anti-beta-tubulin (Sigma Aldrich, T4026, 1:2000).  
Total TACC1 was normalized to beta-tubulin and acetylated TACC1 was then normalized to 
total TACC1.  Efficiency of fractionation and loading consistency was assayed via Western 
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blot with antibodies directed against RNA polymerase II (EMD Millipore, 05-623, 1:500) and 
beta-tubulin (Sigma Aldrich, T4026, 1:2000). 
Co-immunoprecipitation 
Freshly dissected embryonic forebrain tissue or NE-4C cells grown for 16 hours 
after treatment with DMSO, 50µM or 100µM MB-3, 0.1µM RA, or 50 or 100µM MB-3 and 
0.1µM RA were collected and nuclear protein was harvested using the Nuclear Complex 
Co-IP kit according to the manufacturer’s protocol (Clontech).  750µg input (5µg/µL) was 
pre-cleared with 20µL PureProteome Protein G Magnetic Beads (Millipore) before addition 
of rabbit anti-RARα (Santa Cruz, sc-551, 1:200) or normal rabbit IgG (EMD Millipore, 12-
370, 2µg).  Samples were rotated overnight at 4°C before addition of 50µL washed 
PureProteome Protein G Magnetic Beads and subsequent incubation at room temperature 
for 15 minutes on a nutator.  Beads were then washed 5 times in ice-cold wash buffer prior 
to elution in 2X Laemmli buffer at 95°C for 10 minutes.  Protein interactions were assayed 
via Western blot using the following antibodies:  rabbit anti-GCN5L2 (Cell Signaling, #3305, 
1:1000), goat anti-RARα (Santa Cruz, sc-15040, 1:50), rabbit anti-TACC1 (Sigma Aldrich, 
SAB4502910, 1:500), and mouse anti-beta-tubulin (Sigma Aldrich, T4026, 1:2000).     
Chromatin Immunoprecipitation 
NE-4C cells were grown for 24 hours under the indicated conditions before proteins 
were cross-linked to DNA by addition of methanol-free formaldehyde to a final 
concentration of 0.75%.  After quenching of formaldehyde with glycine (final concentration 
125mM), cells were washed with ice-cold PBS and protein was harvested via passive lysis 
with FA lysis buffer (50mM HEPES-KOH pH7.5, 140mM NaCl, 1mM EDTA pH8.0, 1% Triton 
X-100, 0.1% sodium deoxycholate, 0.1% SDS, 1X EDTA-free protease inhibitors).  DNA 
was sheared to ~500bp fragments using a Bioruptor (Diagenode Inc.) at high intensity for 
45 minutes (30 sec on, 30 sec off).  Samples were centrifuged at 8,000g for 30 seconds at 
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4°C and the supernatant was transferred to a new tube.  Protein-DNA complexes were 
incubated with the following antibodies overnight at 4°C on a rotator:  normal rabbit IgG 
(EMD Millipore, 12-370, 2µg), rabbit anti-GCN5L2 (Cell Signaling, #3305, 1:200), rabbit anti-
RARα (Santa Cruz, sc-551, 1:200), rabbit anti-TACC1 (Sigma Aldrich, SAB4502910, 1:100).  
50µL ChIP-grade Protein G Magnetic Beads (Cell Signaling) pre-absorbed with 3.75µg 
sheared single-stranded herring sperm DNA was added to each sample and incubated for 
2 hours at 4°C on a rotator.  Beads were collected via magnet and washed 3 times in ice-
cold wash buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA pH8.0, 150mM NaCl, 20mM 
Tris-HCl pH8.0) before elution in 120µL elution buffer (1% SDS, 100mM NaHCO3) on a 
Thermomixer (Eppendorf) at 750rpm and 30°C for 15 minutes.  DNA was then purified via 
QiaQuick PCR Purification Kit (Qiagen) according to manufacturer’s instructions.  qPCR 
was performed using primers specified in Table 3.3 and the LightCycler 480 SYBR Green I 
Master reagent (Roche).  Reactions were run on the LightCycler 480 (Roche) and analyzed 
with LightCycler 480 Software (Roche, Version 1.5.1).  Target data were first normalized to 
input levels and then normalized to IgG control.  
shRNA Transfection 
shRNAs were transfected using the Xfect Transfection Reagent (Clontech) 
according to manufacturer’s protocol (7.5µg plasmid per well of a 6-well plate).  Media was 
changed 4 hours after transfection and cells were grown for 24 hours before being used for 
experiments.  The following Mission shRNA (Sigma) constructs were used:  pLKO.1-puro 
Non-Target shRNA control (SHC002), TRCN0000027121 (Rarb), and TRCN0000027071 
(Rarb). 
RA Agonist Experiments 
NE-4C cells were plated at a density of 1.0x105 cells/well in individual wells of a 24-
well plate in 500µL culture medium.  Plated cells were allowed to grow overnight before 
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addition of DMSO (1:1000), all-trans retinoic acid (0.1µM), MB-3 (200µM), selective RARα 
agonist BMS 753 (Tocris Bioscience; 1µM), selective RARβ agonist CD 2314 (Tocris 
Bioscience; 1µM), or selective RARγ agonist CD 437 (Tocris Bioscience; 0.1µM).  Some 
wells were treated with a combination of drugs, as indicated in Figure 3.12.  Drug treatment 
was performed for 24 hours.  
Gestational Retinoic Acid Supplementation 
Pregnant dams were provided all-trans retinoic acid (Sigma) at 175mg/kg food 
beginning at gestational day 8.5.  RA was added to 1mL of corn oil and mixed with 8 grams 
of Nutra-Gel diet (BioServ, #S4798-TRAY), which was then provided in place of normal 
mouse chow.  Fresh food and RA were provided each morning for the duration of the diet.  
All wildtype embryos were dissected at E10.5.  Because of variable developmental delay 
observed in Gcn5hat/hat embryos, these embryos were dissected between E10.5 and E11.5 
to obtain stage-matched embryos. 
Statistical Analysis 
All statistical analyses were performed using Prism 6 (GraphPad).  All error bars 
represent standard deviation.  Specific details of statistical analyses can be found in Tables 
3.4-3.10. For all figures, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001). 
Results 
Expansion of the Diencephalon in Gcn5hat/hat Mutants 
GCN5 is an acetyltransferase first identified as a positive regulator of transcription 
that functions through direct lysine acetylation on histone H3 (Grant et al. 1999; 
Georgakopoulos and Thireos 1992; Candau et al. 1996; Brand et al. 1999).  It is a member 
of the SAGA co-activator complex that regulates POLII-mediated transcription (Grant et al. 
1999), and it has been shown to acetylate many non-histone targets (Conacci-Sorrell et al. 
2010; Lerin et al. 2006; Zelin et al. 2012; Jacob 2001).  Gcn5-null mice die early in gestation 
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after failing to specify mesodermal tissues (Xu et al. 2000), but mice engineered to lack 
GCN5 acetyltransferase activity (Gcn5hat/hat) survive to approximately embryonic day 16.5 
(E16.5) and display severe cranial neural tube defects (NTDs) (Bu et al. 2007)(Figure 3.1a).  
Gross morphological examination of Gcn5hat/hat mutants indicated dramatic overgrowth of 
neural tissue in Gcn5hat/hat embryos compared to other cranial NTD models in our lab (data 
not shown).  Sections through the developing forebrain at E10.5 and E12.5 revealed 
significant dorsal expansion of the forebrain neuroepithelium along its rostral-caudal extent 
in Gcn5hat/hat embryos compared to wildtype embryos (Figures 3.1b,d).  In order to identify 
which specific forebrain structures are expanded in Gcn5hat/hat embryos, I first examined 
E12.5 embryos and noted significant overgrowth of diencephalic structures (Figure 3.1b, 
purple) that resulted in compression of telencephalic tissue, as indicated by ventral-lateral 
displacement of the cortex and choroid plexus (Figure 3.1b, blue). Immunohistochemistry 
for FOXG1, a specific marker of the telencephalon, confirmed that the overgrown tissue is 
not of telencephalic origin and also highlighted the compression of the telencephalon in the 
mutant (Figure 3.1c).   
These findings led us to interrogate forebrain patterning at E10.5, when defects in 
tissue specification can be assessed by molecular markers including 
immunohistochemistry for LEF1, PAX6, and P21, which mark the dorsal telencephalon, 
pallium, and cortical hem, respectively (wildtype expression in left panels of Figure 3.1d, 
schematic in Figure 3.1f, Figure 3.2 ). LEF1 and P21 mark the dorsal limit of the 
telencephalon but Gcn5hat/hat mutants display these markers only until midway along the 
greatly expanded dorsoventral axis, with staining for LEF1 and P21 absent in the dorsal half 
of the mutant forebrain tissue (Figures 3.1d and 3.2 ).  These findings are consistent with 
FOXG1 staining and the compression of the telencephalon at later developmental stages.  
PAX6 appeared to be normally expressed in the ventral presumptive telencephalon (Figure 
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3.1d, arrowheads), however, PAX6 was also detected in the mutant tissue that expands 
beyond this domain. Because I observed expansion of diencephalic tissue at later stages of 
development and PAX6 is expressed in the wildtype diencephalon, I examined PAX6 in the 
diencephalon at E10.5 and found that the staining pattern in the expanded dorsal tissue in 
mutants was similar to that of the wildtype diencephalon (Figure 3.1e, outlined by dotted 
line).  Similar results were found for MASH1, which is expressed in the diencephalon (Figure 
3.2 ). Looking a day earlier, forebrain patterning appeared normal in E9.5 Gcn5hat/hat mutant 
embryos (Figure 3.3), indicating a temporal- and tissue-specific function for GCN5 in the 
developing diencephalon that begins between E9.5 and E10.5.  Taken together, these data 
(summarized in Figure 3.1f) suggest that the dorsal expansion of tissue in the forebrains of 
Gcn5hat/hat mutants is caused by the failure of a negative regulatory mechanism controlling 
diencephalic size.    
 The onset of diencephalic growth and patterning is accompanied by specific up-
regulation of Shh expression in a region known as the zona limitans intrathalamica (ZLI; the 
finger-like projection is marked by an asterisk in Figure 3.4a left panel)(Scholpp and 
Lumsden 2010).  As development progresses, the ZLI-associated Shh expression expands 
dorsally, expanding the diencephalon and patterning the developing thalamic nuclei (Vue et 
al. 2009; Haddad-Tóvolli et al. 2012).  Because of the important mitogenic role of SHH in 
the diencephalon and the increased diencephalic size in Gcn5hat/hat mutants highlighted in 
Figure 1, I hypothesized that Shh expression is increased in the diencephalon of Gcn5hat/hat 
embryos.  Indeed, Gcn5hat/hat embryos exhibit a significant expansion of Shh expression that 
correlates closely with the expanded diencephalic tissue (Figure 3.4a).  Studies in chick 
have demonstrated that repression of Gli3 in the alar plate is required to render the 
presumptive ZLI region permissive to dorsal Shh expansion (Martinez-Ferre et al. 2013) and 
in accordance, I observed decreased Gli3 expression in Gcn5hat/hat mutants (Figure 3.4c). 
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qRT-PCR for Shh and Gli3 on forebrain tissue from wildtype and mutant embryos at E10.5 
also showed significant, albeit modest, up-regulation of Shh and down-regulation of Gli3 
transcript levels (Figures 3.4b and 3.4d). The modest changes in expression observed by 
qRT-PCR is likely due to the complex mixture of cells in the isolated tissue, the domain of 
Gli3 expression surrounding the ZLI is small, and the mutant tissue is greatly expanded. 
Taken together with the spatial resolution provided by in situ hybridization, the data in 
Figures 3.1 and 3.4 support the requirement of GCN5 activity in restriction of diencephalic 
SHH signaling.   
WNT signaling promotes diencephalic Shh expression through repression of Gli3 
(Martinez-Ferre et al. 2013), but the WNT ligands important for diencephalic patterning in 
mouse are still unclear.  To investigate whether Gcn5hat/hat mutants exhibit increased WNT 
signaling in the forebrain at the time of ZLI expansion, I performed in situ hybridization for 
Axin2, which provides a reliable readout of WNT signaling (Jho et al. 2002).  This revealed 
increased levels of Axin2 transcript in the expanded diencephalic tissue of mutants (Figure 
3.4e), which was further confirmed by qRT-PCR (Figure 3.4f).  I also examined the 
expression levels of Wnt8b, which has been shown to repress diencephalic Gli3 expression 
in chick.  Again, both ISH and qRT-PCR revealed significant up-regulation of Wnt8b (Figure 
3.4d,e), suggesting a broad activation of WNT pathways in the forebrains of Gcn5hat/hat 
mutants.  Together these data support a mechanism by which GCN5 restricts diencephalic 
expansion through repression of WNT signaling, which acts upon Gli3 to modulate Shh 
expression. 
GCN5 Activity is Required for Diencephalic Retinoic Acid Signaling 
 The significant up-regulation of WNT signaling in Gcn5hat/hat forebrains led us to 
investigate upstream regulators of Wnt and Shh in the diencephalon.  Previous studies in 
chick identified the non-canonical retinoic acid (RA) synthesizing enzyme CYP1B1 as a 
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potential repressor of SHH in the alar plate (Chambers et al. 2007).  Expression of Cyp1b1 
turns on at the time of ZLI-associated SHH expansion and ectopic expression of GFP-
tagged CYP1B1 is sufficient to repress Shh in the diencephalon, even in tissues adjacent to 
the expression domain, suggesting non-cell autonomous effects (Chambers et al. 2007).  
Previously, GCN5 has been implicated in positive regulation of RA signaling in vitro through 
its interaction with retinoic acid receptor-α (RARα) via the SAGA complex member ADA3, 
which directly binds to the RARα coactivator receptor pocket (Li et al. 2010; Brown 2003).  
Additionally, RA has been shown to repress WNT signaling in multiple contexts (Easwaran 
et al. 1999; Li et al. 2008; Shah et al. 2003).  Despite these findings, a direct role for RA in 
development of the diencephalon has not been well studied in mammals and the role of 
GCN5 in RA-mediated forebrain development has not been addressed.  Although 
numerous recent studies have demonstrated roles for forebrain-derived RA in cortical 
migration (Mirzaa et al. 2013; Choi et al. 2014), generation of cortical neurons (Rash and 
Grove 2011; Harrison-Uy et al. 2013; Siegenthaler et al. 2009), and development of the 
choroid plexus (Rash and Grove 2011; Gupta and Sen 2015; Himmelstein et al. 2010; 
Epstein 2012), other studies have concluded that RA signaling is dispensable for gross 
development of the mouse forebrain prior to E12.5 (Chatterjee et al. 2014; Molotkova et al. 
2007; Rash and Grove 2011; Lohnes et al. 1994).  Lohnes et al. argue that the apparent 
lengthening of the neuroepithelium and compression of the telencephalon seen in 
compound mutant mice lacking both RARα and RARγ, a phenotype highly similar to that 
seen in Gcn5hat/hat embryos, is caused by impaired accumulation of cerebrospinal fluid and 
ventricular collapse due to hindbrain exencephaly.  However, our extensive experience with 
exencephaly mutants indicates that hindbrain exencephaly does not cause ventricular 
collapse in the forebrain.  Additionally, although Raldh3-/- mice show normal cortical 
morphology at E10.5, Molotkova et al. did not discuss the diencephalic expansion 
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observed in these embryos (Molotkova et al. 2007). Together with these previous 
observations, our data led us to hypothesize that GCN5 restricts WNT signaling and Shh 
expression in the developing diencephalon through direct promotion of RA signaling.   
To test my hypothesis, I first crossed Gcn5hat/hat mice with an RA reporter line 
harboring multiple retinoic acid response elements (RAREs) upstream of the lacZ gene 
(RAREhsplacZ)(Epstein et al. 2000; Rossant et al. 1991). Wildtype mice with the RA 
signaling reporter display robust beta-galactosidase staining in the telencephalon, as 
previously reported (Maden 2007; Rossant et al. 1991), as well as in two distinct regions of 
the dorsal diencephalon that flank the ZLI (Figure 3.5a).  Gcn5hat/hat;RAREhsplacZ embryos 
show a drastic reduction in reporter activity in the diencephalon (Figure 3.5b), supporting 
the hypothesis that GCN5 is required for diencephalic RA signaling.  Experiments in chick 
have shown that the p3 and p2 domains of the developing diencephalon that flank the ZLI 
are required to restric Shh expression, as removal of one or the other is sufficient to broadly 
expand Shh expression in diencephalic explants (Tanoury et al. 2013; Guinazu et al. 2007).  
Interestingly, these regions correspond with the diencephalic domains of RA signaling that 
are lost in Gcn5 mutants.  Additionally, previous experiments have shown that Raldh3 is 
expressed in a pattern similar to that of the RAREhsplacZ reporter in the dorsal 
diencephalon (Hou et al. 2015; Molotkova et al. 2007; Chakravarti et al. 1996), further 
supporting a role for RA signaling in restriction of diencephalic expansion.   
To test the molecular relationship between GCN5 enzymatic activity and RA 
signaling, I first turned to the RA-responsive NE-4C neuroepithelial cell line that was 
originally isolated from E9.0 mouse forebrain (Chambers et al. 2007; Schlett and Madarász 
1997).  I coupled this with MB-3, a pharmacological inhibitor with specificity for GCN5 
(GCN5 IC50=100µM, CBP IC50=500µM) (Grant et al. 1999; Biel et al. 2004; Georgakopoulos 
and Thireos 1992; Candau et al. 1996; Brand et al. 1999).  Analysis of two bona fide RA 
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target genes, Rarb and Foxa1 (Grant et al. 1999; Merrill et al. 2004; Lalevee et al. 2011; 
Jacob et al. 1999) that are expressed in the forebrain (Conacci-Sorrell et al. 2010; 
Mavromatakis et al. 2011; Lerin et al. 2006; Yamagata et al. 1994; Zelin et al. 2012; 
Besnard et al. 2004; Jacob 2001) showed a significant reduction in RA-mediated 
transcription upon MB-3 treatment (Figure 3.5c).  I also observed a statistically significant 
decrease in expression of the Shh repressor Ptch1, which contains a putative RARE and is 
regulated by RA (Figure 3.5c)(Xu et al. 2000; Busch et al. 2014; Lalevee et al. 2011). These 
changes in RA target gene expression were also reflected in vivo, as forebrain tissue of 
E10.5 Gcn5hat/hat mutants subjected to qRT-PCR revealed decreased expression of Rarb, 
Foxa1, and Ptch1 (Figure 3.5d).  Mutants did not show a significant decrease in Nes 
expression (Figure 3.5d), which also contains a putative RARE (Bu et al. 2007; Balmer 2002; 
Lalevee et al. 2011), suggesting that some RA-responsive genes and/or RAREs are not 
under GCN5-mediated control.  Taken together, these data demonstrate that GCN5 
enzymatic activity is required for diencephalic RA signaling and robust transcription of RA 
target genes.  Furthermore, the diencephalic expansion and telencephalic compression 
observed in Gcn5hat/hat embryos is strikingly similar to that seen in Rara-/-;Rarg-/- embryos 
(Scholpp and Lumsden 2010; Lohnes et al. 1994), suggesting that RA-mediated signaling is 
required to restrict the size of the diencephalon and to maintain its morphology. 
GCN5-mediated Acetylation of TACC1 Regulates an RARα/GCN5/TACC1 Complex 
 I next addressed the mechanism by which GCN5 regulates RA signaling in the 
forebrain.  While GCN5 is best characterized as a histone acetyltransferase, numerous 
studies have suggested that many tissue-specific functions of GCN5 are carried out 
through acetylation of non-histone proteins (Vue et al. 2009; Zelin et al. 2012; Haddad-
Tóvolli et al. 2012; Carradori et al. 2011; Conacci-Sorrell et al. 2010).  Mining of the 
literature for potential non-histone targets of GCN5 that are expressed in the forebrain and 
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involved in RA signaling identified the poorly characterized centrosome-associated protein 
TACC1 (Martinez-Ferre et al. 2013; Gabillard et al. 2011).  GCN5 and TACC1 can physically 
interact (Martinez-Ferre et al. 2013; Gangisetty et al. 2004), but the functional basis of this 
interaction is unclear.  TACC1 is strongly expressed in the developing forebrain 
neuroepithelium at E10.5 (Jho et al. 2002; Lauffart et al. 2006) and has also been shown to 
physically interact with RARα and play a role in RARα-mediated signaling (Chambers et al. 
2007; Guyot et al. 2010).  I therefore hypothesized that GCN5 regulates RA signaling in the 
diencephalon through a mechanism involving direct acetylation of TACC1.  Using NE-4C 
cells treated with RA, I assayed TACC1 acetylation in cytoplasmic and nuclear fractions 
(Figure 3.6 ) via immunoprecipitation using an anti-acetylated lysine antibody and 
subsequent Western blotting for TACC1. Acetylated TACC1 levels were normalized to total 
TACC1 levels.  Wildtype and MB-3 treated NE-4C cells showed almost undetectable levels 
of acetylated TACC1 in both cellular fractions, but treatment of the cells with RA induced 
robust TACC1 acetylation, specifically in the nuclear fraction (Figure 3.7a).  Consistent with 
my hypothesis, concurrent treatment of NE-4C cells with RA and MB-3 inhibited acetylation 
of TACC1, suggesting that GCN5 acetyltransferase activity is required for RA-mediated 
acetylation of TACC1 (Figure 3.7a).  
 It has been suggested that activation of RA target genes by RARα can occur in the 
absence of ligand under certain circumstances, but that this ligand-independent signaling 
is normally negatively regulated by cell-type specific mechanisms (Chambers et al. 2007; 
Park et al. 2010). This made us question whether a tissue-specific regulatory mechanism 
exists in the developing forebrain, perhaps reflected by poised RARα-GCN5-TACC1 
complexes that localize to RA-responsive genes in the absence of RA as a means to 
increase transcriptional efficiency upon ligand binding.  To test the existence of such a 
complex, I first performed a series of co-immunoprecipitation experiments on nuclear 
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fractions of NE-4C cells under varying conditions (Figure 3.8).  Pull-down of RARα revealed 
interaction with both GCN5 and TACC1 in the absence of RA that was unaffected by 
inhibition of GCN5 activity (Figure 3.7b, lanes 1-3).  Induction of neuronal differentiation 
with RA resulted in specific dissociation of TACC1 from the complex (Figure 17b, lane 4).  
Interestingly, inhibition of GCN5 enzymatic activity with MB-3 during RA treatment 
stabilized this interaction (Figure 3.7b, lanes 5-6), strongly suggesting that GCN5-mediated 
acetylation of TACC1 destabilizes TACC1 interaction with the RARα-GCN5 complex.  
Furthermore, to confirm the existence of such a complex in vivo, I performed 
immunoprecipitation of RARα on protein extracts from wildtype E10.5 forebrain tissue, 
which confirmed robust interactions between RARα, GCN5, and TACC1 (Figure 3.7c).   
 To investigate this complex further, I interrogated the genomic localization of RARα, 
GCN5, and TACC1 in NE-4C cells before and after RA treatment via chromatin 
immunoprecipitation (ChIP).  Using primers flanking RAREs associated with Rarb and 
Foxa1, I performed quantitative PCR of DNA immunoprecipitated with antibodies against 
RARα, GCN5, and TACC1.  In the absence of RA, I found significant localization of all three 
proteins at both RAREs (Figure 3.7d).  Upon addition of RA, both RARα and GCN5 were 
bound at the RAREs of both genes, but TACC1 was absent (Figure 3.7d).  Inhibition of 
GCN5 activity with MB-3 significantly stabilized the interaction of TACC1 at both RAREs 
(Figure 3.7d), suggesting that GCN5 acetyltransferase activity is required for the 
dissociation of TACC1 from target RAREs.  Interestingly, I did not observe binding of GCN5 
and TACC1 at a second RARE associated with Rarb (Figure 3.9), supporting the earlier 
observation that GCN5 is only required at a subset of RAREs.  Collectively these data 
describe a novel mechanism of RA signaling in forebrain-derived neuroepithelial cells that is 
regulated by GCN5-mediated acetylation of TACC1.   
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Rescue of Gcn5hat/hat Phenotype by Gestational RA Supplementation 
 The data supporting a role for RA signaling in the restriction of diencephalic 
expansion led to the hypothesis that it may be possible to rescue the embryonic defects 
seen in Gcn5hat/hat embryos with RA supplementation. However, this would require some 
RAR activity to mediate the RA effect.  While Rara-/-;Rarg-/- embryos display forebrain 
defects reminiscent of those seen in Gcn5hat/hat embryos, Rara-/-;Rarb-/- and Rarg-/-;Rarb-/- 
embryos do not show forebrain defects (Li et al. 2010; Lohnes et al. 1994; Brown 2003).  
These data suggest that RARβ may be subject to distinct regulatory mechanisms from 
those of RARα and RARγ.  To test this, I first performed co-immunoprecipitation 
experiments to determine if RARγ and RARβ interact with GCN5 and TACC1 in mouse 
forebrain tissue at E10.5.  As suggested by the genetic data, RARγ co-immunoprecipitated 
both GCN5 and TACC1, but RARβ did not (Figure 3.10a).  Thus, RARβ may act 
independently of GCN5 and RARβ may mediate some of the RA transcriptional response 
seen even when GCN5 activity is inhibited or absent (Figure 3.5c,d). To test these ideas 
further, I knocked-down RARβ in NE-4C cells using a combination of two shRNAs (shRarb; 
Figure 3.11 shows robust knockdown of RARβ) and then treated the cells with MB-3 and 
increasing concentrations of RA.  I then performed qRT-PCR using Foxa1 as a proxy for RA 
signaling. Cells treated with shCtrl exhibited increased levels of Foxa1 expression in 
response to higher levels of RA, suggesting that increased RA can overcome the RA 
signaling deficits caused by MB-3-mediated GCN5 inhibition (Figure 3.10b).  Knockdown of 
RARβ, however, significantly decreased this RA concentration-dependent transcriptional 
response (Figure 3.10b), indicating that RARβ is required for RA-mediated rescue of Foxa1 
expression upon inhibition of GCN5 enzymatic activity.  I further assayed this by treating 
NE-4C cells with MB-3 and a combination of selective RAR agonists, which revealed that 
GCN5 activity is required for robust RARα- and RARγ-mediated gene expression, but not 
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RARβ agonist-mediated expression (Figure 3.12).  Together, these experiments indicate 
that increasing RA concentrations can overcome RA signaling deficiency caused by GCN5 
inhibition and that this rescue phenotype requires expression of RARβ, but not RARα or 
RARγ. 
Rarb is expressed in the forebrain and reduced by ~50% upon loss of GCN5 activity 
(Figure 3.5d). This led us to test in vivo whether it may be possible to rescue the 
diencephalic expansion in Gcn5hat/hat embryos by increasing RA signaling in the embryo, 
perhaps through a RARβ-dependent mechanism.  To test this hypothesis, I performed 
timed matings of Gcn5hat/+ animals and administered 175mg RA/kg food to pregnant dams 
from gestational day 8.5 until embryo harvest at E10.5, followed by analysis for changes in 
the forebrain phenotype.  This diet has been used in previously published experiments and 
is sufficient to drive widespread increases in RA signaling in the murine embryo (Figure 
3.13). Wildtype embryos had normal morphology and forebrain patterning (Figure 3.10c), 
suggesting that the level of RA provided to the pregnant dams was within a safe range for 
the embryos. Gcn5hat/hat embryos from RA-supplemented dams still displayed NTDs, 
suggesting that the level of RA administered was not sufficient to rescue the NTD or that 
the NTD is independent of a RA deficit.  Strikingly, gestational RA supplementation was 
sufficient to rescue forebrain patterning, as indicated by LEF1 and PAX6 staining, with both 
markers extending to the dorsal limit of the open neural tissue (Figure 3.10c).  Furthermore, 
despite the persistent open neural tube, there was also a dramatic reduction in the length 
of the neuroepithelium compared to mutants from dams fed normal mouse chow. 
Specifically, there was no statistically significant difference in length of the diencephalic 
neuroepithelium in RA-treated Gcn5hat/hat mutant embryos compared to RA-treated wildtype 
(Figure 3.10d, Figure 3.14) and similar results were obtained with respect to the 
telencephalic neuroepithelium (Figure 3.15).  Lastly, I observed a rescue of the expression 
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levels of Shh, Gli3, Axin2, and Wnt8b in the forebrain tissue of RA-supplemented Gcn5hat/hat 
embryos (Figure 3.10e).  Thus, RA supplementation can rescue the diencephalic expansion 
caused by loss of GCN5 enzymatic activity. 
Discussion  
My studies identify a novel, non-histone related function of GCN5 that is required to 
restrict diencephalic expansion during early forebrain development via facilitation of RA 
signaling. Gcn5hat/hat embryos, in which GCN5 protein is present but non-functional, show a 
significantly expanded diencephalon and compression of the telencephalon. 
Mechanistically I linked this to tissue-specific loss of RA signaling leading to increased 
WNT activity, decreased Gli3, and increased Shh expression in the ZLI. A physical 
interaction between GCN5, RARa, and TACC1 was identified, this complex is enriched at 
some RARE sites, and GCN5 acts to acetylate TACC1, causing TACC1 dissociation and 
promotion of RA-mediated transcription. Finally, the link between GCN5 activity and 
regulation of RA signaling was shown in vivo by rescue of the diencephalic expansion with 
RA supplementation of pregnant dams.  
Although several previous studies concluded that RA signaling is dispensable for 
gross forebrain development (Easwaran et al. 1999; Molotkova et al. 2007; Li et al. 2008; 
Lohnes et al. 1994; Shah et al. 2003), my data clearly indicate that RA signaling is required 
in the dorsal diencephalon between E9.5 and E10.5.  Furthermore, cell specification 
defects in the ventral telencephalon can be rescued by RA treatment (Figure 3.16), 
indicating that GCN5 is required for proper RA signaling throughout the forebrain.  Rara-/-
;Rarg-/- embryos at E10.5 show similar forebrain morphology defects as Gcn5hat/hat embryos, 
and even though only a small proportion of Rara-/-;Rarg-/- embryos have hindbrain 
exencephaly, the authors hypothesized that the forebrain defects were due to increased 
ventricular pressure caused by hindbrain exencephaly (Lohnes et al. 1994).  My data, 
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however, strongly support an alternative hypothesis: that the neuroepithelial expansion and 
telencephalic compression observed in the absence of proper RA signaling in the forebrain 
are due to SHH-induced overgrowth of the diencephalon. The rescue of the Gcn5hat/hat 
forebrain defects by RA supplementation occurs despite the persistent NTD. This suggests 
that loss of RA signaling is not sufficient to cause neural tube defects in the forebrain and 
that GCN5 controls other non-RA targets during neural tube formation.  
Specification and patterning of the diencephalon have been extensively studied, but 
the hierarchy of necessary signaling molecules is still a topic of debate.  One line of study 
supports a model whereby WNT signaling inhibits Gli3 expression in the alar plate, 
rendering this region competent to express SHH and become the ZLI (Martinez-Ferre et al. 
2013).  Other studies contest that the master regulator of diencephalic specification is SHH, 
with GLI3 playing a necessary role in shaping the ZLI (Rash and Grove 2011).  However, it 
has remained unclear what role, if any, RA signaling plays within this pathway.  In chick and 
quail, the non-canonical RA-synthesizing enzyme CYP1B1 is expressed in the dorsal-most 
region of the ZLI where SHH expression is suppressed (Chambers et al. 2007; Guinazu et 
al. 2007). Diencephalic explant experiments demonstrated that regions flanking the ZLI are 
required to shape the domain of SHH expression (Guinazu et al. 2007), and these regions 
correspond to the diencephalic expression domains of the RA synthesizing enzyme 
RALDH3 (Molotkova et al. 2007).  The finding that the regions flanking the ZLI are sites of 
active RA signaling and that the absence of this RA signaling correlates with increased 
WNT signaling and Shh expression support a direct role of RA in shaping the developing 
diencephalon. RA has been shown to directly inhibit WNT signaling in multiple contexts 
(Easwaran et al. 1999; Li et al. 2008; Shah et al. 2003), and in the context of my data 
suggest that RA is the most upstream factor in determining diencephalic size.  Taken 
together my work supports a model in which RA, WNT, GLI3, and SHH are tightly 
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interrelated and function together to create a fine balance that controls diencephalic size 
and border specification between forebrain structures.        
GCN5 has previously been implicated in RA signaling, although its hypothesized 
role has been restricted to the promotion of transcription through histone acetylation 
(Brown 2003).  While the direct association of SAGA complex member ADA3 with RARα 
supports this hypothesis (Li et al. 2010), functional studies investigating the direct role of 
GCN5-mediated histone acetylation in RA signaling are lacking.  Furthermore, recent 
studies indicate GCN5 elicits some tissue-specific functions through acetylation of non-
histone proteins including alpha-tubulin (Conacci-Sorrell et al. 2010; Li et al. 2015), 
transcription factors (Zelin et al. 2012; Jacob 2001), and the transcriptional coactivator 
PGC1α (Sakai et al. 2012).  My findings identify a new tissue-specific regulatory role for 
GCN5-catalyzed acetylation that involves the substrate TACC1, which appears to act as a 
negative regulator of RA signaling (model Figure 3.17). However, TACC1 may also play a 
positive role in RA signaling as previous work showed that knockdown of Tacc1 results in 
decreased RA target gene expression (Guyot et al. 2010). Thus, TACC1 may serve as an 
adaptor protein necessary for assembly of ‘poised’ RA regulatory complexes on RAREs, 
helping to inhibit transcription in the absence of ligand and then dissociating upon 
acetylation by GCN5 in the presence of RA to allow transcriptional activation.  Moreover, it 
should be noted that GCN5 could play multiple roles in RA signaling, functioning both to 
remove TACC1-mediated transcriptional repression and to increase transcriptional 
efficiency via histone acetylation.  The studies of ADA3 interaction with RARα show 
interaction in the absence of RA that is greatly enhanced by ligand binding (Li et al. 2010), 
similar to the results observed in the ChIP assays (Figure 3.7d).  These results indicate that 
GCN5-mediated acetylation of TACC1 could alleviate transcriptional repression, while 
allowing recruitment and/or activation of other SAGA complex members as a means of 
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driving RA target gene transcription through chromatin modification.  Together, my findings 
identified a novel function of the acetyltransferase GCN5 that is critical for diencephalic size 
restriction.   Furthermore, we identified a previously unknown regulatory mechanism 
required for RA signaling in the forebrain, suggesting that this work may have implications 










Figure 3.1 - Diencephalic Expansion in Gcn5hat/hat Embryos 
Gcn5hat/hat embryos exhibit significant diencephalic expansion.  (a) E12.5 littermates 
highlight the developmental delay and severe exencephaly exhibited by Gcn5hat/hat embryos.  
Dotted line indicates the dorsal margin of the everted neural tissue. (b) False-coloring 
illustrates the normal relative sizes of the telencephalon (blue) and diencephalon (purple) at 
E13.5 in wildtype embryos (+/+) and apparent expansion of the diencephalon in Gcn5hat/hat 
mutants.  Arrows indicate the choroid plexus.  (Scale bars=350µm)  (c) Immunostaining for 
FOXG1 at E13.5 indicates that the expanded tissue observed in mutants is not of 
telencephalic origin (n=4, scale bars=350µm). (d) Immunostaining for LEF1 and PAX6 at 
E10.5 in wildtype embryos (left) shows restriction of dorsal telencephalic staining patterns 
to the dorsal midline region of the neuroepithelium (n=4, scale bars=150µm). In Gcn5hat/hat 
mutants, LEF1 stops midway along the expanded tissue and PAX6 shows two domains of 
expression, with the ventral domain corresponding with the presumptive telencephalic limit 
(arrowheads). (e) Staining for PAX6 in the wildtype diencephalon at E10.5 shows a similar 
pattern to that seen in the dorsally expanded tissue of mutant (analyzed along length of 
dotted line, n=4). (f) Schematic summarizing the staining patterns of PAX6, LEF1, MASH1, 




Figure 3.2 - P21 and MASH1 Expression in Wildtype and Mutant Embryos  
Gcn5hat/hat embryos at E11.5 show P21 expression only in an intermediate region of the 
dorsal-ventral neuroepithelial axis, which is correspondent with the cortical hem in wildtype 
embryos (arrows).  Mutant embryos also show a characteristic ribbon-like tissue that is 
consistent with choroid plexus (arrowheads) located immediately dorsal to the same 
intermediate region (scale bars=150µm).  At E10.5, MASH1 staining in mutants is restricted 
to a ventral stretch of neuroepithelium that corresponds with the subpallium in wildtype 
embryos (middle panels, scale bars = 150µm).  Dorsal MASH1 staining in mutants is 





Figure 3.3 - Normal Telencephalic Patterning in Gcn5hat/hat Mutants at E9.5  
E9.5 embryos indicate normal, dorsally restricted staining patterns of LEF1 (green) and 











Figure 3.4 - Expanded SHH and WNT Signaling in Gcn5hat/hat Mutants 
Gcn5hat/hat mutants display aberrant expression of genes that control diencephalic size at 
E10.5. (a) in situ hybridization for Shh highlights the finger-like projection dorsally of the ZLI 
in wildtype embryos (asterisk) and widespread overexpression throughout the expanded 
mutant tissue (n=3).  Dotted lines indicate dorsal limit of the everted exencephalic tissue. (c) 
Wildtype Gli3 ISH indicates strong expression in the dorsal telencephalon and 
diencephalon, with a notable lack of expression in the ZLI (arrow), while mutants display 
down-regulation throughout the diencephalon (n=3). (e) Gcn5hat/hat mutants show increased 
expression of Axin2 in the dorsally expanded tissue (n=3). (g) Gcn5hat/hat mutants show 
broadened Wnt8b expression throughout the dorsal forebrain (b,d,f,h) qRT-PCR of 
dissected forebrain tissue from wildtype and mutants shows significant dysregulation of 
Shh, Gli3, and Axin2 expression (n=4 biological replicates per genotype). 
 82 
 
Figure 3.5 - GCN5 Enzymatic Activity is Required for Diencephalic RA Signaling 
GCN5 acetyltransferase activity is required for RA signaling in the developing forebrain. (a) 
Wildtype E10.5 RAREhsplacZ embryos show strong β-gal staining in the telencephalon, 
eye, and facial prominence, as well as in two distinct regions of the dorsal diencephalon 
that flank the alar plate (arrows). (b) E10.5 Gcn5hat/hat;RAREhsplacZ embryos maintain RA 
signaling in the telencephalon, facial prominence, and eye, but lack RA signaling in the 
dorsal diencephalon.  Dotted line indicates dorsal limit of open forebrain tissue (n=6). (c) 
NE-4C cells treated with 0.1µM RA for 16 hours show robust expression of Rarb, Foxa1 
and Hoxb1, all of which are significantly down-regulated by inhibition of GCN5 enzymatic 
activity with 100µM MB-3 (n=4 replicates per condition). (d) qRT-PCR using RNA isolated 
from wildtype and Gcn5hat/hat forebrain tissue at E10.5 indicates significant down-regulation 













Figure 3.6 - Input and Fractionation Controls for Figure 3.7a  
Nuclear (POLII) and cytoplasmic (β-TUB) controls for the TACC1 acetylation experiments 
performed in Figure 4A indicate successful fractionation.  The lack of β-TUB in IP lanes 
indicates specific pull-down of acetylated proteins.  POLII is seen in IP lanes because a 










Figure 3.7 - GCN5 Regulates RA Complex Dynamics via Acetylation of TACC1  
GCN5, RARa, and TACC1 form a complex on RA-responsive genes. (a) Treatment of NE-
4C cells with 0.1µM RA for 16 hours induces robust acetylation of nuclear TACC1 in a 
GCN5-dependent manner (N=nuclear, C=Cytoplasmic; n=3). (b) Immunoprecipitation with 
anti-RARα antibody shows association with GCN5 and TACC1 in nuclear extracts. 
Treatment of NE-4C cells with 0.1µM RA disrupts association of TACC1, but not GCN5, 
with RARα.  Inhibition of GCN5 catalytic activity stabilizes the TACC1-RARα interaction in a 
dose-dependent manner.  Densitometry values are normalized to input levels from 
Supplementary Figure 4.  β-tubulin co-IP is displayed as a negative control (n=3). (c) 
Immunoprecipitation of RARα from E10.5 forebrain extracts indicates interactions with both 
GCN5 and TACC1 in vivo. (d) ChIP demonstrates that RARα, GCN5, and TACC1 are 
already associated with Rarb and Foxa1 RAREs prior to RA ligand treatment of NE-4C cells 
(control media with DMSO).  Treatment with 0.1µM RA for 16 hours causes specific 
dissociation of TACC1 from the RAREs, but this dissociation is blocked by inhibition of 









Figure 3.8 - Input and IgG Controls for Figure3.7b  
Input lanes for the experiment performed in Figure 4B representing 10% of the protein 























Figure 3.9 - RARα Binds a Second Rarb RARE Independently of GCN5 and TACC1  
ChIP assays of a second RARE associated with Rarb show significant binding of RARα in 
the presence or absence of RA treatment.  ChIP with antibodies directed against GCN5 
and TACC1, however, revealed a complete lack of binding of either protein under all 
conditions, suggesting that neither protein is involved in RA signaling mediated by this 
RARE.  Furthermore, the lack of staining indicates specificity of the antibodies with respect 



























Figure 3.10 - Gestational RA Supplementation Rescues Diencephalic Expansion  
Gestational RA supplementation rescues diencephalic expansion in Gcn5hat/hat embryos. (a) 
Co-immunoprecipitation with anti-RARβ antibody shows that RARβ does not associate 
with GCN5 or TACC1 in E10.5 forebrain tissue.  Co-IP for RARg indicates association with 
both TACC1 and GCN5 (n=3 biological replicates). (b) Knock-down of Rarb (shRarb) in NE-
4C cells treated with 100µM MB-3 and increasing concentrations of RA followed by qRT-
PCR indicate that RARβ is required for RA concentration-dependent expression of Foxa1 
when GCN5 activity is lost (n=4 per condition). (c) Dietary RA supplementation starting at 
gestational age E8.5 prevents diencephalic expansion in Gcn5hat/hat embryos but does not 
rescue NTD.  RA supplementation normalizes LEF1 and PAX6 in Gcn5hat/hat embryos such 
that LEF1 is restricted to the dorsal-most region of the pallium and PAX6 expression begins 
at the pallial-subpallial border and extends to the dorsal margin of the open neural tissue. 
These expression patterns are similar to wildtype embryos at this dose of RA that does not 
disrupt wildtype patterning (n≥5 RA treated embryos per genotype). (d) Dietary RA 
supplementation rescues the increased diencephalic neuroepithelial (NE) length to wildtype 
length (n≥5 animals per genotype). (e) Gestational RA supplementation rescues expression 




Figure 3.11 - Knockdown of Rarb in Figure 3.12b  
NE-4C cells transfected with either a control shRNA (shCtrl) or two shRNAs directed 
against Rarb (shRarb) were grown for 48 hours and analyzed by Western blot for RARβ 






















Figure 3.12 - Selective RAR Agonists Indicate GCN5-independent Regulation of RARβ  
Treatment of NE-4C cells with varying combinations of RA (0.1µM), MB-3, BMS 753 (a 
selective RARα agonist), CD 2314 (a selective RARβ agonist), and CD 437 (a selective 
RARγ agonist) for 24 hours indicates that only RARβ-mediated target gene expression is 






























Figure 3.13 - Increased RA Signaling from Gestational RA Supplementation  
Beta-galactosidase staining shows that gestational RA supplementation of RAREhsplacZ 
mice results in widespread expansion of lacZ expression, a proxy of RA signaling, in the 




























Figure 3.14 - Diencephalic Size is Normalized by RA Supplementation  
Nuclear staining of wildtype and Gcn5hat/hat embryos demonstrates that gestational RA 
supplementation is capable of rescuing the significant diencephalic expansion observed in 































Figure 3.15 - Telencephalic Size is Normalized by RA Supplementation  
Measurement of neuroepithelial length in the telencephalon of wildtype and Gcn5hat/hat 
embryos on control and high RA diets demonstrates that gestational RA supplementation is 
sufficient to rescue telencephalic expansion seen in Gcn5hat/hat mutants on regular diet (n≥5 

















Figure 3.16 - RA Supplementation Rescues Ectopic Ventral Expression of TBR2  
Gcn5hat/hat mutants show aberrant expression of TBR2, a marker of putative Cajal-Retzius 
cells, in the ventral subpallium (length of dotted line) that is rescued by gestational 





Figure 3.17 - A Proposed Model for GCN5-mediated RA Signaling in the Diencephalon  
A proposed model for GCN5-mediated regulation of diencephalic size. (a) In the absence of 
RA, a poised transcriptional complex containing RARα or RARγ, GCN5/SAGA, and TACC1 
localizes to the RAREs of some RA-responsive genes.  TACC1 acts as a negative regulator 
of transcription in the absence of ligand. (b) Upon RA binding to the RAR, GCN5-mediated 
acetylation of TACC1 causes dissociation of TACC1 from the complex, allowing 





























































































































Panel Target Genotype Mean Std Dev n Replicate Type Statistical Test p-value
b Shh +/+ 1 0.107 4 Biological Unpaired 0.0024
hat/hat 1.334 0.0782 4 Biological t-test
d Gli3 +/+ 1 0.0489 4 Biological Unpaired 0.005
hat/hat 0.564 0.1912 4 Biological t-test
f Axin2 +/+ 1 0.0649 4 Biological Unpaired 0.035
hat/hat 1.935 0.6874 4 Biological t-test
h Wnt8b +/+ 1 0.0449 4 Biological Unpaired 0.037
hat/hat 1.8641 0.4833 4 Biological t-test
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Panel c (Two-way ANOVA)
Target Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
DMSO vs. MB-3 -1.481 -5.285 to 2.323 No ns 0.7308
DMSO vs. RA -81.96 -85.76 to -78.16 Yes **** < 0.0001
Rarb DMSO vs. RA+MB-3 -54.7 -58.50 to -50.90 Yes **** < 0.0001
MB-3 vs. RA -80.48 -84.28 to -76.68 Yes **** < 0.0001
MB-3 vs. RA+MB-3 -53.22 -57.02 to -49.42 Yes **** < 0.0001
RA vs. RA+MB-3 27.26 23.46 to 31.06 Yes **** < 0.0001
Target Foxa1 Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
DMSO vs. MB-3 -0.292 -4.096 to 3.512 No ns 0.997
DMSO vs. RA -11.71 -15.51 to -7.906 Yes **** < 0.0001
Foxa1 DMSO vs. RA+MB-3 -5.333 -9.137 to -1.529 Yes ** 0.0027
MB-3 vs. RA -11.42 -15.22 to -7.614 Yes **** < 0.0001
MB-3 vs. RA+MB-3 -5.041 -8.845 to -1.237 Yes ** 0.0049
RA vs. RA+MB-3 6.377 2.573 to 10.18 Yes *** 0.0003
Target Ptch1 Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
DMSO vs. MB-3 -0.443 -3.133 to 2.247 No ns 0.9718
DMSO vs. RA -10.13 -12.82 to -7.440 Yes **** < 0.0001
Ptch1 DMSO vs. RA+MB-3 -6.91 -9.600 to -4.220 Yes **** < 0.0001
MB-3 vs. RA -9.687 -12.38 to -6.997 Yes **** < 0.0001
MB-3 vs. RA+MB-3 -6.467 -9.157 to -3.777 Yes **** < 0.0001
RA vs. RA+MB-3 3.22 0.5302 to 5.910 Yes * 0.013
Panel d
Target Genotype Mean Std Dev n Statistical Test p-value
Rarb +/+ 1 0.0754 4 Unpaired 1.97E-05
hat/hat 0.4568 0.0492 4 t-test
Foxa1 +/+ 1 0.0751 4 Unpaired 5.74E-03
hat/hat 0.7645 0.0836 4 t-test
Ptch1 +/+ 1 0.0574 4 Unpaired 6.08E-03
hat/hat 0.7799 0.0895 4 t-test
Nes +/+ 1 0.225 4 Unpaired 1.39E-01
hat/hat 0.7504 0.1868 4 t-test
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Rarb  RARE (Two-way ANOVA)
Treatment Condition Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
IgG vs. RARα -9.19 -11.59 to -6.786 Yes **** < 0.0001
IgG vs. GCN5 -3.499 -5.903 to -1.095 Yes ** 0.0021
DMSO IgG vs. TACC1 -3.163 -5.567 to -0.7588 Yes ** 0.0059
RARα vs. GCN5 5.691 3.287 to 8.095 Yes **** < 0.0001
RARα vs. TACC1 6.027 3.623 to 8.431 Yes **** < 0.0001
GCN5 vs. TACC1 0.336 -2.068 to 2.740 No ns 0.9815
IgG vs. RARα -5.266 -7.670 to -2.862 Yes **** < 0.0001
IgG vs. GCN5 -4.975 -7.379 to -2.571 Yes **** < 0.0001
RA IgG vs. TACC1 -1.109 -3.513 to 1.295 No ns 0.6047
RARα vs. GCN5 0.291 -2.113 to 2.695 No ns 0.9878
RARα vs. TACC1 4.157 1.753 to 6.561 Yes *** 0.0002
GCN5 vs. TACC1 3.866 1.462 to 6.270 Yes *** 0.0006
IgG vs. RARα -10.47 -12.87 to -8.066 Yes **** < 0.0001
IgG vs. GCN5 -8.678 -11.08 to -6.274 Yes **** < 0.0001
RA+MB-3 IgG vs. TACC1 -9.23 -11.63 to -6.826 Yes **** < 0.0001
RARα vs. GCN5 1.792 -0.6122 to 4.196 No ns 0.2042
RARα vs. TACC1 1.24 -1.164 to 3.644 No ns 0.5142
GCN5 vs. TACC1 -0.552 -2.956 to 1.852 No ns 0.9255
Foxa1  RARE (Two-way ANOVA)
Treatment Condition Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
IgG vs. RARα -6.041 -10.53 to -1.552 Yes ** 0.0047
IgG vs. GCN5 -5.548 -10.04 to -1.059 Yes * 0.0104
DMSO IgG vs. TACC1 -5.556 -10.04 to -1.067 Yes * 0.0103
RARα vs. GCN5 0.493 -3.996 to 4.982 No ns 0.9908
RARα vs. TACC1 0.485 -4.004 to 4.974 No ns 0.9913
GCN5 vs. TACC1 -0.008 -4.497 to 4.481 No ns > 0.9999
IgG vs. RARα -14.41 -18.90 to -9.922 Yes **** < 0.0001
IgG vs. GCN5 -12.42 -16.91 to -7.928 Yes **** < 0.0001
RA IgG vs. TACC1 -3.866 -8.355 to 0.6226 No ns 0.1124
RARα vs. GCN5 1.994 -2.495 to 6.483 No ns 0.633
RARα vs. TACC1 10.55 6.056 to 15.03 Yes **** < 0.0001
GCN5 vs. TACC1 8.551 4.062 to 13.04 Yes **** < 0.0001
IgG vs. RARα -26.05 -30.54 to -21.56 Yes **** < 0.0001
IgG vs. GCN5 -25.29 -29.78 to -20.80 Yes **** < 0.0001
RA+MB-3 IgG vs. TACC1 -26.03 -30.52 to -21.54 Yes **** < 0.0001
RARα vs. GCN5 0.76 -3.729 to 5.249 No ns 0.968
RARα vs. TACC1 0.02 -4.469 to 4.509 No ns > 0.9999
GCN5 vs. TACC1 -0.74 -5.229 to 3.749 No ns 0.9704
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Rarb RARE #2 (Two-way ANOVA)
Treatment Condition Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value
IgG vs. RARα -17.27 -21.24 to -13.30 Yes **** < 0.0001
IgG vs. GCN5 -0.6 -4.572 to 3.372 No ns 0.9751
DMSO IgG vs. TACC1 -0.092 -4.064 to 3.880 No ns > 0.9999
RARα vs. GCN5 16.67 12.70 to 20.64 Yes **** < 0.0001
RARα vs. TACC1 17.18 13.21 to 21.15 Yes **** < 0.0001
GCN5 vs. TACC1 0.508 -3.464 to 4.480 No ns 0.9846
IgG vs. RARα -13.44 -17.41 to -9.468 Yes **** < 0.0001
IgG vs. GCN5 -1.199 -5.171 to 2.773 No ns 0.8385
RA IgG vs. TACC1 -0.201 -4.173 to 3.771 No ns 0.999
RARα vs. GCN5 12.24 8.269 to 16.21 Yes **** < 0.0001
RARα vs. TACC1 13.24 9.267 to 17.21 Yes **** < 0.0001
GCN5 vs. TACC1 0.998 -2.974 to 4.970 No ns 0.8987
IgG vs. RARα -15.93 -19.91 to -11.96 Yes **** < 0.0001
IgG vs. GCN5 -0.984 -4.956 to 2.988 No ns 0.9024
RA+MB-3 IgG vs. TACC1 -0.212 -4.184 to 3.760 No ns 0.9988
RARα vs. GCN5 14.95 10.98 to 18.92 Yes **** < 0.0001
RARα vs. TACC1 15.72 11.75 to 19.69 Yes **** < 0.0001
GCN5 vs. TACC1 0.772 -3.200 to 4.744 No ns 0.9494
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Panel b (Two-way ANOVA)
Comparison Mean Diff. 95% CI of diff. Significant? Adjusted P Value
0.01µM RA:MB-3 + shCtrl vs. 0.01µM RA:MB-3 + shRarb 0.078 -0.3895 to 0.5455 No 0.7282
0.01µM RA:MB-3 + shCtrl vs. 0.1µM RA:MB-3 + shCtrl -0.4555 -0.9230 to 0.01198 No 0.0555
0.01µM RA:MB-3 + shCtrl vs. 0.1µM RA:MB-3 + shRarb 0.1997 -0.2678 to 0.6671 No 0.3787
0.01µM RA:MB-3 + shCtrl vs. 1.0µM RA:MB-3 + shCtrl -1.323 -1.791 to -0.8559 Yes < 0.0001
0.01µM RA:MB-3 + shCtrl vs. 1.0µM RA:MB-3 + shRarb -0.1055 -0.5730 to 0.3620 No 0.6388
0.01µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shCtrl -2.763 -3.231 to -2.296 Yes < 0.0001
0.01µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shRarb -1.4 -1.867 to -0.9325 Yes < 0.0001
0.01µM RA:MB-3 + shRarb vs. 0.1µM RA:MB-3 + shCtrl -0.5335 -1.001 to -0.06602 Yes 0.0278
0.01µM RA:MB-3 + shRarb vs. 0.1µM RA:MB-3 + shRarb 0.1217 -0.3458 to 0.5891 No 0.5888
0.01µM RA:MB-3 + shRarb vs. 1.0µM RA:MB-3 + shCtrl -1.401 -1.869 to -0.9339 Yes < 0.0001
0.01µM RA:MB-3 + shRarb vs. 1.0µM RA:MB-3 + shRarb -0.1835 -0.6510 to 0.2840 No 0.4176
0.01µM RA:MB-3 + shRarb vs. 10µM RA:MB-3 + shCtrl -2.841 -3.309 to -2.374 Yes < 0.0001
0.01µM RA:MB-3 + shRarb vs. 10µM RA:MB-3 + shRarb -1.478 -1.945 to -1.011 Yes < 0.0001
0.1µM RA:MB-3 + shCtrl vs. 0.1µM RA:MB-3 + shRarb 0.6552 0.1877 to 1.123 Yes 0.009
0.1µM RA:MB-3 + shCtrl vs. 1.0µM RA:MB-3 + shCtrl -0.8678 -1.335 to -0.4004 Yes 0.0012
0.1µM RA:MB-3 + shCtrl vs. 1.0µM RA:MB-3 + shRarb 0.35 -0.1175 to 0.8175 No 0.132
0.1µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shCtrl -2.308 -2.775 to -1.840 Yes < 0.0001
0.1µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shRarb -0.9445 -1.412 to -0.4770 Yes 0.0006
0.1µM RA:MB-3 + shRarb vs. 1.0µM RA:MB-3 + shCtrl -1.523 -1.990 to -1.056 Yes < 0.0001
0.1µM RA:MB-3 + shRarb vs. 1.0µM RA:MB-3 + shRarb -0.3052 -0.7726 to 0.1623 No 0.1854
0.1µM RA:MB-3 + shRarb vs. 10µM RA:MB-3 + shCtrl -2.963 -3.430 to -2.496 Yes < 0.0001
0.1µM RA:MB-3 + shRarb vs. 10µM RA:MB-3 + shRarb -1.6 -2.067 to -1.132 Yes < 0.0001
1.0µM RA:MB-3 + shCtrl vs. 1.0µM RA:MB-3 + shRarb 1.218 0.7504 to 1.685 Yes < 0.0001
1.0µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shCtrl -1.44 -1.907 to -0.9725 Yes < 0.0001
1.0µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shRarb -0.07667 -0.5442 to 0.3908 No 0.7326
1.0µM RA:MB-3 + shRarb vs. 10µM RA:MB-3 + shCtrl -2.658 -3.125 to -2.190 Yes < 0.0001
1.0µM RA:MB-3 + shRarb vs. 10µM RA:MB-3 + shRarb -1.295 -1.762 to -0.8270 Yes < 0.0001
10µM RA:MB-3 + shCtrl vs. 10µM RA:MB-3 + shRarb 1.363 0.8959 to 1.831 Yes < 0.0001
Panel d (Two-way ANOVA)
Comparison Mean Diff. 95% CI of diff. Significant? Adjusted P Value
Control Diet:+/+ vs. Control Diet:hat/hat -1566 -2012 to -1120 Yes < 0.0001
Control Diet:+/+ vs. High RA Diet:+/+ 77.72 -397.4 to 552.8 No 0.9663
Control Diet:+/+ vs. High RA Diet:hat/hat -120.3 -529.8 to 289.2 No 0.8393
Control Diet:hat/hat vs. High RA Diet:+/+ 1644 1150 to 2137 Yes < 0.0001
Control Diet:hat/hat vs. High RA Diet:hat/hat 1445 1015 to 1876 Yes < 0.0001
High RA Diet:+/+ vs. High RA Diet:hat/hat -198.1 -659.4 to 263.3 No 0.6266
Panel e (Two-way ANOVA)
Target Comparison Mean Diff. 95% CI of diff. Significant? Adjusted P Value
+/+ vs. +/+ (RA Diet) -0.095 -0.5301 to 0.3401 No > 0.9999
+/+ vs. hat/hat -0.444 -0.8791 to -0.008858 Yes 0.0431
Shh +/+ vs. hat/hat  (RA Diet) -0.07 -0.5051 to 0.3651 No > 0.9999
+/+ (RA Diet) vs. hat/hat -0.349 -0.7841 to 0.08614 No 0.1927
+/+ (RA Diet) vs. hat/hat  (RA Diet) 0.025 -0.4101 to 0.4601 No > 0.9999
hat/hat  vs. hat/hat  (RA Diet) 0.374 -0.06114 to 0.8091 No 0.1326
+/+ vs. +/+ (RA Diet) -0.046 -0.4811 to 0.3891 No > 0.9999
+/+ vs. hat/hat 0.436 0.0008581 to 0.8711 Yes 0.0493
Gli3 +/+ vs. hat/hat  (RA Diet) -0.019 -0.4541 to 0.4161 No > 0.9999
+/+ (RA Diet) vs. hat/hat 0.482 0.04686 to 0.9171 Yes 0.0224
+/+ (RA Diet) vs. hat/hat  (RA Diet) 0.027 -0.4081 to 0.4621 No > 0.9999
hat/hat  vs. hat/hat  (RA Diet) -0.455 -0.8901 to -0.01986 Yes 0.0358
+/+ vs. +/+ (RA Diet) 0.0118 -0.4233 to 0.4469 No > 0.9999
+/+ vs. hat/hat -0.935 -1.370 to -0.4999 Yes < 0.0001
Axin2 +/+ vs. hat/hat  (RA Diet) -0.036 -0.4711 to 0.3991 No > 0.9999
+/+ (RA Diet) vs. hat/hat -0.9468 -1.382 to -0.5117 Yes < 0.0001
+/+ (RA Diet) vs. hat/hat  (RA Diet) -0.0478 -0.4829 to 0.3873 No > 0.9999
hat/hat  vs. hat/hat  (RA Diet) 0.899 0.4639 to 1.334 Yes < 0.0001
+/+ vs. +/+ (RA Diet) -0.1142 -0.5493 to 0.3209 No > 0.9999
+/+ vs. hat/hat -0.764 -1.199 to -0.3289 Yes < 0.0001
Wnt8b +/+ vs. hat/hat  (RA Diet) -0.057 -0.4921 to 0.3781 No > 0.9999
+/+ (RA Diet) vs. hat/hat -0.6498 -1.085 to -0.2147 Yes 0.0009
+/+ (RA Diet) vs. hat/hat  (RA Diet) 0.0572 -0.3779 to 0.4923 No > 0.9999
hat/hat  vs. hat/hat  (RA Diet) 0.707 0.2719 to 1.142 Yes 0.0003
 103 
Table 3.9 – Statistical Data for Figure 3.12 
 
 
Target Mean Diff. 95% CI of diff. Significant? Adjusted P Value
DMSO vs. RA -48.18 -55.97 to -40.39 Yes < 0.0001
DMSO vs. RA+MB-3 -15.39 -23.18 to -7.597 Yes 0.0002
DMSO vs. α -18.42 -26.21 to -10.63 Yes < 0.0001
DMSO vs. α+MB-3 -6.793 -14.59 to 1.000 No 0.0862
DMSO vs. β -11.81 -19.60 to -4.017 Yes 0.0037
DMSO vs. β+MB-3 -13.03 -20.82 to -5.237 Yes 0.0015
DMSO vs. γ -10.31 -18.10 to -2.514 Yes 0.0105
DMSO vs. γ+MB-3 -2.282 -10.08 to 5.511 No 0.5596
RA vs. RA+MB-3 32.79 25.00 to 40.58 Yes < 0.0001
RA vs. α 29.76 21.97 to 37.55 Yes < 0.0001
RA vs. α+MB-3 41.39 33.59 to 49.18 Yes < 0.0001
RA vs. β 36.37 28.58 to 44.16 Yes < 0.0001
RA vs. β+MB-3 35.15 27.36 to 42.94 Yes < 0.0001
RA vs. γ 37.87 30.08 to 45.67 Yes < 0.0001
RA vs. γ+MB-3 45.9 38.10 to 53.69 Yes < 0.0001
RA+MB-3 vs. α -3.03 -10.82 to 4.763 No 0.4391
Rarb RA+MB-3 vs. α+MB-3 8.597 0.8040 to 16.39 Yes 0.0312
RA+MB-3 vs. β 3.58 -4.213 to 11.37 No 0.3611
RA+MB-3 vs. β+MB-3 2.36 -5.433 to 10.15 No 0.5463
RA+MB-3 vs. γ 5.083 -2.710 to 12.88 No 0.1965
RA+MB-3 vs. γ+MB-3 13.11 5.315 to 20.90 Yes 0.0014
α vs. α+MB-3 11.63 3.834 to 19.42 Yes 0.0042
α vs. β 6.61 -1.183 to 14.40 No 0.0948
α vs. β+MB-3 5.39 -2.403 to 13.18 No 0.1712
α vs. γ 8.113 0.3200 to 15.91 Yes 0.0416
α vs. γ+MB-3 16.14 8.345 to 23.93 Yes 0.0001
α+MB-3 vs. β -5.017 -12.81 to 2.776 No 0.2023
α+MB-3 vs. β+MB-3 -6.237 -14.03 to 1.556 No 0.1144
α+MB-3 vs. γ -3.514 -11.31 to 4.279 No 0.37
α+MB-3 vs. γ+MB-3 4.511 -3.282 to 12.30 No 0.2509
β vs. β+MB-3 -1.22 -9.013 to 6.573 No 0.7548
β vs. γ 1.503 -6.290 to 9.296 No 0.7005
β vs. γ+MB-3 9.528 1.735 to 17.32 Yes 0.0175
β+MB-3 vs. γ 2.723 -5.070 to 10.52 No 0.4866
β+MB-3 vs. γ+MB-3 10.75 2.955 to 18.54 Yes 0.0078
γ vs. γ+MB-3 8.025 0.2320 to 15.82 Yes 0.0438
DMSO vs. RA -35.24 -43.03 to -27.45 Yes < 0.0001
DMSO vs. RA+MB-3 -8.771 -16.56 to -0.9780 Yes 0.0281
DMSO vs. α -30.91 -38.70 to -23.12 Yes < 0.0001
DMSO vs. α+MB-3 -8.704 -16.50 to -0.9110 Yes 0.0293
DMSO vs. β -11.38 -19.17 to -3.587 Yes 0.005
DMSO vs. β+MB-3 -13.27 -21.06 to -5.477 Yes 0.0012
DMSO vs. γ -15.85 -23.64 to -8.057 Yes 0.0002
DMSO vs. γ+MB-3 -4.312 -12.11 to 3.481 No 0.2722
RA vs. RA+MB-3 26.47 18.68 to 34.26 Yes < 0.0001
RA vs. α 4.33 -3.463 to 12.12 No 0.2702
RA vs. α+MB-3 26.54 18.74 to 34.33 Yes < 0.0001
RA vs. β 23.86 16.07 to 31.65 Yes < 0.0001
RA vs. β+MB-3 21.97 14.18 to 29.76 Yes < 0.0001
RA vs. γ 19.39 11.60 to 27.18 Yes < 0.0001
RA vs. γ+MB-3 30.93 23.13 to 38.72 Yes < 0.0001
RA+MB-3 vs. α -22.14 -29.93 to -14.35 Yes < 0.0001
RA+MB-3 vs. α+MB-3 0.067 -7.726 to 7.860 No 0.9863
RA+MB-3 vs. β -2.609 -10.40 to 5.184 No 0.505
Foxa1 RA+MB-3 vs. β+MB-3 -4.499 -12.29 to 3.294 No 0.2522
RA+MB-3 vs. γ -7.079 -14.87 to 0.7140 No 0.0741
RA+MB-3 vs. γ+MB-3 4.459 -3.334 to 12.25 No 0.2564
α vs. α+MB-3 22.21 14.41 to 30.00 Yes < 0.0001
α vs. β 19.53 11.74 to 27.32 Yes < 0.0001
α vs. β+MB-3 17.64 9.847 to 25.43 Yes < 0.0001
α vs. γ 15.06 7.267 to 22.85 Yes 0.0003
α vs. γ+MB-3 26.6 18.80 to 34.39 Yes < 0.0001
α+MB-3 vs. β -2.676 -10.47 to 5.117 No 0.4941
α+MB-3 vs. β+MB-3 -4.566 -12.36 to 3.227 No 0.2453
α+MB-3 vs. γ -7.146 -14.94 to 0.6470 No 0.0715
α+MB-3 vs. γ+MB-3 4.392 -3.401 to 12.19 No 0.2635
β vs. β+MB-3 -1.89 -9.683 to 5.903 No 0.6288
β vs. γ -4.47 -12.26 to 3.323 No 0.2552
β vs. γ+MB-3 7.068 -0.7250 to 14.86 No 0.0746
β+MB-3 vs. γ -2.58 -10.37 to 5.213 No 0.5097
β+MB-3 vs. γ+MB-3 8.958 1.165 to 16.75 Yes 0.0251
γ vs. γ+MB-3 11.54 3.745 to 19.33 Yes 0.0045
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Comparison Mean Diff. 95% CI of diff. Significant? Adjusted P Value
Control Diet:+/+ vs. Control Diet:hat/hat -2607 -2896 to -2318 Yes < 0.0001
Control Diet:+/+ vs. High RA Diet:+/+ -57.83 -380.7 to 265.0 No 0.9549
Control Diet:+/+ vs. High RA Diet:hat/hat -282.2 -605.1 to 40.63 No 0.0979
Control Diet:hat/hat vs. High RA Diet:+/+ 2549 2226 to 2872 Yes < 0.0001
Control Diet:hat/hat vs. High RA Diet:hat/hat 2325 2002 to 2648 Yes < 0.0001




A REQUIREMENT FOR GCN5 ENZYMATIC ACTIVITY IN FOREBRAIN FUNCTION AND 
BEHAVIOR 
Introduction  
 The studies described in Chapters 2 and 3 illustrate the important roles for GCN5 
during early development of the central nervous system. Gcn5 expression remains 
ubiquitous throughout the mouse brain during adulthood (Lein et al. 2007) suggesting that 
GCN5 may continue to serve important functions in the brain postnatally.  In support of this 
idea, a recent study of mice lacking Gcn5 expression in the CA1 region of the 
hippocampus indicated that GCN5 is required for memory-related transcriptional networks 
(Stilling et al. 2014).  Beyond this study, however, additional functions of GCN5 in the adult 
forebrain or associations between misregulation of Gcn5 and neurological disease have not 
been reported.  In this chapter, I will present evidence for the requirement of  GCN5 
enzymatic activity in proper function of forebrain circuits involved in habitual behavior, 
social behavior, motivation, and action selection.  These data indicate that alterations in 
expression of Gcn5 or its subsequent enzymatic activity may underlie a subset of 
neuropsychiatric disorders and suggest novel therapeutic targets for the treatment of such 
diseases. 
Materials and Methods 
Mouse Strains and Genotyping 
All mice were maintained according to protocols approved by the UC Denver 
Institutional Animal Care and Use Committee.  Gcn5hat mice were genotyped according to 
previously published protocols (Bu et al. 2007).  For all experiments in this chapter, male 
Gcn5hat/+ mice were used.  All animals were ±1 week within the described age. 
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Analysis of Behavioral Experiments 
Open-field, elevated zero/plus maze, and marble burying assays were filmed and 
analyzed using EthoVision XT (Version 8.5; Noldus Information Technology). 
Accelerating Rotarod Assay 
The accelerating rotarod assay was performed as previously described (Powell et al. 
2004).  Animals were tested 3 times on the same day at each assayed age.  For all 
timepoints, rotarod speed was increased from 3-30rpm over 5 minutes. 
Open-field Test 
Open-field test was performed as previously described (Powell et al. 2004).  Animals 
were filmed for 5 minutes and distance traveled, velocity, center duration, peripheral 
duration, and nose-point to wall were calculated. 
Elevated Plus and Zero Mazes 
Elevated plus maze and elevated zero maze assays were performed as previously 
described (Powell et al. 2004).  Animals were filmed for 5 minutes and distance traveled, 
velocity, open duration, and closed duration were calculated. 
Marble Burying Assay 
The marble burying assay was performed as previously described (Welch et al. 
2007) with several protocol adjustments.   Mice were placed in a 12”x12” box with 3 liters 
of fresh bedding.  Nine marbles were placed in the arena in a 3x3 array with equidistant 
spacing.  Animals were filmed for 10 minutes and manual calculations of burying actions, 
latency, and total marbles buried were performed. 
Immunohistochemistry 
Mice were anesthetized with pentobarbital (150mg/kg body weight. active 
component) and transcardially perfused with fresh 4% PFA.  Brains were immediately 
dissected and incubated in ice-cold 4% PFA overnight at 4°C on a rocking platform.  
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Brains were frozen in OCT and sectioned onto SuperFrost Plus slides at 20µm using a 
Leica CM3050S cryostat.  Immunohistochemistry was performed as described in Chapter 
2.  Antibody conditions can be found in Table 4.1.  
Golgi Staining 
Golgi staining was performed with the FD Rapid GolgiStain Kit (FD 
Neurotechnologies, Inc.) according to manufacturer’s instructions.  Animals were 
euthanized with CO2 and brains were immediately dissected and quickly rinsed in MilliQ 
water before being placed in Solution A/B.  Following immersion in Solution C, brains were 
dried and immediately frozen on dry ice and stored at -80°C until section.  Brains were 
mounted directly onto sectioning chucks using dH2O and 100µm sections were cut before 
following on-slide staining instructions.  Sections were mounted with Permount and stored 
at 4°C in the dark.  Images of Golgi stained neurons were performed on a Nikon i80.  
Manual z-stacks were performed and in-focus composite images were generated using NIS 
Elements Software (version 4.13).  
Medium Spiny Neuron Tracing and Analysis 
After collecting images, striatal medium spiny neurons were traced with Image J 
(version 2.0.0) and the NeuronJ plug-in.  Analysis of MSN complexity was performed using 
the Sholl Analysis plug-in in ImageJ.  
Volumetric Magnetic Resonance Imaging 
Volumetric MRI was performed in partnership with the UC Denver Small Animal 
Imaging Core.  Animals were anesthetized with isoflurane and imaged on a 4.7 Tesla/16cm 
Bruker PharmaScan using a RARE pulse sequence with a TE of 4,000.0ms and a TR of 
80.0ms. Two-dimensional areas of relevant brain structures were traced using the Allen 
Brain Atlas as a reference.  Three-dimensional volumes were calculated using the Cavalieri 
method (Shmelkov et al. 2010).   
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Statistical Analyses 
Statistical analyses were performed using Prism 6 (GraphPad).  Due to the large 
number of statistical tests performed in this chapter, statistical details are only provided for 
significant findings.  Specific details of statistical analyses can be found in Tables 4.3-4.7. 
Results 
Severe Self-Induced Skin Lesions in Aging Gcn5hat/+ Mice 
 During the course of my studies of GCN5 enzymatic activity and its role in forebrain 
development, I observed a significant number of aging (>6 months) Gcn5hat/+ heterozygous 
males with severe, self-induced skin lesions (Figure 4.1a).  The self-induced nature of these 
injuries was confirmed both through the appearance of lesions in singly-housed males, as 
well as through separation of mice upon the first observation of injury.  Such lesions, which 
ultimately required euthanasia, were consistently located on the flank and neck of injured 
animals, with several exhibiting additional lesions on the face (Figure 4.1a).  Lesions have 
been observed in nearly 50% (18/38) of Gcn5hat/+ male mice beyond 6 months of age, with 2 
additional animals presenting lesions between 2 and 3 months of age (Figure 4.1b).  Similar 
lesions were observed on 2 out of 44 wildtype C57BL6J females housed with Gcn5hat/+ 
males, but these lesions resolved upon separation of the animals, suggesting that they 
were the result of cagemate aggression.  The high incidence of such severe behavioral 
phenotypes in Gcn5hat/+ mice, in addition to the roles of GCN5 in forebrain development and 
RA signaling identified in Chapter 3, prompted me to further investigate forebrain-specific 
phenotypes in these mice, as self-injurious behavior has been observed in mouse models 
of OCD, ASDs, and schizophrenia (Shmelkov et al. 2010; Welch et al. 2007; Peca et al. 




Transcriptional Dysregulation of Forebrain Circuitry Genes 
 To investigate further a potential role for GCN5 enzymatic activity in the 
development of forebrain circuitry, I gained some insights from another preliminary 
microarray dataset that I obtained from E10.5 wildtype and Gcn5hat/hat embryos.  Although 
these data were collected from embryos at the onset of forebrain development and prior to 
differentiation of many adult neuronal cell types, Gcn5hat/hat embryos exhibited significant 
disruption of numerous genes involved in CSTC development and implicated in 
neuropsychiatric disease (Table 4.2).  Of particular interest were two genes from the 
SLITRK family of proteins, Slitrk3 and Slitrk5.  SLITRK proteins, as their name suggests, 
contain homology to both SLIT proteins and the TRK family of neurotrophin receptors that 
are implicated in neuronal cell-cell adhesion and neurite outgrowth (Aruga and Mikoshiba 
2003).  Interestingly, Slitrk3 has been implicated in regulation of GABAergic synapses and 
seizure disorders (Takahashi et al. 2012; Yim et al. 2013).  Furthermore, Slitrk5 is mutated in 
a subset of humans with OCD and mice lacking Slitrk5 also show OCD-like phenotypes 
(Shmelkov et al. 2010).  While Slitrk5-/- mice develop self-induced lesions prior to 12 weeks 
of age, Slitrk5+/- animals do not exhibit self-injurious behavior until ~1 year of age.  This is 
especially interesting considering the late appearance of lesions in Gcn5hat/+ mice.  Based 
on these preliminary observations and the knowledge that the CSTC loop is strongly 
implicated in OCD disease etiology (Shmelkov et al. 2010; Wan et al. 2014; Pauls et al. 
2014), I hypothesized that GCN5 is required for proper development and function of CSTC 
circuitry. To begin to test this hypothesis, I designed a longitudinal study to investigate 
behavioral, cellular, molecular, and anatomical phenotypes in Gcn5hat/+ animals.    
Design of a Longitudinal Study of Gcn5hat/+ Mice 
 The observed self-mutilation in older Gcn5hat/+ mice and dysregulation of pathways 
implicated in such behavior in Gcn5 mutant embryos during early neural development 
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prompted me to design a longitudinal study investigating the development and progression 
of behavioral, cellular, molecular, and anatomical phenotypes in these animals (Figure 4.2).  
This ongoing study was funded by a pilot grant provided by the Colorado Clinical and 
Translational Sciences Institute (award CNSBI-14-65) and was designed to follow 
phenotypic progression in small groups (n=9 per genotype) of wildtype and Gcn5hat/+ mice 
in hopes of better understanding the behavioral consequences of heterozygous loss of 
GCN5 enzymatic activity.  Furthermore, through multi-faceted analysis of additional age-
matched mice, the study aims to understand the underlying cellular and molecular 
dysfunction that contributes to such phenotypes.   
The study was designed to longitudinally assess groups of wildtype and mutant mice 
subjected to motor and behavioral analyses (rotarod, open-field, elevated zero/plus maze, 
and marble burying) at 6, 8, and 12 months of age, as well as volumetric MRI at 3, 8, and 
12 months of age.  Behavioral experiments were not initiated until 6 months of age because 
of the emergence of self-injurious behavior beyond this age.  With respect to the elevated 
maze tests, zero maze assays were performed at 6 and 12 months of age, while the 
elevated plus maze was performed at 8 months of age.  This was specifically designed to 
avoid memory of the maze apparatus and provide an accurate analysis of anxiety-like 
behaviors.  Additionally, MRI analyses were performed ~2 weeks after behavioral assays to 
avoid confounding results due to isoflurane anesthesia.  In order to identify cellular and 
molecular correlates, additional wildtype and mutant mice were sacrificed at 3, 6, 8, and 12 
months of age for analysis of sustained neuronal activity, MSN morphology, D2DR 
expression, proliferation and apoptosis, and synaptic protein composition.  As these 
studies are still ongoing, I will discuss the currently available results in the following 
sections.       
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Behavioral Phenotypes in Gcn5hat/+  
Motor Coordination and Learning 
 In order to evaluate general locomotor function in Gcn5hat/+ mice, I performed 
accelerating rotarod assays beginning at 6 months of age.  As illustrated in Figure 4.3, 
Gcn5hat/+ mice do not exhibit statistically significant differences in motor function at any of 
the specified ages, suggesting that GCN5 enzymatic activity does not play a role in motor 
function. 
Anxiety 
 The observed self-injurious behavior in Gcn5hat/+ mice is reminiscent of that seen in 
animal models of OCD, which also show signs of anxiety (Shmelkov et al. 2010; Welch et 
al. 2007).  I therefore tested Gcn5hat/+animals in multiple anxiety assays to determine 
whether they show similar behavior.  The open-field test is a widely accepted anxiety assay 
based on the knowledge that mice will avoid open spaces (e.g.-the center of a box) in 
response to anxiety.  In this assay, mice are placed in a box representing a novel 
environment and filmed for 10 minutes.  Behavioral tracking software is then utilized to 
determine the amount of time the animals spend in the periphery and center of the 
environment, as well as their distance traveled, velocity, and amount of time spent 
exploring the walls (‘wall, nose-point’ in Figure 4.4).  Surprisingly, in all parameters 
examined, Gcn5hat/+ mice showed indistinguishable behavior from control mice, suggesting 
that novel, open spaces do not induce anxiety in these animals (Figure 4.4). 
 I next performed a series of elevated zero and plus maze experiments as another 
method of assaying anxiety in Gcn5hat/+ mice.  Both the elevated zero and plus mazes rely 
upon the same principles as the open-field test.  Animals are placed on an elevated zero- 
or plus-shaped platform with two distinct regions.  The open region, which is thought to 
induce anxiety, does not have any walls.  The closed region is a safe region for the animals 
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because it is surrounded by walls on each side. Therefore an increased amount of time 
spent in the closed region of either maze is considered to be indicative of anxiety-like 
behavior.  Once again, Gcn5hat/+ mice did not exhibit signs of anxiety in these assays (Figure 
4.5).  Furthermore, in accordance with the locomotor data obtained in Figure 4.3, Gcn5hat/+ 
mice did not show any significant difference in distance traveled or velocity in any anxiety-
related assays (Figures 4.4 and 4.5).  Together, these experiments indicate that loss of 
GCN5 enzymatic activity does not result in anxiety.  While this is surprising in the context of 
current models of OCD, recent studies indicate that anxiety and repetitive behaviors 
observed in OCD are separable phenotypes with differing cellular and molecular causes 
(Smith and Graybiel 2013; Thomas et al. 2009; Glahn et al. 2015).  It is therefore possible 
that GCN5 plays a role in repetitive and/or habitual behavior, but not anxiety. 
Marble-burying Activity 
 To test the role of GCN5 in repetitive behavior, I performed a modified version of a 
commonly used assay referred to as the marble-burying assay.  In this assay, mice are 
placed in a novel arena with a 3x3 array of clean marbles set in fresh bedding.  Typically, 
mice are left in this arena for 30 minutes and the number of marbles buried (<30% left 
visible) is quantified.  Recent studies, however, have indicated that a 10-minute time period 
is sufficient for this assay and that leaving mice in the arena for 30 minutes can mask some 
behavioral phenotypes.  I therefore performed this assay using a 10-minute testing window 
and filmed the behavior of the animals throughout that time period.  Surprisingly, this 
revealed additional behavioral data, as mice routinely were observed burying, unburying, 
and reburying the same marble.  Based on these observations, I quantified burying actions 
and latency to initiate burying actions in addition to total marbles buried as a means of 
obtaining more behavioral data. 
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 The preliminary data illustrating self-injurious behavior and dysregulation of Slitrk 
genes in Gcn5hat/hat embryos led me to hypothesize that Gcn5hat/+ mice would exhibit an 
increase in marble burying activity, as both Slitrk5-/- and Sapap3-/- mice show this behavior 
that is indicative of OCD.  Surprisingly, Gcn5hat/+ mice show a statistically significant 
decrease in burying actions and total marbles buried at all ages assayed (Figure 4.6).  
Interestingly, Gcn5hat/+ mice showed no difference in latency to the first digging action, 
suggesting that the decreased burying activity is not a result of an inability to dig or to 
recognize the marbles (Figure 4.6, bottom row).  As a whole, the behavioral experiments 
performed in this study therefore indicate that while Gcn5hat/+ mice do not represent a 
model of OCD, they do exhibit significant behavioral phenotypes suggesting a role for 
GCN5 enzymatic activity in adult forebrain function.  
Cellular and Molecular Phenotypes 
Sustained Neuronal Activity 
 The requirement of GCN5 enzymatic activity for suppression of self-injurious 
behavior and proper marble-burying activity led me to first examine neuronal activity in 
forebrain regions associated with these behaviors.  Although Gcn5hat/+ mice exhibit 
decreased marble burying activity, several studies have shown that this type of stereotyped 
behavior requires proper function of the orbitofrontal cortex (OFC) and dorsal striatum 
(DStr).  Immunostaining for FOSB, a marker of prolonged neuronal activity, in forebrain 
tissue collected from wildtype and mutant mice at 12 months of age indicated a significant 
increase in activity in the OFC of Gcn5hat/+ mice (Figure 4.7a,b).  Furthermore, these animals 
exhibited a significant decrease in activity in the DStr (Figure 4.7a,b).  These data were 
somewhat surprising considering the fact that excitatory efferents from the OFC target cells 
of the DStr within the CSTC loop, with the expectation that an increase in OFC activity 
would result in a subsequent increase in DStr activity.  Based on our current understanding 
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of CSTC biology, three hypotheses could account for this paradoxical observation: (1) OFC 
efferents form fewer synapses with MSNs of the DStr in Gcn5hat/+ mice, (2) disruption of 
neuromodulation in the DStr of Gcn5hat/+ mice desensitizes MSNs to OFC activity, and/or (3) 
the DStr region of Gcn5hat/+ brains contain less cells than wildtype animals.  In the following 
sections, I will discuss the results of ongoing experiments to address these three 
hypotheses.   
Medium Spiny Neuron Morphology 
 Previous studies have shown that changes in the morphology of MSNs are 
observed in animal models of OCD and ASDs, though how these changes relate to the 
behavioral phenotypes is still somewhat unclear.  To examine MSN morphology, I 
performed Golgi-COX staining on brain tissue from 12-month-old wildtype and mutant 
animals and manually traced MSNs using NeuronJ (Figure 4.7c).  MSNs were identified by 
morphology, location within the striatum, and density of dendritic spines.  Analysis of MSN 
complexity via Sholl analysis, which quantifies the number of times a given neuron 
intersects concentric circles surrounding its soma, indicates that Gcn5hat/+ mice exhibit 
significantly decreased MSN complexity in regions proximal to the soma (Figure 4.7d).  
These observations support the hypothesis that decreased DStr activity in Gcn5hat/+ mice 
results, at least partially, from a decreased connectivity between OFC efferents and DStr 
MSNs.  Nonetheless, further analysis using genetic reporters and monosynaptic retrograde 
tracing with pseudorabies virus (Wall et al. 2010) will be required to fully address spine 
density and functional connectivity between OFC and striatum in Gcn5hat/+ animals. 
Dopamine Receptor D2 Expression 
 My previous studies identifying a role for GCN5 in RA signaling in the embryonic 
brain, as well as the known role of RA signaling in D2 receptor expression leads to the 
suggestion that decreased dopaminergic modulation of D2 and D1/D2 MSNs could be 
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responsible for the decreased neuronal activity observed in the DStr of Gcn5hat/+ mice.  To 
test this, I examined D2 receptor expression by immunohistochemistry in forebrain tissue 
from 6-month-old mice and observed statistically significant decreases in the number of 
D2DR-positive cells in both OFC and DStr (Figure 4.8).  It is unclear at this moment, 
however, whether this represents a decrease in Drd2 expression, failure of these cells to 
differentiate, or death of D2DR-positive cells.  Further studies will be required to assess 
these questions and additional analysis is required to determine whether the decrease in 
D2DR-positive cells is specific to certain structures in the forebrain or ubiquitous.  
Nonetheless, these data support the hypothesis that altered dopaminergic 
neuromodulation plays a role in the changes in activity observed in the DStr, and possibly 
the OFC, of Gcn5hat/+ mice.      
Decreased Cerebellar Volume in Gcn5hat/+ Mice 
 Numerous studies of neuropsychiatric disorders have found volumetric changes in 
specific forebrain regions in both humans and animal models.  The studies described in 
Chapter 3 indicating that GCN5 enzymatic activity is required for controlling the size of the 
thalamus during development, as well as the behavioral phenotypes observed in 
heterozygous Gcn5 mutants, prompted me to perform longitudinal volumetric MRI on these 
animals.  While the analysis of these studies is still ongoing, 3-month-old Gcn5hat/+ mice 
show a significant decrease in cerebellar volume (Figure 4.9), consistent with the results of 
Gcn5fl/fl;Nes-Cre mice (Martínez-Cerdeño et al. 2012) suggesting defects in neural stem cell 
proliferation and hindbrain volume.  Volumetric changes were not observed in other 
forebrain structures at this age, but the progressive nature of the behavioral phenotypes 





 My ongoing preliminary studies of Gcn5hat/+ mice suggest that these animals exhibit 
significant behavioral phenotypes that are accompanied by cellular, molecular, and 
anatomical changes in specific regions of the brain throughout life.  Specifically, 
Gcn5hat/+mice frequently develop delayed-onset self-injurious behavior, decreased activity 
in the marble burying assay, significant changes in OFC and DStr neuronal activity, 
decreased MSN complexity, decreased D2DR-positive cell numbers, and decreased 
cerebellar volume.  These results support a broad role for GCN5 activity in the function of 
forebrain circuits required for complex behaviors, similar to the disruptions observed in 
numerous neuropsychiatric disorders.  As genetic studies increase in statistical power and 
sequencing technologies improve in sensitivity, it is becoming apparent that 
neuropsychiatric disorders are highly heterogeneous (Arnedo et al. 2015; Sanders et al. 
2015).  Furthermore, the continued failure with respect to developing novel therapeutics for 
these diseases highlights that we must better understand the cellular and molecular causes 
of specific disease symptoms in order to create targeted and effective treatments.  With 
this in mind, I will discuss the potential relevance of my preliminary data for understanding 
the roles that GCN5 plays in the CSTC loop and cerebellum, as well as how these findings 
have the potential to impact human health. 
 The aforementioned genetic diversity in neuropsychiatric disease is compounded by 
accumulating data supporting multigenic disease etiology (Sanders et al. 2015; Ripke et al. 
2013).  Additionally, animal models generated based on human genetic studies of 
neurological illness indicate that many of the genes implicated in such disorders are highly 
pleiotropic.  These observations have led to the hypothesis that successful treatment of 
neuropsychiatric illness will require the identification of specific endophenotypes, which 
allow for the segregation of complex behaviors into simpler contributing phenotypes with 
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defined genetic contributions (Homberg et al. 2015).  Taking into account the preliminary 
data implicating numerous brain structures and molecular mechanisms in the phenotypes 
observed in Gcn5hat/+ mice, I will attempt to use the concept of endophenotypes to better 
understand how GCN5’s numerous known functions could potentially contribute to the 
complex behaviors observed in these mice. 
 Gcn5hat/+ mice exhibit decreases in cerebellar volume, MSN complexity, cortical and 
striatal D2DR-positive cell numbers, and neuronal activity in the dorsal striatum, as well as 
increased neuronal activity in the orbitofrontal cortex.  While these findings indicate 
widespread disruption of CSTC loop structure and function, the behavioral phenotypes 
observed in these mutants paint a more complicated picture.  Self-injurious behavior is 
observed in numerous mouse models of neuropsychiatric disease, indicating that 
disruption of more than one signaling pathway or circuit can lead to such behavior.  In 
general, self-injury in animal models is thought to be an anxiety-related phenotype, though 
recent advances in behavioral testing methods indicate that this is not necessarily the case, 
even in mutants that display anxiety phenotypes (Burguière et al. 2013).  Interestingly, 
Gcn5hat/+ mutants do not exhibit signs of anxiety based on multiple anxiety assays, 
suggesting that the self-mutilation observed in these animals is either independent of 
anxiety or caused by acute onset of anxiety.  Furthermore, although quantitative analysis of 
repetitive behaviors in Gcn5hat/+ mice is ongoing, extensive observation of these animals 
does not seem to indicate repetitive grooming that is observed in most animal models 
exhibiting self-injurious behavior (Shmelkov et al. 2010; Welch et al. 2007; Speed et al. 
2015).  While self-mutilation is most often observed in animal models of OCD, Gcn5 
mutants do not exhibit the increased burying activity that is seen in these models 
(Shmelkov et al. 2010).  Instead, Gcn5 mutants display significant decreases in marble 
burying that are reminiscent of those observed in Shank3 models of autism and Phelan-
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McDermid syndrome (Speed et al. 2015).  These distinct phenotypes in Gcn5hat/+ animals 
further support the need for understanding how pathway and circuit-specific functions of 
GCN5 contribute to behavioral traits.  
 Genetic and optogenetic studies have successfully identified much of the relevant 
circuitry and cell types for habitual behavior (Gremel and Costa 2013; Smith et al. 2012; 
Smith and Graybiel 2013; Welch et al. 2007).  In animal models with dysfunction of these 
cells and circuits, over-grooming and self-injury can be ameliorated with optogenetic 
activation of cortical CSTC efferents or striatum-specific re-expression of the mutated gene 
(Burguière et al. 2013; Welch et al. 2007; Burguiere et al. 2013).  These studies, which 
strongly focus upon the dorsal striatum and medial OFC, suggest that the self-injurious 
behavior seen in Gcn5 mutants results specifically from the observed dysregulation of 
neuronal activity in the OFC and DStr, potentially due to disrupted MSN complexity.  
Because these regions also show decreased numbers of D2DR-positive cells, there is a 
distinct possibility that disruption of dopaminergic signaling also contributes to the 
observed phenotypes. 
 While Gcn5hat/+ mice may show dysregulation of forebrain regions strongly 
associated with OCD-like behavior, they do not show the typical increased marble burying 
behavior seen in OCD models.  Instead, Gcn5hat/+ mice show significant decreases in 
marble burying activity, which could be indicative of decreased motivation, novel object-
induced anxiety, or novel object-induced sensory overstimulation.  It is also possible that 
the behavior represents a combination of these responses, suggesting that further 
behavioral tests for social behavior, novel object recognition, and motivation are required to 
identify more tractable endophenotypes.  Preliminary analyses, however, appear to show 
decreased D2DR-positive cell numbers in the ventral striatum, which is implicated in 
motivation and addictive behavior.  It is therefore likely that the marble burying phenotype 
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observed in Gcn5 mutants is at least partially due to dopaminergic dysregulation in the 
nucleus accumbens that interferes with motivation.   
 The potential for dopaminergic contributions to the phenotypes exhibited by 
Gcn5hat/+ mice suggests that these phenotypes can be reversed by administration of 
dopaminergic drugs.  However, while this is useful for proving a hypothesis, it does not 
necessarily represent a novel improvement with respect to ameliorating these behaviors in 
humans.  Furthermore, the hypothesis that Drd2 down-regulation in Gcn5 mutants results 
from defects in RA signaling suggests that amelioration of the behavioral phenotypes 
without unintended side effects would require increasing Drd2 expression, as opposed to 
specifically activating D2 receptors or increasing dopamine levels.  Although RA signaling 
has been implicated in neuropsychiatric disease through genetic studies, modulation of RA 
signaling has not been used to treat any such disorders to-date (Goodman 1998; Maden 
2007).  Therefore, modulation of RA signaling for the purpose of ameliorating behavioral 
phenotypes in Gcn5hat/+ embryos represents a novel therapeutic avenue with the potential 
to treat a specific constellation of behaviors with less side effects. 
 The observation that Gcn5hat/+ mice share numerous phenotypes with the Shank3 
animal models and show a decrease in cerebellar volume indicates that GCN5 may be 
relevant to the etiology of ASDs.  While ASDs are primarily associated with defects in 
forebrain circuitry, significant evidence supports additional contributions from cerebellar 
dysfunction (Kloth et al. 2015).  Although Gcn5 mutations or deletions have not been 
identified in ASD patients, a recent study identified Pcaf mutations in patients with autism 
(Sanders et al. 2015).  Interestingly, both the E9.5 and E10.5 microarray experiments 
indicated significant downregulation of Pcaf.  Furthermore, because the mutated protein in 
Gcn5hat mutants is capable of incorporating into its native complexes it is possible that it 
has dominant-negative effects on PCAF and the ability of PCAF to associate with the SAGA 
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and ATAC complexes.  Lastly, Gcn5-/-;Pcaf-/- compound mutants show worse 
developmental phenotypes than Gcn5-/- even though Pcaf-/- mice develop normally, 
suggesting that PCAF and GCN5 have some overlapping functions (Xu et al. 2000).  It is 
therefore plausible that Pcaf downregulation in Gcn5hat/+ mutants contributes to the 
observed phenotypes.  Together, these data suggest that defects in GCN5 function or 
expression, as well as associated RA signaling defects, may be involved in ASDs and that 
















Figure 4.1 – Self-induced Lesions Exhibited by Aging Gcn5hat/+ Mice 
(a) As early as 3 months-of-age, but typically beyond 6 months-of-age, Gcn5hat/+ mice 
exhibit severe, self-induced skin lesions requiring euthanasia.  Lesions are consistently 
localized to the flank, neck, and ears, with occassional injuries observed between the eyes.  
(b) Approximately half of Gcn5hat/+ mice will go on to exhibit self-injurious behavior.  Two 
wildtype female mice were observed with similar lesions, but the lesions healed after 
separation from the Gcn5hat/+ male they were housed with, suggesting that the lesions were 








Figure 4.2 – A Longitudinal Study of Gcn5hat/+ Mice 
Wildtype and Gcn5hat/+ mice (n=9 per genotype) were followed for 1 year and subjected to 
repeated volumetric MRI and behavioral analysis. The MRI studies were done ~2 weeks 
after the behavioral experiments.  Gene expression, neuronal activity, and cellular 
morphology experiments were performed using age-matched animals (n≥3 per genotype 



















Figure 4.3 – Normal Locomotor Function in Gcn5hat/+ Mice 
Accelerating rotarod performance testing (3-30rpm over 5 minutes) indicates normal motor 




















Figure 4.4 – Gcn5hat/+ Mice Perform Normally in the Open-field Test 
Gcn5hat/+ mice display indistinguishable behavior from wildtype mice in the open-field test in 







Figure 4.5 – Gcn5hat/+ Mice Perform Normally on the Elevated Zero & Plus Mazes 
Gcn5hat/+ mice exhibit normal behavior in both the elevated zero maze (left and right 










Figure 4.6 – Decreased Marble Burying Activity by Gcn5hat/+ Mice 
Gcn5hat/+ mice show persistent and worsening deficits in the marble burying assay at all 
ages beyond 6 months.  Although Gcn5hat/+ mice do not show differences in latency to the 
first burying action (bottom row), they consistently perform less burying actions (top row) 












Figure 4.7 – Changes in Neuronal Activity and MSN Morphology in Gcn5hat/+ Mice 
(a,b) Immunohistochemistry of 12-month-old forebrain sections reveals significantly 
increased FOSB staining in the orbitofrontal cortex (OFC) and decreased FOSB staining in 
the dorsal striatum (DStr) of Gcn5hat/+ mice, indicating changes in long-term neuronal 
activity. (b) represents n=3 mice per genotype (c) Representative neurite traces of MSNs 
from 12-month-old wildtype and Gcn5hat/+ mice. (d) Sholl analysis of MSNs (n=40 per group) 
from 12-month-old wildtype and Gcn5hat/+ mice shows significantly decreased complexity 







Figure 4.8 – Decreased D2DR-positive Cell Numbers in Gcn5hat+/+ Mice 
Quantification of D2DR immunohistochemistry in 8-month-old wildtype and Gcn5hat/+ mice 
shows significant decreases in the number of D2DR-positive cells in the orbitofrontal cortex 















Figure 4.9 – Decreased Cerebellar Volume in 3-month-old Gcn5hat/+ Mice 
Volumetric MRI of 3-month-old wildtype and Gcn5hat/+ mice indicates decreased cerebellar 
volume in mutants.  Representative images at top illustrate decreased cerebellar size and 






























Antigen Company Catalog # Species Concentration Antigen Retrieval Blocking Buffer
FOSB Santa Cruz sc-48 Rb 1:50 10mM sodium citrate, 12 minutes in steamer 0.1% Tween-20, 3% NGS, PBS
D2DR Santa Cruz sc-9113 Rb 1:50 10mM sodium citrate, 12 minutes in steamer 0.1% Tween-20, 3% NGS, PBS
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Gene Fold Change p-Value Function and/or Disease Relevance
Slitrk3 -1.228879763 0.009082456 Axon Guidance, OCD
Slitrk5 -1.484573439 8.71E-04 Axon Guidance, OCD
Map6 1.523885391 0.001054333 Axonal Transport, Schizophrenia
Fezf2 -1.30384262 0.004942673 Corticofugal neuron differentiation, thalamic development
Gabrp -3.392880058 0.001677501 GABA receptor subunit, Bipolar Disorder
Lgi1 1.518751996 0.001246236 Glutamatergic synapse function, epilepsy
Lhx2 -1.367387902 0.002263796 Hippocampal Development
Ntrk3 -1.385296121 0.002851689 Hippocampal function, anxiety/panic disorders
Sim2 1.40969561 0.00687791 Hypothalamic development and function
Gpr50 -1.504958577 0.001243017 Neurite outgrowth
Mmp14 -1.391634444 -1.391634444 Neurite outgrowth, plasticity
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Time P value Mean1 Mean2 Difference SE of difference t ratio df
00:00-05:00 0.236539 38.556 21.6667 16.8889 14.0896 1.19868 48
05:00-10:00 0.242673 38.667 22 16.6667 14.0896 1.1829 48
00:00-10:00 0.0212516 77.222 43.6667 33.5556 14.0896 2.38158 48
Time P value Mean1 Mean2 Difference SE of difference t ratio df
00:00-05:00 0.0411582 76.778 32.3333 44.4444 20.0137 2.2207 16
05:00-10:00 0.00108942 49.444 17.8889 31.5556 7.93998 3.97426 16
00:00-10:00 0.00784261 126.22 50.2222 76 25.0214 3.0374 16
Time P value Mean1 Mean2 Difference SE of difference t ratio df
00:00-05:00 0.0386796 46.25 18.8889 27.3611 12.0746 2.266 15
05:00-10:00 0.0150818 49.25 16.2222 33.0278 12.0385 2.74351 15
00:00-10:00 0.0129518 95.5 35.1111 60.3889 21.4217 2.81906 15
Age P value Mean1 Mean2 Difference SE of difference t ratio df
6 months 0.00586114 5.6667 2.77778 2.88889 0.909484 3.17641 16
8 months 0.00129088 6.2222 2.44444 3.77778 0.970236 3.89367 16
12 months 0.00015728 5.75 1.33333 4.41667 0.882704 5.00356 15
Total Marbles Buried, Multiple t-tests (one per timepoint)
6 months, Burying Actions, Multiple t-tests (one per timepoint)
8 months, Burying Actions, Multiple t-tests (one per timepoint)
12 months, Burying Actions, Multiple t-tests (one per timepoint)
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Region P value Mean1 Mean2 Difference SE of difference t ratio df
OFC 0.0250507 42.983 56.4284 -13.4459 5.25448 2.55893 12
DStr 0.000498952 57.457 32.6679 24.789 5.25448 4.71768 12
Multiple t-tests (one per region)
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Radius (µm) P value Mean1 Mean2 Difference SE of difference t ratio df
10 0.429341 13.64 12.69 0.950001 1.2018 0.790484 1958
20 0.250993 16.88 15.5 1.38 1.2018 1.14828 1958
30 0.0685662 19.88 17.69 2.19 1.2018 1.82227 1958
40 0.0287588 20.76 18.13 2.63 1.2018 2.18839 1958
50 0.0159107 20.37 17.47 2.9 1.2018 2.41306 1958
60 0.0152008 18.42 15.5 2.92 1.2018 2.4297 1958
70 0.00841262 16.33 13.16 3.17 1.2018 2.63772 1958
80 0.00862054 14.13 10.97 3.16 1.2018 2.6294 1958
90 0.0117734 11.41 8.38 3.03 1.2018 2.52123 1958
100 0.0114988 9.07 6.03 3.04 1.2018 2.52955 1958
110 0.159815 6.35 4.66 1.69 1.2018 1.40623 1958
120 0.172528 4.95 3.31 1.64 1.2018 1.36462 1958
130 0.264988 3.56 2.22 1.34 1.2018 1.115 1958
140 0.414916 2.76 1.78 0.98 1.2018 0.815446 1958
150 0.521787 1.99 1.22 0.77 1.2018 0.640708 1958
160 0.565938 1.47 0.78 0.69 1.2018 0.574141 1958
170 0.68964 0.98 0.5 0.48 1.2018 0.399402 1958
180 0.683521 0.8 0.31 0.49 1.2018 0.407723 1958
190 0.720533 0.59 0.16 0.43 1.2018 0.357798 1958
200 0.790061 0.38 0.06 0.32 1.2018 0.266268 1958
210 0.815798 0.28 0 0.28 1.2018 0.232985 1958
220 0.861303 0.21 0 0.21 1.2018 0.174739 1958
         Multiple t-tests (one per radial analysis point)
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Region P value Mean1 Mean2 Difference SE of difference t ratio df
OFC 0.000506122 53.751 33.0942 20.6571 3.04991 6.77304 6
DStr 0.00231071 42.58 18.4356 24.1444 4.23219 5.70494 5
Multiple t-tests (one per region)
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Region P value Mean1 Mean2 Difference SE of difference t ratio df
Whole Brain 0.266481 1 1.05229 -0.05229 0.0467284 1.11902 80
Cortex 0.240094 1 0.944694 0.0553057 0.0467284 1.18356 80
Thalamus 0.149189 1 0.931944 0.0680564 0.0467284 1.45643 80
Striatum 0.400732 1 0.960523 0.0394769 0.0467284 0.844817 80
Cerebellum 8.50985E-05 1 0.806497 0.193503 0.0467284 4.14102 80




CONCLUSIONS AND FUTURE DIRECTIONS 
 The findings described in this dissertation strongly support an essential role for 
GCN5 in multiple aspects of brain development and function.  First, I showed that loss of 
GCN5 acetyltransferase activity during primary neurulation causes neural tube defects and 
widespread transcriptional dysregulation, as well as phenotypes indicative of defective 
terminal neuronal differentiation.  Next, I showed that GCN5 acetyltransferase activity is 
required for regulation of a novel RA signaling mechanism that restricts diencephalic size 
through repression of WNT and SHH.  Last, I illustrated behavioral, cellular, molecular, and 
anatomical defects in Gcn5hat/+ adults that are reflective of defects in cortico-striato-
thalamo-cortical circuitry.  While the results presented in Chapter 3 clearly demonstrate the 
mechanism of GCN5-mediated regulation of diencephalic development, the mechanistic 
details of the phenotypes described in Chapters 2 and 4 remain unclear.  Though it is 
convenient to speculate that the transcriptional dysregulation observed at E9.5 and the 
numerous phenotypes in adults are caused by defects in chromatin modification and/or RA 
signaling, it is important to keep in mind the multitude of additional known functions of 
GCN5 and the fact that there may be additional functions that have yet to be discovered.  It 
is therefore essential that future studies of these phenotypes take all known functions of 
GCN5 into account, as well as remain unbiased to expand the exploration of possible new 
mechanisms (Figure 5.1). 
 The significant number of dysregulated genes in Gcn5hat/hat mutants at the time of 
neural tube closure suggests defects in genome-wide transcriptional regulatory 
mechanisms.  Although this supports a chromatin-based function for GCN5 at this 
developmental timepoint, defects in RA signaling, glucose homeostasis, or p23/GCN5-
mediated transcription factor acetylation could also serve as the basis for such widespread 
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transcriptional dysregulation. Recent advances in mass spectrometry now allow for 
proteome-wide assessment of alterations in lysine acetylation. Large amounts of tissue are 
required but instrument sensitivity continues to increase and it is possible to pool wildtype 
and Gcn5hat/hat embryos to further address the role of transcription factor acetylation in 
neural tube closure (Henriksen et al. 2012).  Coupled with techniques like ChIP-seq and 
ATAC-seq, which can assess genome-wide changes in histone modifications and the 
binding of transcription factors with known consensus binding sequences (Buenrostro et al. 
2013), it will be possible to determine the extent of contribution from chromatin and 
transcription factor modification in Gcn5-related NTDs.  Furthermore, these genomic and 
proteomic methods can serve as valuable tools for interrogating novel regulatory 
mechanisms of neural tube closure and may uncover previously unappreciated risk factors 
for these devastating birth defects.  Indeed, our collaborators, Dr. Hongyan Wang (Fudan 
University) and Dr. Ting Zhang (Capitol Institute of Pediatrics, Beijing) have identified 
predicted deleterious mutations in Gcn5 (Kat2a) in tissues from humans with NTDs. The 
insights derived from the studies outlined in this thesis will be important in modeling the 
functional impact of these gene variants.   
In addition to expanding our understanding of the role that GCN5 enzymatic activity 
plays in neural tube closure, Gcn5hat/hat embryos offer a potential opportunity to interrogate 
multigenic contributions to NTDs.  The observed dysregulation of more than 30 genes 
already known to be involved in neural tube closure indicates that GCN5 coordinates 
multiple pathways that are necessary for successful neurulation.  Next-generation 
sequencing of DNA from patients with neural tube defects often identifies multiple 
potentially causative mutations per patient and studies of NTD risk in families suggest 
compound genetic contribution (Wilde et al. 2014).  Until recently, the combinatorial effects 
of transcriptional dysregulation across pathways were difficult to test.  However, the recent 
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development of CRISPR/Cas-based technologies now allows multiplexed disruption, 
activation, and repression of multiple genes of interest in vitro and in vivo (Platt et al. 2014; 
Cong et al. 2013; Ran et al. 2013).  As future studies of Gcn5hat/hat mutants identify 
important genes and pathways that are regulated by GCN5, CRISPR/Cas will enable in 
vitro testing of their combinatorial effects on proliferation and differentiation of NE cells and 
cytoskeletal dynamics in MEFs, as well as in vivo testing of their effects on neural tube 
closure.  Together, these types of studies will be essential for advances in our 
understanding of the complex etiology of human NTDs.  
 Understanding mechanisms of cell cycle regulation and differentiation in NE cells is 
not only important for understanding how defects in these processes can lead to 
neurodevelopmental disorders, but also for ongoing attempts to repair brain injuries using 
neural stem cells and induced pluripotent stem cells, as well as those based on activation 
of resident stem cell populations.  The intriguing observation that GCN5 activity is required 
for both maintenance of NE cell identity and completion of neuronal differentiation suggests 
that GCN5 or its downstream targets may represent important pharmacological targets for 
precise regulation of stem cell maintenance and generation of new neurons.  While 
understanding the function of GCN5 in NE cell maintenance may require deep epigenomic 
and transcriptomic analysis, several plausible candidates exist to help explain its role in 
neuronal differentiation.  First, down-regulation of Neurod1 expression in Gcn5hat/hat mice 
and prolonged expression of the intermediate neuronal differentiation marker Ptrg in RA-
treated NE-4C cells in response to MB-3 treatment suggests a failure of these cells to 
activate the terminal differentiation programs normally initiated by NEUROD1 (Pataskar et 
al. 2015).  By re-expressing Neurod1 in NE-4C cells treated with RA and MB-3, it should be 
possible to at least partially rescue the defects observed in these cells, resulting in down-
regulation of Prtg and increased neuronal differentiation.  A confounding factor for these 
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experiments, however, is the decreased response to RA treatment caused by disruption of 
GCN5-mediated TACC1 acetylation in NE-4C cells.  Therefore, it will be important to 
perform these studies in other models of neural differentiation that do not rely on RA 
treatment.  Also, NE-4C cells readily differentiate after 24-48 hours of RA treatment, 
suggesting that GCN5 inhibition after RA washout will allow future studies to address RA-
independent functions of GCN5 activity in the differentiation of NE cells.  These studies 
have the potential to uncover novel, temporal regulatory mechanisms of neural 
differentiation mediated by a single factor that could significantly aid strategies for neural 
stem cell-based therapeutics.   
 The behavioral phenotypes uncovered in heterozygous Gcn5hat/+ mice represent a 
significant challenge in terms of identifying the underlying mechanisms of forebrain 
dysfunction.  Although Gcn5hat/+ phenotypes are consistent, the presentation of behavioral 
deficits at advanced ages presents a significant hurdle. The onset and/or robustness of the 
phenotypes studied may be more penetrant in Gcn5hat/hat mice, but these animals do not 
survive postnatally.  In order to increase phenotypic robustness and enable cell type-
specific interrogation of GCN5 enzymatic function, the first step in future studies must be to 
generate mice with a cassette that allows for Cre-mediated homozygous introduction of the 
Gcn5hat mutation in the endogenous Gcn5 locus (Schnütgen et al. 2003).  These mice will 
undoubtedly increase our understanding of cell- and circuit-specific functions of GCN5 and 
provide novel approaches for addressing circuit-specific contributions to behavioral 
phenotypes. 
While the transcriptional regulatory mechanisms discussed with respect to neural 
tube closure and neural differentiation are undoubtedly involved in the adult behavioral 
phenotypes (Figure 5.1, right), ample evidence suggests contributions related to other 
functions of GCN5 enzymatic activity.  As previously discussed, modulation of RA signaling 
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through administration of targeted pathway agonists and/or antagonists represents a novel 
therapeutic avenue for treating a subset of neuropsychiatric disorders, especially if Gcn5 
mutations are uncovered in the human population.  It is quite possible, however, that RA 
signaling is only critical for some of the phenotypes observed in Gcn5hat/+ mutants, in 
particular the decreased D2DR-positive cell counts (Figure 5.1, top).  Furthermore, subtle 
changes in thalamic development mediated by dysregulation of the diencephalic signaling 
pathways discussed in Chapter 3 could alter activity through the CSTC loop.  Experiments 
involving in vivo administration of RA agonists will be critical in assessing these possibilities 
and further evaluating the potential for modulating RA signaling in a therapeutic setting. 
It is well-known that energy homeostasis is critical for brain function and it is 
therefore possible that defects in GCN5-mediated acetylation of PGC-1α (Ppargc1a-/-) 
contribute to the phenotypes observed in Gcn5 mutant mice (Figure 5.1, left)(van Praag et 
al. 2014).  Recent publication of work with Ppargc1a-/- mice identified defects in inhibitory 
synaptic transmission in the motor cortex, which functions in conjunction with striatal 
circuits to regulate both directed movement and habitual behavior (Dougherty et al. 2014; 
Graybiel et al. 1994).  Because PGC-1α typically regulates gluconeogenesis, which occurs 
in both the liver and brain to supply the CNS with glucose (Bhattacharya and Datta 1993), it 
would be interesting to test the effects of glucose restriction on Gcn5hat/+ animals with a 
particular focus on how changes in glucose availability alter behavior and neuronal activity.    
In addition to the potential contribution of PGC-1α to the Gcn5hat/+ phenotype, it is 
possible that defects in cytoskeletal dynamics lead to altered function of the Gcn5 mutant 
brain.  Mice lacking the α-tubulin acetyltransferase Atat1 show defects in structure of the 
dentate gyrus, suggesting an important role for tubulin acetylation in the CNS (Kim et al. 
2013).  Because GCN5 has also been shown to acetylate α-tubulin (Conacci-Sorrell et al. 
2010), this raises the likelihood that some of the phenotypes seen in Gcn5 mutants arise 
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from decreased α-tubulin acetylation and subsequent alterations in neuronal cytoskeletal 
structure and function.  This possibility is further supported by the observed defects in 
MSN morphology, the dysregulation of microtubule stability factors like Dcx and Stmn2 
observed in early CNS development in Gcn5hat/hat mice, and the known association of 
ATAT1 with DCX (Figure 5.1, bottom)(Kim et al. 2013).   
Regardless of whether or not GCN5 dysfunction or dysregulation contributes to 
human neuropsychiatric disorders, Gcn5hat/+ mutants can play an important role in better 
understanding forebrain circuit dysfunction.  Much like NTDs, neuropsychiatric disorders 
are thought to be multigenic and highly complex, suggesting that our understanding of their 
etiology requires our understanding of the way that disruption of numerous pathways and 
cellular function can contribute to specific endophenotypes.  Recent evidence strongly 
supports a significant contribution from chromatin-modifying enzymes to neuropsychiatric 
disorders (Sanders et al. 2015; Ripke et al. 2013; Lewis et al. 2003).  Interestingly, because 
of their ability to regulate numerous pathways simultaneously, animal models with 
mutations in these enzymes may also help to increase our understanding of genetic 
contributions to disease in patients lacking disruption of chromatin modifiers.  By building 
our knowledge base of how these proteins coordinately regulate genome-wide 
transcriptional networks, either directly or indirectly, we will increase our comprehension of 
the genes required for forebrain function and how these genes act in concert.  Additionally, 
by attempting to partially rescue the phenotypes observed in Gcn5hat/+ mice through 
targeted modulation of specific GCN5 functions, we may elucidate the etiology of multiple 
endophenotypes in a single mouse model and add to the growing body of research 
suggesting that neuropsychiatric diseases should be treated based on personalized 
endophenotype profiles instead of disease-based diagnostics.  Together these studies will 
 143 
help contribute to the overarching goal of increasing therapeutic efficacy and decreasing 

















Figure 5.1 – Mechanistic Insights into GCN5-mediated Functions in the Forebrain 
A schematic representing the known functions of GCN5 acetyltransferase activity (solid 
black lines) and their possible relevance for phenotypes observed in Gcn5hat mutants 
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